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Abstract 
Congenital hypopituitarism is a complex variable genetic disorder that is known to be 
caused by multiple mutated genes, both in isolation and in variably penetrant cases 
of digenic inheritance. In only <10% of cases, a mutation in a known causative gene 
has been identified in the patient, leaving the vast majority of patients yet to have a 
genetic mutation detected that is responsible for the pathogenicity and that has 
functional significance to their condition. This study investigates novel genes and 
pathways involved in hypothalamo-pituitary development. Our large cohort of 
consanguineous and non-consanguineous pedigrees with hypothalamo-pituitary 
disease are routinely screened for variants in the known causative genes. In 
pedigrees where there are no variants in these particular genes, exome sequencing 
in collaboration with GOSgene is carried out to uncover novel genes and regions of 
interest that are abnormal in the individual. Upon the identification of any novel variant 
in known or novel genes, functional assays are conducted to further show the 
significance of the change. Firstly this study identifies the first novel homozygous 
mutation in the LHX4 gene, p.T126M, in two deceased brothers from a pedigree with 
combined pituitary hormone deficiency with subsequent fatal consequences. 
Functional luciferase assays showed that there was no significant difference between 
mutant p.T126M and WT constructs in transactivating the αGSU and prolactin 
promoters, and that mutant LHX4 could synergise with POU1F1 similar to WT LHX4. 
Secondly, six new candidate genes; CTPS2, RNPC3, PRMT6, FASN, APEX2 and 
EIF2S3, were identified in phenotypically unique pedigrees submitted to GOSgene 
for exome sequencing. The human embryonic expression profiles of these novel 
candidate genes were analysed in this study in a hypothalamo-pituitary context, as 
well as in related tissues that are affected in the individuals. Thirdly, the role of eIF2γ, 
encoded by EIF2S3, which was found to be mutated in an X-linked pedigree with 
congenital hypopituitarism, hypothyroidism and hyperinsulinism causing 
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hypoglycaemia, was investigated in this study. A lentiviral shRNA knock out of the 
EIF2S3 gene in human pancreatic cells resulted in significantly higher apoptosis 
compared to WT cells. This study has used both a Sanger sequencing and an exome 
sequencing approach to identify novel variants in known and novel candidate genes 
respectively.   
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1.1. Hypothalamo-pituitary development 
The pituitary gland is a major endocrine gland, also known as the hypophysis, the 
function of which is to control growth, metabolism, reproduction and development. It 
regulates the function of other endocrine glands in the body. The pituitary gland is 
situated within the sella turcica recess of the sphenoid bone at the base of the brain 
and is made up of three lobes; the anterior, intermediate and posterior (Figure 1.1) 
that have a dual embryonic origin. The anterior and intermediate derive from the oral 
ectoderm, whilst the posterior originates from the neural ectoderm (see Figure 1.2 for 
murine pituitary development, similar to human embryogenesis) (Cohen, 2012, 
Bancalari et al., 2012). Hypothalamo-pituitary development is determined by the 
communication between the oral and overlying neural ectoderm. This occurs through 
a complex spatio-temporal genetic cascade of transcription factors and signalling 
molecules that may be either intrinsic or extrinsic to the developing Rathke's pouch, 
the primordium of the anterior pituitary (AP) (Kelberman et al., 2009), which when 
fully developed will become a central regulator of growth, reproduction and 
homeostasis (Davis et al., 2010).  
 
 
 
26 
 
Figure 1.1: The pituitary gland and its position within the brain. Diagrams taken 
and adapted from two different web pages respectively; (www.usmanscience.com, 
www.Emaze.com). (A) A schematic diagram showing the location of different 
segments of the brain. (B) An enlarged diagram of the pituitary gland showing the 
anterior and posterior lobes, and their link to the hypothalamus via the infundibulum.   
 
 
Figure 1.2: Development of the murine pituitary gland. Taken from Sheng et al. 
(Sheng et al., 1997), animated sagittal sections during mouse embryonic 
development. (a) At E8.5 the thickening of the oral ectoderm signifies the onset of 
pituitary organogenesis. (b) Twenty four hours later the rudimentary pouch 
invaginates towards the overlying ventral diencephalon. (c) The definitive Rathke's 
pouch is formed as its connection to the oral ectoderm is severed. The posterior 
pituitary forms by the infundibulum evaginating from the ventral diencephalon. (d) 
Progenitors of the hormone-secreting cell types proliferate and terminally differentiate 
to produce the mature pituitary gland consisting of the anterior lobe, intermediate lobe 
and posterior lobe. E = Embryonic day; I = infundibulum; NP = neural plate; N = 
notochord; PP = pituitary placode; OM = oral membrane; H = heart; F = forebrain; MB 
= midbrain; HB = hindbrain; RP = Rathke's pouch; AN = anterior neural pore; O = oral 
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cavity; PL = posterior lobe; OC = optic chiasm; P = pontine flexure; PO = pons; IL = 
intermediate lobe; AL = anterior lobe; DI = diencephalon; SC = sphenoid cartilage.  
 
1.1.1: The intermediate lobe and posterior lobe 
The intermediate lobe contains a group of endocrine cells called the melanotrophs 
that essentially synthesise a precursor protein called proopiomelanocortin (POMC). 
This in turn generates biologically active peptides, such as adrenocorticotropic 
hormone (ACTH), endorphins and melanocyte-stimulating hormone (MSH), through 
proteolytic cleavage (Lamacz et al., 1991). In humans, by adulthood the intermediate 
lobe is either very small or totally absent. The posterior lobe of the pituitary contains 
neuronal axon projections which stem from magnocellular neurosecretory cell bodies 
that reside in the hypothalamus. Two main hormones are synthesised in these 
hypothalamic nuclei; arginine vasopressin (AVP) in the supraoptic nuclei and oxytocin 
in the paraventricular nuclei, which in turn travel via the hypothalamo-
neurohypophyseal tract and short portal vessels to the posterior lobe of the pituitary 
where they are released (Zimmerman and Antunes, 1976, Duncan and Shipston, 
2016). 
 
A series of tightly regulated steps that result in cell proliferation and differentiation, 
give rise to the five different specialized AP cell types that secrete six different 
hormones: somatotrophs [growth hormone (GH)], thyrotrophs [thyroid-stimulating 
hormone (TSH)], gonadotrophs [luteinizing hormone (LH) and follicle-stimulating 
hormone (FSH)], lactotrophs [prolactin (PRL)] and the corticotrophs 
[adrenocorticotropic hormone (ACTH)] (Figure 1.3) (Alatzoglou and Dattani, 2009). 
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Figure 1.3: A basic overview of the temporal expression of different genes 
during embryonic murine pituitary development. A spatio-temporal genetic 
cascade of transcription factors and signalling molecules, culminating in the 
differentiation of the five anterior pituitary cell types. Image taken from Romero CJ et 
al (Romero et al., 2011). 
 
1.1.2. The anterior pituitary hormones 
The synthesis of each one of the six anterior pituitary hormones is stimulated by 
specific ligands. Many of these ligands are released from the hypothalamus that then 
travel via the hypophyseal portal system into the bloodstream, a transport system that 
allows rapid communication and migration of hormones to the anterior pituitary. The 
ligands bind to their respective receptors on each specific anterior pituitary cell type, 
giving rise to the six hormones that have distinct roles in endocrine regulation 
elsewhere in the body. The stimulation of each anterior pituitary cell type, the 
hormones secreted, and their role in the maintenance of growth, reproductive 
development and homeostasis, are discussed in this section.  
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The growth hormone-releasing hormone receptor (GHRHR), expressed on 
somatotroph cells, binds its ligand GHRH that is released from the hypothalamus. 
Binding to the receptor results in the synthesis and release of GH, in the presence of 
the transcription factor POU1F1 (Iguchi et al., 1999). GH then binds to its receptors 
on target tissues, primarily the liver, leading to the release of insulin-like growth factor 
1 (IGF1) and its binding protein, IGFBP3, which in turn form a ternary complex with 
the acid-labile subunit (ALS), to promote cell growth through mitosis, with inhibition of 
apoptosis (Boisclair et al., 2001, Baxter and Dai, 1994). In addition to the promotion 
of growth, IGF1 stimulates glucose uptake from the blood, enhances glucose 
utilization by peripheral tissues, and suppresses hepatic glucose production in a 
similar manner to insulin (Boulware et al., 1992). Hypothalamic thyrotrophin releasing 
hormone (TRH) binds to its receptor on the thyrotroph cells of the pituitary. It 
stimulates gene expression of the TSHβ subunit, and the conjugation of TSH α and 
β subunits to form TSH molecules, as well as regulating its glycosylation which results 
in TSH secretion from the thyrotrophs. TSH then binds with receptors on the thyroid 
gland to stimulate the production of the thyroid hormone, thyroxine (T4), which can 
feed back to the hypothalamus and pituitary to inhibit the production and secretion of 
TRH and TSH. Additionally, T4 is converted into triiodothyronine (T3) via deiodinase 
enzymes, type I and II (D1 and D2), and enters cell nuclei to bind to thyroid receptor 
α and β isoforms that are differentially expressed in tissues, thereby regulating gene 
transcription (Yamada and Mori, 2008). The thyroid hormones are essentially 
required for normal development, the regulation of metabolism, linear growth and 
bone maintenance.  
 
During embryogenesis, gonadotrophin-releasing hormone (GnRH) neurons migrate 
with olfactory neurons from the olfactory placode to their normal position in the 
hypothalamus (Wierman et al., 2004). GnRH is secreted from the hypothalamus in a 
pulsatile fashion, to bind to its receptors (GnRHR) on the gonadotroph cells, thereby 
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stimulating the release of the gonadotrophins, LH and FSH. Following the withdrawal 
of placental steroids at birth, gonadotrophins rise and remain elevated for the first 1–
2 years in girls, and first 6 months in boys, with a subsequent decrease during the 
remainder of childhood. Pulsatile gonadotrophin secretion then resumes again at 
puberty, with pulses occurring approximately every two hours in adult males. In 
females, the pulses are more variable, depending on the time of the menstrual cycle 
(McCartney, 2010, Ehlers et al., 2013). LH and FSH bind to receptors on the 
reproductive organs, the testes and the ovaries, stimulating sex steroid production. In 
men, LH stimulates Leydig cells to produce testosterone, which in turn provides 
negative feedback to both the anterior pituitary and the hypothalamus. FSH release 
stimulates the Sertoli cells in men to produce sex hormone-binding globulin (SHBG) 
and inhibin, thereby stimulating spermatogenesis and giving negative feedback to the 
anterior pituitary to decrease FSH secretion, respectively (Jin and Yang, 2014). In 
women, there is a surge of LH and FSH that triggers ovulation during the mid-cycle 
of menstruation, where the oocyte lives for up to only 24 hours without fertilisation. 
FSH stimulates the ovaries to produce oestrogen, with the most potent and prevalent 
oestrogen being oestradiol, during the follicular phase, and LH stimulates 
progesterone from the corpus luteum during the luteal phase of the menstrual cycle. 
Oestrogen is part of a negative feedback loop to the hypothalamus that inhibits 
gonadotrophin release (Hillier, 2001).  
 
In contrast to the other anterior pituitary hormones so far discussed, the production 
of prolactin is normally suppressed by a hypothalamic hormone, dopamine, rather 
than stimulated by one. Dopamine binds to its receptors on the lactotroph cells and 
thus inhibits prolactin secretion. Therefore when this suppression is interrupted by 
specific hormones, which interfere with dopamine secretion or receptor binding, it 
leads to an enhanced secretion of prolactin (Torre and Falorni, 2007). Thus, if 
transcription factors and signalling molecules involved in prolactin regulation are 
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mutated, then respective disorders more often elicit an increase in prolactin, 
diagnosed in patients as hyperprolactinaemia (Turankar et al., 2013), rather than a 
decrease as seen in most other anterior pituitary hormone abnormalities. Prolactin is 
positively regulated by TRH, GnRH, vasoactive intestinal polypeptide, and oestrogen. 
The latter increases in the blood stream in late pregnancy, elevating concentrations 
of prolactin, thus preparing the mammary glands at the end of gestation for lactation 
after delivery of a baby. Furthermore, prolactin has a multitude of roles in reproduction 
other than lactation, in addition to possessing multiple homeostatic roles (Freeman et 
al., 2000, Guclu et al., 2015).  
 
The release of ACTH, also known as corticotrophin, from corticotroph cells, is 
stimulated by vasopressin and catecholamines, but most potently by corticotrophin-
releasing factor (CRF) released from the hypothalamus. CRF activates both 
adenylate cyclase and cAMP-dependent protein kinase to stimulate ACTH secretion. 
CRF also upregulates POMC expression, the precursor of ACTH within the anterior 
pituitary (Reisine et al., 1985). In contrast ACTH secretion in the corticotrophs is 
negatively regulated by serum glucocorticoids (Birnberg et al., 1983). The main 
essential role of ACTH is to stimulate cortisol production and release from the cortex 
of the adrenal gland in a circadian rhythm. Thus, concentrations of ACTH are 
generally higher in the morning and fall throughout the day, in conjunction with cortisol 
release. Moreover, ACTH has additional roles in the production of various chemical 
compounds that trigger an increase in other hormones, such as adrenaline and 
noradrenaline. As cortisol concentrations rise in the bloodstream, a negative 
feedback loop to the hypothalamus slows CRF release, thereby decreasing ACTH 
production and its stimulating abilities on cortisol. This is counteracted by physical or 
psychological stress, which inhibits this feedback, thus stimulating cortisol secretion 
once again (Dallman, 2005).    
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1.2. Human conditions arising from disordered hypothalamo-pituitary 
development 
Congenital hypopituitarism (CH) is a syndrome with a wide variation in severity, which 
may present early in the neonatal period or later in childhood. CH is characterized by 
deficiencies in one or more of these 6 hormones mentioned above, with GH being the 
predominant hormone deficiency, often seen in isolation (Kelberman et al., 2009). 
Midline and craniofacial structural abnormalities are often associated with CH, giving 
rise to a range of characterized disorders; from incompatibility with life, to 
holoprosencephaly (HPE), septo-optic dysplasia (SOD) and hypogonadotropic 
hypogonadism (HH) (McCabe et al., 2011b). Thus disordered embryogenesis can 
cause variable phenotypes involving a range of craniofacial midline defects, 
associated with hypothalamo-pituitary disorders. The isolated and combined 
deficiencies, and the spectrum of these disorders are discussed in this chapter.   
 
1.2.1. Isolated growth hormone deficiency 
The most common isolated deficiency is congenital isolated GH deficiency (IGHD) 
with an incidence varying between 1/4000 to 1/10,000 live births. The majority of 
cases are sporadic with a small percentage (3-30%) of familial cases, although for 
most patients its aetiology remains unknown (Alatzoglou et al., 2015, Alatzoglou et 
al., 2014b). IGHD essentially involves short stature ranging from moderate to severe, 
delayed growth velocity, and delayed skeletal maturation. Children with GHD are 
treated with recombinant human GH (rhGH), and generally respond well to this 
treatment (Alatzoglou et al., 2014b). Heterozygous dominant negative mutations in 
the GH1 gene usually affect splicing and lead to the most common autosomal 
dominant form of GHD, known as type II GHD. Exon skipping occurs as a result of 
such mutations, in which one exon is essentially missed out of the transcript. For 
example one such shorter GH isoform of 17.5kDa has been reported to exert a 
dominant negative effect on GH secretion, of which expression levels directly relate 
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to the severity of the disorder (Ryther et al., 2003). GHD type II patients have variable 
height deficit and severity of GHD, and may develop additional pituitary hormone 
deficiencies over time, including ACTH, TSH and gonadotrophin deficiencies 
(Alatzoglou et al., 2015). Autosomal recessive IGHD type IA present with severe 
growth failure in the first 6 months of life with undetectable GH concentrations, and 
patients frequently develop anti-GH antibodies after receiving exogenous GH. These 
antibodies can prevent the growth response that is usually expected after patients 
receive rhGH therapy (Cogan and Phillips, 2006). Patients with IGHD type IA were 
first described to have homozygous GH1 deletions (Wagner et al., 1998); however, 
other severe loss of function GH1 gene mutations have since been described in such 
cases. Patients with severe autosomal recessive type IB GHD, also known as Sindh 
dwarfism (Baumann and Maheshwari, 1997), often have mutations in the GHRHR 
gene, which is more common in pedigrees from Brazil or the Indian subcontinent 
(Baumann, 1999), that are often consanguineous. This GHD type IB elicits a 
phenotype that is not of the classic IGHD phenotype, in that these patients have 
minimal facial hypoplasia and no microphallus, but do manifest anterior pituitary 
hypoplasia (APH) on their magnetic resonance imaging (MRI) (Shohreh et al., 2011). 
The vast majority of GHRHR mutations have a complete loss of function that usually 
affects cAMP production, such as p.K329E which failed to show any cAMP response 
following GHRH treatment in in vitro studies (Salvatori et al., 2002). However a recent 
study performed by myself and colleagues described a novel partial loss of function 
homozygous GHRHR mutation, p.P79L, which gives rise to an unusually mild form of 
IGHD in two unrelated families. The patients were compound homozygous, with the 
second homozygous variant in GHRHR, p.R4Q, suggesting a possible founder effect 
of these variants in patients with IGHD that originates from a certain area of South-
East Asia (Gregory et al., 2016). In addition to GH1 and GHRHR, mutations have 
occasionally been described in IGHD patients in genes encoding early (HESX1, 
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SOX2, SOX3 and OTX2) or late (PROP1 and POU1F1) transcription factors 
(Alatzoglou et al., 2014b, Ashkenazi-Hoffnung et al., 2010, Thomas et al., 2001) 
 
1.2.2. Other isolated hormone deficiencies and abnormalities 
Congenital functional failure of a single lineage has been reported for all pituitary cell 
types, giving rise to isolated hormone deficiencies other than IGHD, such as isolated 
TSH deficiency (TSHD), isolated gonadotrophin (LH and FSH) deficiency; namely 
isolated HH (IHH) (discussed in section 1.2.6), isolated ACTH deficiency (IAD) and 
very rarely isolated PRL deficiency (PRLD) (Douchi et al., 2001). As briefly 
mentioned, abnormalities associated with prolactin are more often due to an increase 
as opposed to a decrease in the hormone. Hyperprolactinaemia may emanate from 
a prolactinoma, a benign prolactin-secreting tumour in the lactrotroph cells, or is 
sometimes apparent in pregnancy when production of prolactin is above the normal 
threshold. There is a higher prevalence for this condition in women, not only due to 
problems during pregnancy, but also due to the fact that most prolactinomas are 
present in women rather than men. Phenotypic features of this disorder include sexual 
dysfunction and infertility, neurological and visual problems, and headaches (Hayes 
et al., 2000). Interestingly, hyperprolactinaemia has also been reported in some 
patients with primary hypothyroidism (Bahar et al., 2011). Patients with the latter have 
elevated TRH concentrations, which are therefore directly thought to be the cause of 
the prolactin upregulation (Croissandeau et al., 1994). Although rare, isolated PRLD 
may occur and clinically manifests only in women as a failure in puerperal 
alactogenesis; namely the production of milk in breastfeeding (Kauppila, 1997). There 
have been very few reports of this, one such familial case involved a mother and 
daughter who between them had eight pregnancies all followed by puerperal 
alactogenesis that resulted from isolated PRLD (Zargar et al., 1997). The etiology of 
isolated PRLD is yet unknown and candidate genes often screened are those found 
to be mutated in patients with PRLD as part of combined pituitary hormone deficiency 
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(CPHD) that are known to be involved in the lineage differentiation of lactotroph cells, 
such as POU1F1, PROP1, LHX3, LHX4, HESX1, and OTX2 transcription factors 
(Iwama et al., 2013). PRLD, also termed hypoprolactinaemia, may also result from a 
hypophysectomy; surgical removal of the pituitary gland often performed to treat 
craniopharyngiomas, or from pharmacological suppression of the pituitary, which in 
turn have been reported to adversely affect the luteal phase of the menstrual cycle 
(Kauppila et al., 1988). A recent report identified elevated autoantibodies in an 
isolated PRLD patients’ serum that specifically recognized a subset of PRL-secreting 
cells but not PRL itself or any other pituitary cells or hormones, thus uncovering a 
new autoimmune etiology for the condition (Iwama et al., 2013).  
 
In TSHD inadequate thyroid hormone biosynthesis occurs, due to defective 
stimulation of the thyroid gland by TSH, therefore causing central, or secondary, 
hypothyroidism in the patient. In some rare cases, mutations in genes controlling the 
TSH biosynthetic pathway, TSHB, TRHR, IGSF1, have been described in patients 
with isolated TSHD (Garcia et al., 2014). IGSF1 mutations have been reported to be 
responsible for an X-linked type of central hypothyroidism associated with 
macroorchidism (Sun et al., 2012); however this latter phenotypic feature is not 
present in all patients with such mutations (Hughes et al., 2016). Interestingly, 
parental heterozygous female carriers of these IGSF1 mutations may sometimes 
manifest mild hypothyroidism (Joustra et al., 2013). Lastly, IAD is a very rare 
heterogeneous condition making diagnosis very difficult, due to the varied clinical 
presentation. It can be a lethal condition due to the hypocortisolism, and has in turn 
been known to cause neonatal hypoglycaemia, convulsions, hypercalcaemia and/or 
cholestasis that can reach a 20% mortality rate in the latter if unrecognised (Alsaleem 
et al., 2016) (Bigos and Carnes, 1982). IAD patients have also presented with an 
empty sella and severe hyponatraemia. Usually patients with an empty sella remain 
asymptomatic, however in those who develop IAD, corticosteroid treatment should be 
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commenced to avoid fatal consequences (Doroftei et al., 2016). The TBX19 gene has 
a critical role in the terminal differentiation of the corticotroph and melanotroph cell 
types, the pituitary POMC lineages. Mutations in TBX19 have been associated with 
IAD, and been found in up to 2/3 of neonatal cases, with complete or severe loss of 
function in DNA binding and/or transactivation (Lamolet et al., 2001). These TBX19 
mutations are most often substitutions in the DNA binding Tbox domain, thus 
producing impaired DNA binding or protein-protein interaction. However premature 
stop codons, aberrant splicing and chromosomal deletions have also occurred in this 
gene (Couture et al., 2012). Mutations in the POMC gene have also been reported in 
IAD, in which patients usually have the distinct phenotypic hallmarks of early-onset 
obesity and red hair pigmentation, in addition to adrenal insufficiency (Krude et al., 
1998). In contrast to IAD, excess amounts of ACTH may be secreted from a benign 
pituitary tumour namely an adenoma within the corticotroph cells, termed Cushing's 
disease. This disease may cause a wide variety of non-specific symptoms such as 
abnormal weight gain, polycystic ovary syndrome, deep vein thrombosis, localized 
adiposity amongst many others, thus often making the diagnosis delayed and highly 
challenging  (Broder et al., 2016). 
 
1.2.3. Combined pituitary hormone deficiency 
Combined pituitary hormone deficiency (CPHD) is the presence of at least two or 
more pituitary hormone deficiencies including GH, TSH, PRL, ACTH and 
gonadotrophin deficiencies. Depending on which deficiencies are present in the 
patient, the phenotypic features may include hypothyroidism, delayed or absent 
puberty which may lead to infertility, intellectual disability, midline defects such as 
cleft lip or palate, short stiff neck (specifically caused by LHX3 mutations), and 
underdeveloped optic nerves. Mutations in transcription factors PROP1, POU1F1, 
LHX3, and LHX4 underlie CPHD, and as they act at different stages of pituitary 
development, they often result in unique patterns of hormonal deficiencies that reflect 
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their differential expression during organogenesis (Pfaffle and Klammt, 2011). For 
example, the early acting transcription factors LHX3 and -4, as opposed to the later 
acting PROP1 and POU1F1, cause deficiencies of most, if not all, pituitary hormones, 
often referred to as panhypopituitarism or multiple pituitary hormone deficiency 
(MPHD). All four genes, when mutated, are known to affect somatotroph cell 
development and therefore can all give rise to severe forms of short stature, thus 
reasoning that GHD is the most prevalent deficiency to occur. Additionally, mutations 
in HESX1, SOX3 and OTX2 may occasionally give rise to CPHD with different 
combinations of endocrine deficits (Thomas et al., 2001, Woods et al., 2005, Diaczok 
et al., 2008). Mutations in the Kallmann syndrome (KS) genes, discussed in section 
1.2.6, have also been described in such cases, once again demonstrating the genetic 
overlap that diseases related to hypopituitarism can have. For example, a CPHD 
patient with right microphthalmia, right renal aplasia and severe developmental delay 
had a hemizygous variant in KAL1 that was predicted to cause functional damage by 
in silico analysis (Takagi et al., 2014). The known PROKR2 p.R85H mutation 
previously identified in KS, was also found in a patient diagnosed with CPHD. This 
patient manifested GH, TSH, ACTH, LH and FSH deficiencies with a microphallus, 
with the latter suggesting neonatal GnRH deficiency (Raivio et al., 2012) and thus 
features that overlap with HH and KS in this case. In addition a recent report described 
a novel PROKR2 variant, p.R248W, predicted to be deleterious, in a patient with 
CPHD. This substituted residue at this highly conserved region had previously been 
mutated to glutamine in a patient with HH (Asakura 2015). Mutations in FGFR1, 
another Kallmann gene, have also been implicated in this disorder, for example a 
novel loss of function mutation, p.R448W, was recently identified in a patient with GH 
and TSH deficiency (Correa et al., 2015). Despite these reports implying a genetic 
overlap in CPHD and HH/KS cases, digenic inheritance cannot be ruled out here. 
There may be an unidentified additional mutation in another gene other than the 
mutation in the Kallmann gene described in these patients that is involved in the 
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etiology of one of the deficiencies in their CPHD. Despite the genes reported in the 
aetiology of this heterogeneous disease, the majority of CPHD cases remains 
unexplained, suggesting the involvement of other genes yet to be identified.  
 
1.2.4. Holoprosencephaly  
HPE is a complex heterogeneous brain malformation resulting from incomplete 
cleavage of the prosencephalon, the two hemispheres of the brain, affecting both the 
forebrain and the face (Dubourg et al., 2004). The 3 classic types of HPE include 
alobar (virtually no forebrain division) with the most severe cases resulting in cyclopia, 
semilobar (some degree of hemispheric cleavage), and lobar HPE (more complete 
separation) (Figure 1.4). Mildly affected patients may have a normal central nervous 
system (CNS) but often have microform features of HPE, with microcephaly, 
hypotelorism, a single central maxillary incisor, and cleft lip and/or palate being 
among the most common (Solomon et al., 2010). Several recurrent chromosomal 
anomalies, termed cytogenetic abnormalities, are estimated to be present in ~25-50% 
of HPE patients (Bendavid et al., 2010). These have implicated a spectrum of 
candidate genes in the aetiology of HPE, many of which are components of the Sonic 
Hedgehog (SHH) signalling pathway. SHH signalling is required during multiple 
stages of rostroventral midline development, and many heterozygous mutations in its 
pathway have been identified in HPE patients (Hong and Krauss, 2013). Previous 
studies have shown that mutations in the SHH gene affect distinct steps of SHH 
biogenesis to attenuate its activity to variable levels. Thus contributing to the 
phenotypic variation seen in HPE patients (Singh et al., 2009). Haploinsufficiency of 
the SHH gene represents the most frequent genetic cause identified in these patients, 
with most being loss-of-function mutations (Lami et al., 2013). The GLI family zinc 
finger 2 (GLI2) transcription factor is a component of the SHH signalling pathway and 
is a known causative gene that when mutated is widely known to cause 
holoprosencephaly (Roessler et al., 2003). Unlike mutated SHH which fundamentally 
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causes HPE in the hypothalamo-pituitary spectrum, mutated GLI2 is also associated 
with CH without the presence of midline brain defects (Gregory et al., 2015a, Arnhold 
et al., 2015). Mutated ZIC2, SIX3 and TGIF1 genes are other SHH pathway 
components implicated in HPE on rare occasions (Gripp et al., 2000, Wallis et al., 
1999, Brown et al., 1998). These have in turn led to the identification of a larger array 
of causative genes that include PTCH1, DISP1, TDGF1, GAS1, EYA4, and FOXH1 
(Bendavid et al., 2010). Mutations in the FGF8 gene, important for GnRH neuronal 
development, are usually associated with Kallmann syndrome (KS). However, a 
homozygous FGF8 mutation has been implicated in a consanguineous family with 
semilobar HPE, diabetes insipidus, and TSH and ACTH insufficiency (McCabe et al., 
2011b), making this Kallmann gene a new candidate for HPE. Digenic inheritance 
has recently been described in cases of HPE, where two mutations in different genes 
have given rise to the phenotype (Mouden et al., 2016). Furthermore, sub-
microscopic deletions at a number of loci believed to be implicated in HPE have been 
identified in a number of patients (Rosenfeld et al., 2010), suggesting that there are 
many more mutations that need to be defined and characterized for this disease. 
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Figure 1.4: MRI scans of holoprosencephaly patients. Taken and adapted from 
Plawner et al. (Plawner et al., 2002). (A, B and C) MRI of a patient with alobar 
holoprosencephaly (HPE). (A) A transverse image with incomplete separation of the 
two hemispheres, striatum, and thalami, and a large dorsal cyst (dc). (B) Coronal 
image showing continuity of grey matter over the two hemispheres without an 
interhemispheric fissure. The ventricular system is composed of a single midline 
ventricle, monoventricle (mv). (C) Sagittal image with absence of the corpus callosum 
and a monoventricle that communicates freely with the dorsal cyst. (D, E and F) MRI 
of two patients with semilobar HPE. (D-E) Transverse and coronal images 
respectively, from the same patient. Posterior portions of the hemispheres are well 
separated, however the anterior cerebral hemispheres are not cleaved and there is 
presence of a dorsal cyst (dc). Posterior horns of the lateral ventricles are well formed 
but frontal horns are poorly developed. (E) Posteriorly there is a monoventricle 
demonstrated on a coronal image. (F) Sagittal image showing that the posterior 
portion of the corpus callosum is formed (arrowhead), however the anterior portion is 
not developed; highly characteristic of semilobar or lobar HPE. (G, H and I) MRI of a 
patient with lobar HPE. (G) Transverse image of the cerebral hemispheres showing 
fair separation both anteriorly and posteriorly. There is some development of the 
frontal horns (arrowheads). (H) Coronal image showing failure of complete cleavage 
of the frontal lobe. (I) Sagittal image showing that the posterior portion of the corpus 
callosum (arrowhead) is formed, however the anterior portion is not developed. (J-K) 
MRI scans from a normal control individual for comparison to all other images A - I. 
(J) A sagittal image showing a normal fully formed corpus callosum (arrowhead). (K) 
A coronal image showing normal separation of the two hemispheres of the brain.   
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1.2.5. Septo-optic dysplasia 
SOD, also known as de Morsier Syndrome, occurs in 1/10,000 live births with equal 
prevalence in males and females. It is a heterogeneous disorder with a variable 
phenotype, loosely defined by any combination of the triad of optic nerve hypoplasia 
(ONH), midline neuroradiological abnormalities (such as agenesis of the corpus 
callosum and absence of the septum pellucidum), and pituitary hypoplasia with 
consequent endocrine deficits (De Morsier, 1956, Brodsky and Glasier, 1993). 
Although an absent septum pellucidum is usually associated with endocrine deficits, 
around 40% of SOD patients may actually present with normal endocrinology. 
Intriguingly SOD is associated with a younger maternal age compared with isolated 
defects of the hypothalamo-pituitary axis (McNay et al., 2007). The reason for this 
SOD maternal age bracket has remained unknown, but has been suggested to be 
associated with increased maternal drug and alcohol abuse. (Webb and Dattani, 
2010, Lippe et al., 1979). Approximately 75–80% of patients exhibit ONH, which may 
be unilateral or more commonly bilateral (88% as compared with 12% unilateral 
cases), and may be the first presenting feature with later onset of endocrine 
dysfunction (Kelberman and Dattani, 2007a). In rare cases, the eye abnormality may 
be more severe, resulting in microphthalmia or anophthalmia (Kelberman and 
Dattani, 2008); where one or both of the eyes are abnormally small or completely 
absent respectively. The association of midline abnormalities with hypopituitarism has 
long been established, suggesting a common developmental origin (Mehta et al., 
2009). Mutated HESX1, a transcriptional repressor, is known to play a role in the 
pathogenesis of rare cases of SOD (McCabe et al., 2011a, Dattani et al., 1998). 
Significant insights into the pathogenesis of the disorder were provided by the original 
studies, whereby murine transgenesis resulted in murine phenotypes highly 
reminiscent of SOD. Thereafter, human mutations have been cloned into mouse 
models and studied in depth; such as the first HESX1 mutation p.R160C ever 
identified (Sajedi et al., 2008b). The SOX2, SOX3 and OTX2 genes have been shown 
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to be mutated in rarer forms of SOD, often involving bilateral eye defects including 
microphthalmia or anophthalmia in patients harbouring SOX2 and OTX2 mutations, 
and often abnormalities in the infundibulum and the corpus callosum in patients with 
SOX3 mutations (Woods et al., 2005). Mutations in the Kallmann genes have also 
been linked with SOD, such as two heterozygous KAL1 mutations that were identified 
in three females from two unrelated families with SOD, through work undertaken by 
my colleagues and I (McCabe et al., 2015). Prior to this, three SOD patients were 
reported to have heterozygous mutations in FGFR1 that altered receptor signalling, 
with one predicted to affect splicing (Raivio et al., 2012). The same report also 
identified the heterozygous loss of function mutation, p.R268C, in the PROKR2 gene 
in a Caucasian and African SOD proband respectively, that had previously been 
implicated in normosmic HH and KS. In addition they identified a PROKR2 variant in 
a third proband that was predicted to be a loss of function mutation (Raivio et al., 
2012). Thus broadening the spectrum of candidates to span the Kallmann genes 
associated with this rare disorder. Aside from mutations in the Kallmann genes, two 
TCF7L1 missense variants were identified in two unrelated SOD patients in a very 
recent report (Gaston-Massuet et al., 2016). SOD can be associated with a wide 
range of phenotypic variability, highlighting the complexity of the disorder and 
suggesting the impact of both genetic and environmental factors involved in the 
aetiology of the disease (Polizzi et al., 2006). Other associated features include 
developmental delay, seizures, visual impairment, sleep disturbance, precocious 
puberty, obesity, anosmia, sensorineural hearing loss and cardiac anomalies (Webb 
and Dattani, 2010).  
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1.2.6. Hypogonadotropic hypogonadism 
Congenital HH and KS are rare disorders with an occurrence rate of 1-10 in 100,000 
births (Fraietta et al., 2013). The major underlying cause is a failure to activate 
pulsatile secretion of GnRH, causing deficiencies in gonadotrophins (LH and FSH), 
and thus sex hormones; namely oestrogen in girls and testosterone in boys. This in 
turn causes a delay in the onset or a complete/partial failure of puberty in patients 
(Layman, 2007). HH is difficult to differentiate from a diagnosis of constitutional delay 
in puberty, making it challenging for clinicians to make a diagnosis. GnRH testing can 
be useful, and may be used in combination with human chorionic gonadotrophin 
(hCG) testing to discriminate between the two and to make a reliable diagnosis 
(McCabe et al., 2014, Segal et al., 2009). It is associated with genital abnormalities 
such as micropenis (Bin-Abbas et al., 1999), and/or systemic abnormalities such as 
cleft lip/palate, renal agenesis, synkinesis (Conrad et al., 1978) and hearing defects 
(Bianco and Kaiser, 2009). Additionally, anosmia; a total or partial loss of olfaction 
(sense of smell), often accompanies HH and occurs in approximately 60% of HH 
patients. It results from incomplete embryonic migration of GnRH-synthesizing 
neurons, and when present in patients is termed KS (Cariboni and Maggi, 2006). 
Isolated HH (IHH) and KS are both clinically and genetically heterogeneous, with over 
25 known causative genes implicated to date (Boehm et al., 2015). All such genes 
encode proteins that have a role in regulating GnRH neuronal development, their 
migration from the nasal placode to the hypothalamus, and GnRH secretion and/or 
action. The genes that have been found to be most frequently mutated in IHH/KS 
patients are: KAL1 in approximately 5% of cases, PROKR2 or PROK2 in ~9%, 
FGFR1 in ~10% and FGF8 in ~2%, which are known as the Kallmann genes. GnRHR 
is the most commonly mutated gene in IHH; in approximately ~11% of cases 
(Topaloglu and Kotan, 2016). However these only account for <37% of cases 
cumulatively. Many other mutated genes have been reported in a few cases 
respectively, with an increasing number of novel candidate genes constantly being 
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identified (known causative genes associated with HH are listed in Table). For 
example, a recent next generation sequencing study has implicated an additional 19 
new candidate genes in IHH/KS patients (Quaynor et al., 2016) not listed in Table 
1.1. This heterogeneity indicates that IHH/KS can arise from a multitude of different 
genetic sources to give rise to a variable phenotype. This signifies great difficulty in 
identifying a genotype in these patients and makes genetic screening a timely and 
costly ordeal. Exome sequencing would be beneficial in such cases to uncover 
mutations that are bespoke to each particular patient, enabling future personalised 
treatments that can be suited to the individual’s need. Furthermore, the optimal timing 
of treatment in these individuals is critical to their sexual development and 
progression through puberty, as well as for their bone and metabolic health, which 
can otherwise result in debilitating consequences both physically and psychologically 
for the patient. 
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Hypogonadotropic hypogonadism known causative genes 
Mechanism affected Mutated 
Disorders of the embryonic migration of 
GnRH neurons (KS) 
KAL1, FGFR1, PROK2, PROKR2, FGF8, 
HS6ST1, CHD7, WDR11, SEMA3A, FGF17, 
IL17RD, DUSP6, SPRY4, FLRT3, NELF, 
FEZF1 
Disorders of the GnRH pulse generator TAC3 (IHH), TACR3 (IHH), KISS1 (IHH), 
KISS1R (IHH), GNRH1 (IHH) 
Disorders of the pituitary gonadotrophs GNRHR (IHH), FSHB, LHB 
Developmental disorders of the 
hypothalamo-pituitary region 
DAX1, HESX-1, LHX3, PROP-1, SOX2, 
OTX2 
Disorders of IHH associated with obesity LEP, LEPR, PC1 
Disorders of IHH associated with 
neurodegenerative syndromes 
POLR3A, POLR3B, PNPLA6, RNF216, 
OTUD4, STUB1, RAB3GAP1, RAB3GAP2, 
RAB18, TBC1D20 
 
Table 1.1: Genetic causes of isolated hypogonadotropic hypogonadism (IHH) 
and Kallmann syndrome (KS). Adapted from Topaloglu et al. (Topaloglu and Kotan, 
2016). The six genes highlighted in red are the most common genes to be mutated 
in patients in the known IHH/KS population. All other genes listed have occurred less 
frequently in reported cases. The four genes that have been found to be mutated in 
IHH only and not KS patients are denoted with ‘(IHH)’.   
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1.3. Genes implicated in human hypothalamo-pituitary disorders 
 
1.3.1. Genetic analysis and known causative genes 
The majority of CH cases are sporadic, although familial cases have been described. 
The latter have led to the identification of mutations in key developmental genes that 
are involved in normal pituitary development; including HESX1, SOX2, SOX3, OTX2, 
ARNT2, LHX3, LHX4, POU1F1 and PROP1 (Alatzoglou and Dattani, 2009). These 
genes are commonly screened for mutations, and many are functionally deleterious 
in the form of missense point mutations, frameshifts, insertions and deletions that 
have been identified and shown to most likely account for hypothalamo-pituitary 
phenotypes (Reynaud et al., 2012). Variable penetrance is often apparent where a 
patient has a heterozygous mutation with functional consequences that is also 
present in the unaffected parent (Ming and Muenke, 2002). Additionally, digenic 
inheritance may account for the variable penetrance in some cases, as is well 
established in KS (Falardeau et al., 2008), where more than one mutation in the 
Kallmann genes has been known to be inherited from either parent causing the 
phenotype (Dode et al., 2006). The apparent overlap in KS, CPHD and SOD 
genotypes opens up a new source of potential genetic associations (Bancalari et al., 
2012, Raivio et al., 2012).  
 
A vast array of genes, which is constantly increasing, encoding transcription factors 
and signalling molecules, have been reported to be mutated and give rise to the 
different hypothalamo-pituitary disorders that have been discussed. The known 
causative genes are among the most prevalent to be mutated, and thus the ones 
routinely screened in our laboratory. These genes are discussed in the following 
section.  
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1.3.2. HESX1 
The transcription factor HESX1 is a member of the paired-like class of homeodomain 
proteins which acts as a transcriptional repressor essential for pituitary 
organogenesis (Dattani et al., 1998). Binding partners of human HESX1 such as 
transducing-like enhancer of split 1 (TLE1) (ortholog of Groucho in Drosophila), the 
nuclear corepressor (N-COR) and DNA methyltransferase 1 (DNMT1), can all form 
complexes to enable it to exert this repressive activity (Dasen et al., 2001, Sajedi et 
al., 2008a). Hesx1 is one of the earliest markers of murine pituitary development, 
expressed initially during gastrulation in the region fated to form the forebrain and 
ventral diencephalon, and is then restricted to Rathke’s pouch by embryonic day (E) 
9.0 (Thomas and Beddington, 1996). Hesx1 continues to be expressed in the 
developing AP until E12, when it then disappears in a spatio-temporal sequence that 
corresponds to progressive pituitary cell differentiation (Kelberman and Dattani, 
2009). Hesx1 transcripts have totally disappeared from the entire ventral portion by 
E13, giving rise to the anterior lobe of the pituitary (Hermesz et al., 1996). A 
homozygous null mutation in mice results in a phenotype that resembles SOD, with 
5% of Hesx1 null mice exhibiting a severe phenotype with no AP (Dasen et al., 2001). 
This is consistent with an insertion mutation in exon 3 in the ‘Alu’ element; a sequence 
that encodes the major part of the homeodomain of HESX1, which was identified in 
a retinal coloboma patient with aplasia of the AP. Thus patients have subsequent 
undetectable concentrations of all AP hormones (Sobrier et al., 2005). Patients with 
HESX1 mutations have phenotypes ranging from evolving hypopituitarism in the 
absence of midline and eye defects, through to SOD and pituitary aplasia (Kelberman 
and Dattani, 2007b). Hesx1 null mice show great variability with features that include 
a reduction in forebrain tissue, craniofacial dysplasia with a short nose and absence 
of developing optic vesicles. These mice also have significantly decreased head size, 
absence of telencephalic vesicle or infundibulum development, absence of olfactory 
placodes, hypothalamic abnormalities and irregular morphogenesis of Rathke’s 
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pouch (Dattani et al., 1998). Rathke’s pouch formation was variably affected, and 
abnormal bifurcations were apparent resulting in multiple pituitary glands, due to 
multiple invaginations in the oral ectoderm in a proportion of the mice (Newbern et 
al., 2013, McCabe et al., 2011a, Dattani et al., 1998). Although of variable severity, 
both neonatal and adult homozygous mutant mice manifested phenotypes that 
presented with eye defects such as microphthalmia and anophthalmia, with 
abnormalities of the septum pellucidum and corpus callosum, closely resembling 
SOD in humans (section 2.5). 
 
1.3.3. SOX2 and SOX3 
SOX2 and SOX3 are members of the SOXB1 subfamily of ‘SRY-related HMG box’ 
transcription factors. They have an N-terminal domain of unknown function, a DNA-
binding High Mobility Group (HMG) box domain and a longer C-terminal domain 
involved in transcriptional activation (Stevanovic et al., 1993). Members of the SOXB1 
subfamily are expressed throughout the CNS and are among the earliest neural 
markers that play a role in neuronal determination (Hutton et al., 2009). Murine Sox3 
is shown to be involved in neurogenesis through its expression in actively dividing 
undifferentiated neural progenitor cells, and is maintained throughout development 
(Bylund et al., 2003). Expression of Sox3 is also seen in the ventral diencephalon, 
infundibulum and presumptive hypothalamus, a similar expression pattern to that of 
Wnt5a expression (Solomon et al., 2004). Due to the importance of inductive signals 
from these areas in the normal formation of the AP, hypopituitarism with consequent 
endocrine dysfunction may be associated with Sox3 mutations. Sox3, as well as Tcf4 
and Wnt5a, deficient mice exhibit expanded BMP and FGF signalling domains as well 
as abnormalities in Rathke's pouch (Rizzoti et al., 2004), suggesting a possible 
mechanism underlying the hypopituitary phenotype in these mutants (Potok et al., 
2008). The mutant mice exhibited variable complex phenotypes including craniofacial 
abnormalities, midline CNS defects and a reduction in size and fertility (Rizzoti et al., 
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2004). Duplications as well as loss-of-function mutation expansions of the polyalanine 
tract in SOX3 have been described in a number of patients with hypopituitarism 
(Woods et al., 2005). Mutations such as these are usually associated with infundibular 
hypoplasia and an ectopic or undescended PP, and have been shown to result in 
aggresome formation (a mass of misfolded proteins in the cell) and impaired 
transactivation (Wong et al., 2007). Submicroscopic duplications on chromosome 
Xq27.1, which include SOX3, are associated with variable hypopituitary phenotypes 
including CPHD, absence or hypoplasia of the infundibulum, and an abnormality of 
the corpus callosum (Woods et al., 2005). Additionally, a 2.31-Mb deletion on Xq27 
incorporating SOX3, was identified in a patient with CH and the unusual phenotype 
of a persistent craniopharyngeal canal (Alatzoglou et al., 2014a). Furthermore, an 
18bp deletion in the polyalanine tract of SOX3 was identified in a CH patient, resulting 
in an increase in transcriptional activation (Alatzoglou et al., 2011b). These data 
highlight the critical gene dosage of SOX3 in normal development of the diencephalon 
and infundibulum, and consequently the AP. 
 
SOX2 is expressed in neural progenitor populations throughout the developing and 
adult CNS, and is necessary to maintain their progenitor identity (Hutton and Pevny, 
2011). After gastrulation, murine Sox2 expression is restricted to the presumptive 
anterior neuroectoderm and by E9.5 is expressed throughout the CNS, brain, sensory 
placodes, branchial arches, gut endoderm, oesophagus and trachea. Homozygous 
null Sox2 mice fail to survive and die shortly after implantation (Avilion et al., 2003), 
whereas heterozygous mice have hypoplasia and abnormal morphology of the AP, 
with subsequent reduction in GH, LH, ACTH and TSH concentrations (Kelberman et 
al., 2006). Other studies have shown that retinal progenitor cells with conditionally 
ablated Sox2 lose competence to both proliferate and terminally differentiate. 
Additionally, Sox2 hypomorphic/null mice, with a 40% reduction of Sox2 expression 
compared to wild-type (WT) mice, present with variable microphthalmia as a result of 
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aberrant neural progenitor differentiation. Furthermore, this study suggests that 
Sox2/SOX2 activity functions in a dose-dependent manner in retinal progenitor cell 
differentiation (Taranova et al., 2006). The first description of SOX2 mutations in 
humans was in a cohort of individuals with severe eye phenotypes. De novo 
mutations were associated with bilateral anophthalmia, or severe microphthalmia, 
with accompanying developmental delay, learning difficulties, oesophageal atresia 
and genital abnormalities (Williamson et al., 2006). Conclusively, the majority of 
males with SOX2 mutations had abnormalities in genital development. SOX2 
expression in humans is observed throughout the human brain, including the 
developing hypothalamus, as well as Rathke’s pouch, and the eye (Kelberman et al., 
2008). Following on from these studies, SOX2 mutations have also been associated 
with AP hypoplasia and HH (Kelberman et al., 2006), and are usually loss of function 
mutations. These result in a loss of DNA binding, nuclear localisation or transcriptional 
activation, suggesting that the phenotypes arise as a result of haploinsufficiency of 
SOX2 in development. In the murine pituitary, conditionally deleted Sox2 mutant mice 
have abnormal gonadotrophin secretion as well as TSH and GH deficiencies. This 
suggests a likely role for Sox2 in the hypothalamus and/or the developing pituitary, 
particularly with respect to GnRH neurons (Jayakody et al., 2012), which reflects the 
SOX2 mutations described in HH patients. In addition, loss of function SOX2 
haploinsufficiency mutations have been implicated in the generation of slow 
progressing pituitary tumours of early onset in patients (Alatzoglou et al., 2011a). 
Furthermore, a very recent study (Goldsmith et al., 2016) has implicated a role for 
SOX2 in melanotroph cell fate acquisition, independent of its early role in promoting 
progenitor proliferation. This study showed that SOX2 is maintained at low levels in 
melanotrophs (Goldsmith et al., 2016) where its expression is likely regulated by P27 
(Li et al., 2012). 
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1.3.4. OTX2 
OTX2 (Orthodentic homeobox 2) is a transcription factor that is required for the 
formation of anterior structures and maintenance of the forebrain, and has been 
implicated in 2–3% of anophthalmia/microphthalmia related syndromes in humans 
(McCabe et al., 2011a). In mice, the expression of Otx2 is localised to developing 
neural and sensory structures of the brain such as the cerebellum, the eye, nose and 
ear, and is required at multiple steps in brain development and neuronal differentiation 
(Frantz et al., 1994). Mice homozygous for mutations die from severe brain 
abnormalities after exhibiting malformations in both the forebrain and the eye due to 
impaired gastrulation. Heterozygous mice can display a range of phenotypes from 
normal to severe forms of eye/brain abnormalities such as anophthalmia and 
holoprosencephaly (Ang et al., 1996). During retinal development, Otx2 regulates 
retinal pigment epithelium specification, and photoreceptor and bipolar cell 
differentiation and maturation, with expression being maintained in these three cell 
types throughout life (Housset et al., 2013). Otx2 transcripts and protein are normally 
detectable at E10.5 in both the ventral diencephalon and Rathke’s pouch. By E12.5 
Otx2 transcripts are undetectable in Rathke’s pouch, but persist in the ventral 
diencephalon until E14.5, and by E16.5 no Otx2 transcripts are detected in either 
structure (Mortensen et al., 2011). A previous study showed that Otx2 expression in 
Rathke’s pouch in Prop1-mutant mice continued until E16.5; four days after Prop1 
peak expression, and two days after any pituitary defects become apparent 
(Mortensen et al., 2011). This study suggests that Prop1 regulates expression of other 
factors that suppress Otx2; implying a role for Otx2 in murine pituitary development. 
Another study reported an HH phenotype in GnRH-neuron-Otx2 knockout mice 
(Diaczok et al., 2011). These murine data are consistent with OTX2 human mutations, 
where phenotypes exhibit highly variable pituitary defects ranging from IGHD, 
panhypopituitarism through to HH. All of which commonly include the accompanying 
severe ocular malformations discussed (Gorbenko Del Blanco et al., 2012). Despite 
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this knowledge, the role of OTX2 in hypothalmo-pituitary development still remains 
largely unclear (Bancalari et al., 2012).  
 
1.3.5. ARNT2 
ARNT2 (aryl-hydrocarbon receptor nuclear translocator 2) is a member of the basic-
helix-loop-helix-Per-Arnt-Sim (bHLH-PAS) superfamily of transcription factors. This 
protein forms heterodimers with sensor proteins from the same family that then bind 
regulatory DNA sequences. Arnt2(-/-) embryos die perinatally and exhibit impaired 
hypothalamic development (Keith et al., 2001). Recent studies showed expression 
of ARNT2 within the CNS, including the hypothalamus, as well as the renal tract 
during human embryonic development. A homozygous frameshift ARNT2 mutation 
has been associated with congenital hypopituitarism, progressive neurological 
abnormalities, renal tract abnormalities and post-retinal visual pathway dysfunction in 
certain individuals. This is an example of how ARNT2 is essential in hypothalamo-
pituitary development, post-natal brain growth, and visual and renal function in 
humans (Webb et al., 2013). 
 
1.3.6. LHX3 and LHX4 
LHX3 and LHX4 are members of the ‘LIM homeobox’ protein family, containing the 
characteristic two LIM domains; unique cysteine-rich zinc-binding domains known to 
play a role in transactivation and protein-protein interaction (Pfaeffle et al., 2008, 
Tajima et al., 2010, Takagi et al., 2012). These proteins are multifunctional as they 
act as scaffolds and adaptors to mediate interactions that modulate target gene 
transactivation. LHX3/LHX4 are transcription factors that possess overlapping but 
distinct functions during the establishment of the specialized cells of the mammalian 
pituitary gland and the nervous system (Colvin et al., 2009). In mice, Lhx3 and Lhx4 
are expressed at embryonic day 9.5 (E9.5) in Rathke’s pouch. By E12.5, Lhx4 is 
concentrated in the tissue that will become the anterior lobe of the pituitary gland 
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whereas Lhx3 expression continues throughout the pouch. Later transcription from 
the Lhx4 gene is reduced and transcripts are found at lower levels than Lhx3 in the 
mature gland (Sheng et al., 1997). Both Lhx3/4 work in conjunction to form a definitive 
Rathke’s pouch and regulate proliferation and differentiation of pituitary lineages; 
pituitary development halts at the rudimentary pouch stage in mice lacking both of 
these genes. In humans and rodents, LHX4/Lhx4 expression is in the developing 
hindbrain, cerebral cortex, pituitary gland and spinal cord (Liu et al., 2002). Lhx3 null 
mutant pituitary precursor cells cease to proliferate before differentiation, whereas in 
Lhx4 null mutants, these cells differentiate albeit in reduced numbers. A lack of 
cellular proliferation in Lhx4 mutants causes failure to respond to inductive signals 
and subsequent misregulation of other transcription factor genes e.g. Lhx3, which 
inevitably leads to increased cell death. Following on from this, mouse studies have 
shown that Lhx4 is required for the correct temporal expression of regulatory genes 
such as Lhx3 (Pfaeffle et al., 2008). Therefore patients with LHX4 mutations may 
have a partial loss of LHX3 function. Mutations in LHX3 may give rise to CPHD, and 
in specific cases loss of neck rotation resulting in a short stiff neck, considered to 
result from nervous system abnormalities (Netchine 2000). Mice homozygous for 
Lhx4 mutations die shortly after birth with immature lungs that fail to inflate, whereas 
heterozygous mice appear normal (Li et al., 1994). Additionally, Lhx4 null mice exhibit 
incomplete pituitary gland development. Heterozygous LHX4 mutations in humans 
are usually associated with variable and variably penetrant CPHD (Pfaeffle et al., 
2008), and are usually due to haploinsufficiency rather than having a dominant-
negative effect. 
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1.3.7. POU1F1 and PROP1 
POU Class 1 Homeobox 1 (POU1F1), formally known as PIT1, is a pituitary-specific 
transcription factor characterised by the presence of a highly conserved bi-partite 
DNA binding domain, comprising the POU-specific domain (POU-S) and the POU 
homeodomain (POU-H) (Herr and Cleary, 1995). POU1F1 is expressed during 
differentiation steps that take place at later stages in the development of the AP gland, 
and its expression is restricted to the somatotroph, thyrotroph and lactotroph cell 
lineages. This is consistent with functional studies of this protein which show that 
expression of the GH, PRL, TSH-β subunit and GHRHR genes is regulated by 
POU1F1 (Dattani, 2004). Furthermore, studies have also shown that Pou1f1/POU1F1 
binds to its own proximal promoter and upregulates its own expression (Delhase et 
al., 1996). Homozygous loss-of-function mutations in a lesion in the Pou1f1 gene 
have been reported to give rise to the Snell dwarf mouse model phenotype (Camper 
et al., 1990), which results in the absence of the three cell types in which Pou1f1 is 
expressed, as mentioned above. Mutations in POU1F1, that are usually homozygous 
recessive, have been implicated in CPHD, with the spectrum of hormone deficiency 
varying considerably in patients. Patients usually manifest with GH and PRL 
deficiencies initially, often with the development of secondary hypothyroidism (Pfaffle 
et al., 1992), although some maintain a normal TSH concentration (Turton et al., 
2005). In addition, a recent study has described an autosomal dominant heterozygous 
missense POU1F1 mutation in a large family with IGHD (Sobrier et al., 2016). Thus 
presenting a novel aetiology for IGHD and demonstrating further variability in patients 
with POU1F1 mutations. The first POU1F1 mutation; a homozygous nonsense 
mutation, resulted in a severely truncated protein of 171 amino acids, lacking half of 
the POU-S and all of the POU-H domain (Tatsumi et al., 1992). This first novel 
mutation was identified in a patient with GH, PRL and TSH deficiencies, due to the 
mutant POU1F1 protein being completely incapable of binding to the GH and prolactin 
promoters and resulting in loss of transcription. The Prophet of Pit-1 (PROP1) 
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pituitary-specific paired-like homeodomain transcription factor is important for the 
production and secretion of GH, PRL, TSH and gonadotrophins, and is believed to be 
required for the expression of POU1F1. This was first characterized in the Ames dwarf 
mouse model, which harbours a homozygous missense Prop1 mutation (p.S83P) 
causing a lack of Pou1f1 gene activation and absence of progression to mature cells 
(Andersen et al., 1995, Dattani, 2004). It is known that mutant PROP1 causes failure 
of cells to differentiate, due to retained progenitor cells in the periluminal area (Ward 
et al., 2005). In addition, recent studies have shown that PROP1 stimulates stem cells 
to undergo an epithelial to mesenchymal transition-like process, which is essential for 
cell migration and differentiation (Perez Millan et al., 2016). Thus suggesting that 
PROP1 is a central transcriptional component of pituitary stem cell differentiation. 
Mutations in Prop1/PROP1 can elicit a CPHD phenotype commencing initially with 
GH, PRL and TSH deficiencies, often with evolution of secondary hypogonadism, 
although this may also be present at birth (Pfaffle et al., 1999). Other phenotypic 
features include evolving ACTH deficiency (Bottner et al., 2004), as well as an 
enlarged anterior pituitary suggestive of a tumour (Mendonca et al., 1999), that can 
regress with time and lead to complete pituitary involution and an empty sella 
syndrome. POU1F1 and PROP1 are the best characterized intrinsic signalling 
molecules in terms of function in both humans and mice (Dattani, 2004).  
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1.4. Investigating the genotype of patients  
 
1.4.1 Genetic analysis 
CH patients are routinely screened for mutations in respective known causative genes 
in the laboratory via a polymerase chain reaction (PCR) and direct sequencing 
analysis approach, also known as Sanger sequencing. Instead of screening one gene 
at a time in this way, which can be a time consuming process, with low frequency hit 
rates due to a large number of genes with many exons, panel screening is often the 
preferred choice. Multi-gene panel tests use next-generation sequencing to screen 
several known causative genes simultaneously, which enables variants to be 
identified, or for mutations in all these known genes to be excluded, more rapidly and 
cost effectively than Sanger sequencing provokes (Slavin et al., 2015). Despite these 
known genes implicated in CH and related phenotypes, the potential genetic cause 
remains unknown in the majority of cases (80% according to our unpublished data). 
This signifies the need for further investigation into genes involved in pituitary 
development and that may be potentially responsible for the phenotypic manifestation 
of the disease. A range of different genetic strategies are now used in the search for 
novel candidate genes, and these include homozygosity mapping and exome 
sequencing. Homozygosity mapping uses single nucleotide polymorphisms (SNPs) 
to compare the DNA of affected individuals from a consanguineous pedigree, to find 
regions that are homozygous by descent, reflecting potential loci of interest (Bocquet 
et al., 2013). Identified areas of homozygosity can then be further sequenced using 
next generation sequencing, to identify novel genes of interest related to a particular 
disease. Exome sequencing can be used to sequence the entire coding region of the 
genome, identifying any variants in the affected patients. Following any variants 
identified, comparisons are made within the family and online control databases are 
consulted for their presence, such as 1000 Genomes, dbSNP, EVS and the ExAC 
Browser. Variants found in genes or regions that are known to be involved in pituitary 
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development, or genes that are expressed in specific areas of the midline brain 
structures that are affected in the individual, can then be identified and studied further. 
The flowchart below illustrates the filtering process of how patient genotypes were 
analysed in this study (Figure 1.5).
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Figure 1.5: A summary of the gene screening process. The flowchart illustrates 
how the patients in our cohort are screened for mutations in genes, and how unknown 
genes and regions of interest associated with hypothalmo-pituitary development are 
identified and characterised.  
 
1.4.2. Expression studies 
Upon the identification of a mutated novel gene of unknown function in an individual, 
expression will initially be analysed in relevant tissues in mice. If the expression 
pattern is already known, this information will be available on the mouse genome 
informatics (MGI) database (www.informatics.jax.org). The expression pattern can 
then be verified in human embryonic tissue, if available. We have access to human 
embryonic tissue that forms part of a unique resource at the ICH with the Institute of 
Genetic Medicine in Newcastle, organised by the MRC Wellcome Trust Human 
Developmental Biology Resource (HDBR). This resource provides valuable human 
embryonic tissue sections for in situ hybridisation analysis of new candidate genes. 
A detailed hypothalamo-pituitary expression profile for the gene is then established 
before any functional analysis is undertaken. It is important to perform this first to see 
whether the gene is expressed in the hypothalamo-pituitary axis, as well as in tissues 
that are affected in the patient phenotype, before designing an appropriate functional 
assay that can potentially allow for comparison between the WT and mutated gene. 
These would include, for example, luciferase reporter transactivation assays or DNA-
binding assays in the case of transcription factors. This particular procedure is 
executed through the generation of genetic constructs, involving the insertion of 
relevant variants into a specific plasmid via site-directed mutagenesis. Changes in 
the function induced by the mutated allele can then be assessed via a functional 
assay, such as a dual-luciferase reporter assay, which is just one of the many assays 
described in this thesis. However, one needs to bear in mind that if expression is 
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absent from a particular tissue it should not be completely excluded from further 
study, as the secreted protein in which the gene encodes may act on target tissues 
that do not express the relevant gene. Therefore the expression profile determined 
should act as a guide and not an absolute criterion for further study of a gene. 
 
1.4.3. Cohort of patients 
We have a large cohort of patient DNA (>2000) here at Great Ormond Street Hospital 
(GOSH) and the UCL ICH, consisting of both consanguineous and non-
consanguineous pedigrees from many different ethnic backgrounds around the world. 
These patients have a variety of different hypothalamo-pituitary phenotypes that 
range in severity. Essentially these patients have forms of congenital hypopituitarism, 
with phenotypes ranging from IGHD, CPHD/MPHD, HPE, SOD and HH/KS. 
Endocrine dysfunction includes different combinations of deficiencies; GH, TSH, 
ACTH, FSH, LH, PRL deficiencies, and sometimes arginine vasopressin deficiency 
(AVPD), with GHD occurring in the majority. Accompanying craniofacial midline 
defects and other associated abnormalities are present in many of the individuals, 
including cleft lip and/or palate, anophthalmia/microphthalmia, blindness, micropenis, 
microcephaly, hydrocephalus, obesity and developmental delay amongst many 
others. Usually, a number of known causative genes are initially screened for 
mutations in the CH patients in our cohort. If no mutations are identified we then, in 
selected familial cases, proceed to perform exome sequencing analysis to potentially 
uncover novel variants in new genes that are not previously implicated in the aetiology 
of congenital hypopituitarism. However, some pedigrees within our cohort have a very 
unique phenotype, including hypopituitarism in combination with an additional 
phenotype, e.g. hyperinsulinism, that has not been previously reported in the 
literature. Pedigrees such as these may be more efficiently analysed by exome 
sequencing in the first instance due to there being no clear known genes that are 
implicated in congenital hypopituitarism that could account for these new and unusual 
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phenotypes. Patients such as these are also often likely to have more than one, or 
multiple, mutations that are contributing to their unique phenotype, which exome 
sequencing analysis would be able to identify. 
 
1.5. Aims and objectives  
This thesis describes novel genetic variants leading to novel phenotypes in pedigrees 
within this large cohort, using both a Sanger sequencing approach (Chapter 3) and 
an exome sequencing approach (Chapters 4, 5) respectively. The first aim of this 
study is to investigate the functional significance of the homozygous LHX4 (p.T126M) 
variant identified by Sanger sequencing, in two deceased siblings that had CPHD. 
Protein modelling, western blot analysis and luciferase assays were used to 
investigate the p.T126M mutation, and its effect on the transactivation of αGSU 
(glycoprotein hormones alpha subunit) and prolactin reporters, as well as its ability to 
synergise with POU1F1, compared to WT LHX4. Additionally, novel variants in new 
candidate genes that have not been previously associated with CH, have been 
identified in a subset of phenotypically unique pedigrees submitted to GOSgene for 
exome sequencing. An expression profile in human embryonic tissue is established 
in this study for each of these potential novel candidate genes, in a hypothalamo-
pituitary context, as well as in tissues that are known to be affected in the respective 
patients. Patients from one of these pedigrees (Pedigree 8) with severe short stature 
and GHD, central hypothyroidism and hyperinsulinism causing hypoglycaemia, 
harboured a novel variant in the EIF2S3 gene, p.P432S. The role of this mutation in 
this potential novel candidate gene has been functionally analysed in this study in a 
hypothalamo-pituitary and pancreatic context. 
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2.1. Primer Design 
Primers for PCR were designed using the Ensembl Genome Browser 
(http://www.ensembl.org/index.html), the UCSC genome browser 
(https://genome.ucsc.edu/) and the Primer3 input (version 0.4.0) 
(http://bioinfo.ut.ee/primer3-0.4.0/) databases. Specifications were entered and 
altered from the default within Primer3 as follows: product size ranges: 150 - 1000, 
number of primers to return in output: 25, primer temperature (Tm): 55°C - 65°C, 
maximum Tm difference: 2°, GC%: minimum 30, optimum 45, maximum 60, 
maximum self-complementarity: 5, maximum poly X (number of same bases in a row): 
4.   
 
2.2. PCR and direct sequencing analysis 
DNA was extracted from blood samples taken from our patients and was screened 
for variants in known causative genes, namely HESX1, PROP1, POU1F1, LHX3, 
LHX4, SOX2, SOX3, OTX2, SHH, GLI2, KAL1, PROK2, PROKR2, FGFR1, FGF8, 
WDR11 and NELF, in accordance with the patient phenotype. The coding regions of 
these genes were amplified by PCR using the BIOTAQ™ DNA Polymerase kit 
(Bioline, BIO-21060) and exon flanking primers, on an Eppendorf Thermocycler; 
initially heating the reaction to 95°C for 2 minutes (mins) followed by 35 cycles of: 
95°C for 30 seconds (denaturation step), 55°C - 62°C for 30 seconds (annealing step) 
and 72°C for 45 seconds (extension step). PCR products were treated with 
MicroClean reagent (Web Scientific, 2MCL-10) in order to clean the product, spun on 
a centrifuge at 4000rpm, and subsequently upside down on tissue paper at 600rpm 
to remove liquid. The precipitate was sequenced with either the forward or reverse 
respective primer at any one given time, using the BigDye® Terminator v1.1 Cycle 
Sequencing Kit (Life Technologies Ltd., 4337450). The sequencing plate was put into 
an Eppendorf Thermocycler and heated to 95°C for 2 mins, followed by 39 cycles of 
95°C for 30 seconds, 55°C for 15 seconds and 60°C for 4 mins. The sequencing 
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products were washed by spinning with 100% ethanol containing 3 molar (M) sodium 
acetate for 40 mins, followed by 70% ethanol for 5 mins, and upside down on tissue 
paper to remove liquid for 1 min, on a centrifuge at 3050, 3000 and 300rpm 
respectively. The precipitate was then resuspended in 1M TE buffer before analysis 
on a 3730XL DNA Analyzer (Applied Biosystems/Hitachi, Japan, cat # 625-0020). 
Detailed PCR conditions for each exon in each gene are available upon request 
including primer sequences, amplicon sizes, annealing temperatures, which range 
from 55°C to 62°C, and whether dimethyl sulfoxide (DMSO) was added to the PCR 
reaction or not. For any variants identified, control databases were consulted; 1000 
Genomes (www.1000genomes.org), dbSNP NCBI National Institutes of Health 
(www.ncbi.nlm.nih.gov/SNP/), Exome Variant Server (EVS) 
(www.evs.gs.washington.edu/EVS/), and The Exome Aggregation Consortium 
(ExAC) Browser (www.exac.broadinstitute.org) which includes approximately 
100,000 reference alleles per gene alone.  
 
Aside from screening many patients for mutations in the known causative genes listed 
above, specific to this study, I have screened the following: 103 patients for variants 
in the EIF2S3 gene and 95 patients for RNPC3 variants (please refer to Chapters 4-
5 for more details on each cohort screening respectively). 
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2.3. Functional Studies for LHX4 variants 
 
2.3.1. Cell culture 
Human embryonic kidney (HEK293T) cells were maintained in a humidified CO2 
incubator at 37oC in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma, Cat: 
D5796) supplemented with 5% penicillin/streptomycin (penstrep) (Invitrogen) and 
10% fetal calf serum (PAA). Media was replaced every 2 days, cells were washed 
with x1 phosphate buffered saline (PBS) (VWR International) and passaged when 
80% confluent. The cells were tested for mycoplasma and cell identity before use. 
 
2.3.2. Preparation of constructs for qualitative analysis 
Variants were introduced by site-directed mutagenesis (2.4.11) into full length human 
LHX4, in the mammalian expression vector pc.DNA3.1 that contained a FLAG-tag 
(Invitrogen), using the following primer pairs respectively: 
 
LHX4_R84C_F: GGACTTCTTCAAGTGCTTCGGC 
LHX4_R84C_R: GCCGAAGCACTTGAAGAAGTCC 
 
LHX4_T126M_F: GGCAGCTGGCCATGGGGGACGAATTC 
LHX4_T126M_R: GAATTCGTCCCCCATGGCCAGCTGCC 
 
These PCR products were then transformed using XL10 ultracompetent cells. 
Colonies from each reaction were then picked and grown overnight in liquid broth (LB) 
at 37oC on a shaker, and amplified via miniprep the following day (QIAprep Spin 
Miniprep Kit, Qiagen, Cat: 27106). An aliquot of each miniprep was sent to Source 
Bioscience for the whole LHX4 cDNA inserts to be verified by direct sequencing 
analysis, to check that the correct bases and that no unwanted errors had been 
introduced. Maxipreps were then made for each verified construct using the HiSpeed 
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Plasmid Maxi Kit (Qiagen, Cat: 12662) to yield enough DNA for multiple transfections 
and other subsequent experiments. 
 
2.3.3. Western Blot for LHX4 protein 
Protein extracts were taken from 80% confluent T25 flasks of HEK293T cells 
transfected with the constructs expressing WT LHX4 (wtLHX4), LHX4 (p.R84C) and 
LHX4 (p.T126M) mutants respectively. Protein extracts were quantified using a 
bicinchoninic acid assay (BCA assay) (Pierce, Thermo Scientific, Cat: 23225) and a 
total of 10µg of each was added to each well. The negative control used in this assay 
was a pcDNA3.1 empty vector. Rabbit anti-FLAG Tag polyclonal primary antibody 
(SIGMA, Cat: SAB4301135) and goat anti-rabbit Immunoglobulin G (IgG) 
Horseradish Peroxidase (HRP)-conjugated secondary antibody (Cell Signaling, Cat: 
#7074S) were used to stain for LHX4. Please refer to the protocol used for the EIF2S3 
western blot analysis (Chapter 2.4.8), including the antibodies used to stain for 
GAPDH, as this is the same method used for the LHX4 western blot. 
 
2.3.4. Transfection of constructs for qualitative analysis 
HEK293T cells were seeded into 24-well plates at 1 x 106 cells/well 48 hours prior to 
transfection. Transient transfection of mutant and wtLHX4 constructs were conducted 
using Fugene-6 transfecting reagent (Promega, Cat: E2691). The cells were co-
transfected with 125ng/well of firefly-luciferase reporter plasmid with either an αGSU 
or prolactin promoter, and 62.5ng/well of expression plasmid; these values were 
consistent with the reporter/expression vector concentrations/ratios used in previous 
established LHX4 transfection studies (Pfaeffle et al., 2008). In addition, the cells 
were transfected with 50ng/well of Renilla-luciferase reporter vector (pRL-TK from 
Promega) and 10ng of mCherry vector (Cherry-N1 from Clontech) as a control and to 
visualise transfection efficiency under the microscope during the 24 hours after 
transfection respectively. All wells contained the same DNA concentration. In assays 
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analysing synergy between LHX4 and POU1F1, a lower dose of 31.25ng/well of 
expression vector was also applied in addition to the described value (62.5ng/well) to 
look at dose dependency; pcDNA3.1 empty vector was added to the wells containing 
the lower dosage to maintain the same concentration of DNA per well. Cells were 
lysed 24 hours after transfection using Passive Lysis Buffer (Promega) and 
measurement of luciferase activities was performed using the Dual-Luciferase 
Reporter Assay System (Promega) on a luminometer (FLUO star, Optima, BMG 
Labtech). Two-sample Wilcoxon rank-sum (Mann-Whitney) non-parametric statistical 
tests, and two-tailed unpaired parametric T-tests were performed on the data 
generated from these assays. Results are shown as means ± SD of 3 independent 
experiments in triplicate.  
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Figure 2.1: Constructs transfected into HEK293T cells. Four different expression plasmids containing mutant and WT LHX4 genes and the 
WT POU1F1 gene respectively, were transiently transfected into wells seeded with HEK293T cells in a 24-well plate. These were either 
transfected alone at a concentration of 62.5ng/well, or in combination with another at 31.25ng/well, as noted in the diagram. A firefly luciferase 
reporter plasmid containing either an αGSU or a prolactin promoter that directly drives luciferase was also transfected at 125ng/well. In addition 
a Renilla-luciferase reporter plasmid (pRL-TK from Promega) at 50ng/well driven by the HSV-TK promoter, and an mCherry reporter plasmid 
(Cherry-N1 from Clontech) at 10ng/well driven by the CMV promoter, were both added to every well. The black arrow-headed shapes with 
labelling beginning with ‘p’ in the constructs represent the plasmid promoter that drives expression of the gene noted in the respective adjacent 
labelled black shape in that construct. HSV-TK, herpes simplex virus thymidine kinase; CMV, cytomegalovirus.  
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2.4. Functional studies for EIF2S3 
 
2.4.1. Cell culture 
A hybrid cell line (1.1B4 cells) formed by the electrofusion of a primary culture of 
human pancreatic islets with PANC-1, a human pancreatic ductal carcinoma cell line, 
were obtained from Public Health England (PHE) (Cat: 10012801). The cells were 
maintained in a humidified CO2 incubator at 37°C in Roswell Park Memorial Institute 
(RPMI) medium 1640 containing L-glutamine (Life Technologies, Cat: 21875-034), 
supplemented with 10% fetal calf serum (PAA-The Cell Culture Company) and 5% 
penstrep (Invitrogen). The cells were washed in x1 Hanks Balanced Saline Solution 
(HBSS) bought in as x10 stock (Gibco, Cat: 14185045) and diluted with autoclaved 
water, and trypsinised with x1 tryspin bought in as x10 stock (Gibco, Cat: 15400054) 
and diluted with x1 HBSS in line with manufacturer’s instructions. Mouse insulinoma 
pancreatic beta cells (MIN6) were obtained from Professor Peter Jones’ laboratory at 
Kings College, London. The cells were maintained in a humidified CO2 incubator at 
37°C in DMEM supplemented with 15% fetal calf serum (PAA), 5% penstrep 
(Invitrogen) and 5% L-Glutamine. Cells were washed in x1 PBS (VWR International) 
and trypsinised with x1 tryspin containing phenol red (Life Technologies, Cat: 
25300054). All cells were passaged when >80% confluent. All cells were tested for 
mycoplasma and cell identity before use. 
 
2.4.2. Constructs containing shRNA cassettes 
Four different GFP-IRES-Puromycin-Zeomycin plasmids (pGIPZ) (11,744bp) referred 
to in this study as Clone 1-4 respectively, were obtained from the UCL Cancer 
Institute that contained small hairpin RNA (shRNA) cassettes targeting the EIF2S3 
human gene. The shRNA cassette sequence of each had been validated by the UCL 
Cancer Institute prior to being obtained and matched 100% with the expected hairpin 
72 
 
sequence according to the Open Biosystems library database. An additional pGIPZ 
plasmid containing a scrambled shRNA sequence was also obtained that was non-
silencing and used as a control in transduction experiments. All five plasmids had a 
lentiviral (LV) backbone, which essentially consists of two long terminal repeats 
(LTR’s) and a packaging signal that allow the genome to be packaged into LV 
particles. In the LV vectors used in this study, one of these repeats contains a deletion 
to prevent the LV particles replicating, making this virus self-inactivating and therefore 
a safer option to use in the laboratory. There is a promoter in front of the transgene 
(in this case the EIF2S3 shRNA cassette) to drive expression, and also a woodchuck 
post-transcriptional regulatory element (WPRE) that is known to improve translation 
of the protein in mammalian cells (Zufferey et al., 1999). In addition to the shRNA 
cassette, the pGIPZ plasmids also contained green fluorescent protein (GFP) and a 
puromycin-resistance cassette. This co-expression enabled the cells to be monitored 
for GFP expression and puromycin selected following transduction (the standard map 
of the pGIPZ plasmid is available upon request). A maxiprep of each plasmid was 
prepared and used in LV packaging and transduction assays. 
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2.4.3. Lentiviral packaging 
LV packaging was carried out in the Immunology lab in the ICH with a trained licensed 
member of staff, due to this procedure being classed as a Safety Activity Class 2, 
which requires specific Health Safety Executive project notifications. LV particles 
were produced by transient co-transfection of HEK293T cells (4.0x105 cells/well of a 
6 well plate seeded 24h prior transfection) with 500ng of the pGIPZ vector constructs, 
333ng of encapsidation plasmid (p8.9) and 333ng of VSV-G envelope expressing 
plasmid (pMDG2). The transfecting agent used was Fugene HD (3.5µl/well) 
(Promega, Cat: E2311) and the total volume pipetted into each well was 80µl made 
up with opti-mem media (Thermo Fisher Scientific, Cat: 31985070). Mastermixes 
were made for each pGIPZ plasmid for ease when pipetting, and each was 
transfected as above, in duplicate. The cells were then incubated at 37°C for 24 
hours, after which the medium was changed and incubated for an additional 24 hours 
before harvesting the viable lentiviruses. Infectious titres were determined by doing 
limiting dilution of LVs on HEK293T cells. Titres were comprised between 105 and 106 
transducing units/ml.  
 
2.4.4. Transduction of 1.1B4 cells using packaged LV vectors for stable gene 
knockdown 
1.1B4 cells were seeded into 6-well plates and transduced at a multiplicity of infection 
(MOI) of 5, using the previously generated lentivirus under strict sterile and contained 
conditions. MOI refers to the number of transducing LV particles per cell. Cells were 
then incubated at 37°C for 72 hours, after which the media was removed from each 
well. Fresh RPMI medium containing 10% serum and 5% penstrep that was also used 
on non-transduced cells, was supplemented with puromycin and added to the cells to 
positively select the transduced cells expressing the respective shRNA. The cells 
were monitored and kept under puromycin selection for a further 10 days, trypsinised 
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when confluent and expanded into T25cm² flasks respectively. The cells were washed 
in x1 HBSS, the media was changed when appropriate, and the cells were visualised 
under an Olympus IX71 inverted Fluorescence microscope for the presence of GFP 
until ready for lysing.  
 
2.4.5. Cell lysis and RNA extraction 
Media was removed from all wells and 1.1B4 cells were washed with HBSS. An 
aliquot of RNeasy lysis buffer (RLT) was prepared by adding β-mecaptoethanol at a 
ratio of 10µl/1ml. The β-mecaptoethanol is added to completely inactivate the activity 
of RNases. RLT buffer mix was then added to each well (350µl/well in a 12-well plate). 
A cell scraper was used followed by pipetting the buffer up and down for 2-3 mins to 
lyse the cells. Lysates were transferred into fresh labelled Eppendorf tubes on ice. 
RNA was then extracted from the lysate using an RNeasy MiniKit (Qiagen, Cat: 
74104). The standard protocol from this kit was followed with the addition of a DNase 
digestion step using the RNase-Free DNase Set (Cat: 79254 Qiagen). Aliquots of 
RNA were then stored at -80°C until use. 
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Population of RNA RNA concentration in 
ng/µl 
Non transduced  652 
Scrambled non-silencing 1700 
Clone 1 300 
Clone 2 1575 
Clone 3 1310 
Clone 4 99 
 
Table 2.1: RNA concentrations derived from transfected cells. The concentration 
of RNA derived from 1.1B4 cells transduced with shRNA cassette-containing pGIPZ 
LV constructs. These values were used to calculate the reverse transcription 
quantities (Table 2.2). LV, lentiviral. 
 
2.4.6. Reverse transcription 
The High Capacity RNA-to-cDNA Kit (Cat: 4387406 Applied Biosystems, Life 
Technologies LTD) was used to yield cDNA from each RNA population. 891ng of 
each RNA (protocol suggests using up to 2µg) was used to make the cDNA due to 
Clone 4 having the lowest RNA concentration (99ng/µl) (Table 2.1) and needing the 
whole 9µl volume allowance in the protocol, which was equal to 891ng in total. The 
standard concentration of components were added to each reaction consistent with 
the supplied kit, please see Table 2.2. 
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Reaction 
component 
Constructs used in transduction on 1.1B4 cells 
 
Non 
transduced 
Scrambled Clone 1 Clone 2 Clone 3 Clone 4 
2X RT buffer 10 10 10 10 10 10 
20X RT Enzyme 
Mix 
1 1 1 1 1 1 
Sample (891ng of 
RNA) 
1.37 0.52 2.97 0.57 0.68 9 
Nuclease-free 
water 
7.63 8.58 6.03 8.43 8.32 0 
Total per reaction 20 20 20 20 20 20 
 
Table 2.2: The volume of RNA and reagents used in reverse transcription. The 
values are calculated based on the RNA concentrations in Table 2.1. All volumes are 
in µl. Scrambled: non-silencing shRNA. 
 
2.4.7. qPCR primer design and analysis 
The Fast SYBR Green Master Mix (Life Technologies, Cat: 4385612) was used in the 
qPCR reactions in this study and the standard protocol was followed, as 
demonstrated in Table 5 below. Primers for qPCR were designed using the Universal 
Probe Library database by Roche 
(lifescience.roche.com/shop/CategoryDisplay?identifier=Universal+Probe+Library), 
which generate intron flanking primers in the default setting. This database was used 
for the target gene (EIF2S3) and the three housekeeping genes (GAPDH, β-ACTIN 
and HPRT), as the primers generated bind to complementary bases within the 
exon/DNA coding region (cDNA), and not within introns which are absent at the qPCR 
stage due to the DNase digestion step performed during the RNA extraction 
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procedure. This ensures that complete complementary binding will occur during the 
qPCR reaction.  
A pilot qPCR was performed initially with serial dilutions of the non-transduced cDNA 
as follows: undiluted, 1:5, 1:10, 1:20, 1:50 and 1:100, to define which dilution of cDNA 
began exponential growth at the appropriate cycle number and thus which would be 
used in future qPCR experiments with all cDNA populations.  
The cDNA derived from the reverse transcription was diluted 1:5 in all further qPCR 
reactions. Nuclease-free water was used as the blank for each gene in all qPCR 
assays. 
 
 
SYBR green Real time 
PCR 
x1 reaction (per well) in 
µl 
x18 reactions 
(Mastermix) in µl 
SYBR green 2X 10 180 
Forward primer (10µM) 
stock = 100uM 
1 18 
Reverse primer (10µM)  
stock = 100uM 
1 18 
Nuclease-free water 7 126 
cDNA (1:5) 1 - 
TOTAL   
          
20  
 
Table 2.3: Volumes and concentrations of reagents and primers used in qPCR. 
The table contains volumes for 1 well/reaction and volumes for 18 wells/reactions, a 
mastermix. The forward and reverse primer volumes in the table are from 1:10 
dilutions of the stock primer aliquots respectively. 
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2.4.8. Western Blot analysis – Method used for both LHX4 and eIF2γ protein 
analysis 
 
2.4.8.1. Protein extraction  
Human 1.1B4 cells were trypsinised respectively in a 15ml falcon tube by spinning for 
5 mins at 1000rpm and supernatant was removed carefully leaving the smallest 
volume of media possible. The cell pellet was then washed with x1 HBSS by re-
suspending the pellet in 5ml and by spinning as before. The HBSS buffer was 
carefully removed and the pellet resuspended in as small amount of RIPA buffer 
(Sigma, Cat: R0278-50ML) containing a protease inhibitor (Complete™, Mini, EDTA-
free Protease Inhibitor Cocktail. Roche Cat: 11836170001), as possible; e.g. for a 
pellet derived from a confluent T25 flask, 200-350µl of RIPA buffer was added. The 
resuspended pellet was vortexed and put on ice for 60 mins. It was then vortexed 
briefly and centrifuged for 20 mins at 4°C at 13,000rpm (top speed). The supernatant 
was transferred into a fresh tube, being careful not to disturb the pellet containing the 
insoluble substance, and aliquots were snap frozen on dry ice and stored at -80°C 
until use. A BCA protein assay (Pierce, Thermo Scientific, Cat: 23225) was conducted 
on these lysates using manufacturer’s instructions, to quantify the total protein 
concentrations of each population.    
 
2.4.8.2. Running the gel 
The x20 stock of NuPAGE MOPS SDS Running Buffer (Life Technologies Ltd, Cat: 
NP0001) was diluted to x1 using MilliQ H20. The green protective strip was removed 
from the bottom of a Mini-PROTEAN TGX Stain Free gel (4-20%) (Biorad, Cat: 
4568094) and placed into a gel clamp inside a tank, with another gel or plastic balance 
on the opposing side. The middle chamber of the holder was filled with the x1 running 
buffer, and the combs were carefully removed, before topping up the tank with x1 
running buffer to the bottom of the gel, to enable the electric current to pass through. 
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The wells were washed out by pipetting up and down with an empty pipette before 
the samples were loaded. 
 
The BCA values generated were used to normalize the protein quantity thus 
determining the volume of lysate needed to total the desired protein concentration 
(5µg, 10µg, 30µg). Please refer to Table 2.4 for the samples that were loaded into 
wells in the pilot assay performed. This pilot assay used total protein derived from 
HeLa cells and human 1.1B4 non-transduced cells. The HeLa cell lysate was used 
as a positive control for the anti-EIF2S3 antibody as recommended by the 
manufacturer.  
 
Cell 
population 
Protein  
lysate 
concentration 
(µg/µl) 
Total 
protein 
added into 
well (µg) 
Protein 
lysate 
volume 
added to 
well (µl) 
ddH20 
added to 
well (µl) 
x4 Laemmli 
buffer added 
to well (µl) 
(Total volume 
40µl) 
Hela (1:10)  1.39 5 3.60 26.40 10 
Hela (1:10)  1.39 10 7.19 22.81 10 
Hela (1:10)  1.39 30 21.58 8.62 10 
1.1B4 WT  1.34 5 3.73 26.27 10 
1.1B4 WT  1.34 10 7.46 22.54 10 
1.1B4 WT  1.34 30 22.38 7.62 10 
 
Table 2.4: The calculation of protein samples used in the pilot western blot 
assay. The pilot western blot assay used HeLa cell lysate and 1.1B4 WT cell lysate 
at three different concentrations respectively. 1:10, 1 in 10 dilution of the stock lysate 
was used in the HeLa protein calculation. WT, wild-type. 
80 
 
Following preparation of the samples calculated in Table 2.4, 2µl of DTT (10%) was 
added to each sample aliquot and then denatured at 95°C for 5 mins using a heat 
block.   
 
10µl of Pageruler prestained protein ladder (Generon, Cat: 26616) was loaded into 
the first well and up to 40-50µl of each sample respectively into subsequent wells. 
The gel was run at ~100 volts (V) until the blue dye was only ~5 mm from the bottom 
of the gel; approximately 45 mins depending on protein size.  
 
2.4.8.3. Transfer  
A Trans-Blot Turbo Transfer Pack, PVDF, 7 x 8.5 cm (BioRad, Cat: 1704156) was 
used for transfers. The side labelled ‘bottom’ was laid into the Trans Blot Turbo 
machine tray, with the attached membrane facing up. The supplied roller was used to 
roll over the membrane to remove any bubbles. The gel was then prized out of the 
plastic after it had finished running using the supplied green device and placed onto 
the membrane manually. The roller was used again to smooth out the gel, and the 
side labelled ‘Top’ was placed on top of the gel (either side can face up). The tray 
applicator was closed, making sure all 4 edges were clipped in before slotting into the 
Trans Blot Turbo machine. To operate this machine the following options were 
pressed: ‘Turbo’, ‘1 mini gel’ (or however many gels are transferring), ‘A run’ ‘B run’ 
or both, depending on which draw (A or B) had the gel in. The gel took 7 mins to 
transfer completely. Whilst the above was transferring, blocking agent was prepared 
in a 50ml falcon tube: 2.5g of milk powder in 50ml of x1 TBS/TWEEN detergent 
(Calbiochem, Cat: 524753-1EA). 
 
When transferred, the transfer ‘sandwich’ was separated and the membrane placed 
in approximately 20ml of blocking agent in a falcon tube and put on a rotator for 1 
hour at room temperature.  
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The membrane was incubated with the primary antibody; 10ml of blocking agent 
containing 20µl of anti-EIF2S3 rabbit polyclonal antibody (Proteintech Europe, 
Cambridge Bioscience, Cat: 11162-1-AP) to result in a 1:500 dilution and rotated on 
a roller at 4°C overnight. The supplier of the antibody used the gene name for the 
antibody rather than the protein name, therefore it is termed as ‘anti-EIF2S3’, as 
opposed to ‘anti-eIF2γ’, throughout this study. A monoclonal mouse anti-GAPDH 
(Merck Millipore, Cat: MAB374) primary antibody, diluted to 1:4000, was used as the 
control. 
 
The next day, the membrane was taken out and washed in 40ml of x1 TBS/TWEEN 
for 10-15 mins x4 times in a rotating 50ml falcon tube.  
 
The membrane was incubated with a secondary antibody; 10ml of blocking agent 
containing 2µl (1:5000 dilution) of goat anti-rabbit IgG HRP-conjugated antibody (Cell 
Signaling, Cat: #7074S), and rotated on a roller for 1 hour at room temperature. For 
the GAPDH control, a polyclonal goat anti-mouse IgG HRP-conjugated secondary 
antibody (Dako, Cat: P0447) diluted to 1:4000 was used. The membrane was then 
washed at least x4 times in the x1 TBS/TWEEN as before (the washing is essential 
at this stage).  
 
The developing mix was prepared using Clarity Western ECL substrate (Biorad, Cat: 
1705061) at a 1:1 ratio and 2ml was pipetted onto the membrane. It was incubated 
for 5 mins and developed on the ChemiDoc via the following settings: ‘single channel’, 
‘Blot’, ‘Higher Chemi sensitivity’, ‘Setup’: start at 1 second, end at ~30 seconds and 
set to take 5 images. Manual exposure at 0.5 was set for the first analysis and the 
exposure time was adjusted if no image emerged. 
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2.4.9. Insulin Secretion Assay 
Krebs Ringer Bicarbonate (KRB) Buffer (1x) was prepared in a final volume of 1 
Litre of MilliQ water (store at 4°C) using the volumes in Table 2.5. A magnetic stirrer 
was used to dissolve the powder into solution and the pH was adjusted to 7.4 using 
a pH meter. 
 
Solution Volume in grams Concentration mM 
NaCl 7.95 34 
KCL 2.5 1.175 
KH2PO4 0.163 0.3 
NaHCO3 0.42 1.25 
MgSO4 (7H20) 0.295 0.3 
 
Table 2.5: How to make KRB buffer. The volume and concentration of chemicals 
used to make the KRB buffer for use in an ultrasensitive insulin ELISA assay. KRB, 
Krebs Ringer Bicarbonate. 
 
Pre-incubation buffer was prepared by adding 0.5g of bovine serum albumin (BSA) 
powder and 2mM of glucose (0.18g) to 500ml of the 1x KRB buffer. This was then 
aliquoted into 50ml falcons and stored at 4°C in cold room. 
 
Day 1 
MIN6/1.1B4 cells were plated at 3 x 105 per well in a 6-well plate, in a total volume of 
2ml of each cell types respective media, and left overnight in an incubator at 37°C 
until cells grew to 80-90% confluency (usually 24 hours).  
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Day 2 
The media was removed and 2ml of the pre-incubation buffer was added and left for 
60 mins before turning the plate upside down onto tissue paper to remove the 
solution. Test agents were added (1ml/well) (Chapter 2, Table 2.6) and incubated at 
37°C for 24 hours. Media was aspirated carefully so as not to blow holes in the cells, 
aliquoted and frozen at -20°C until use.  
 
1x KRB buffer only (0% glucose) Make as Table 2.5 states 
1x KRB buffer with 10mM glucose (0.09g 
in 50ml) 
Measure 0.09g glucose and dissolve 
in 50ml of the 0% glucose 1x KRB 
buffer to make 10mM glucose buffer 
Forskolin 10µM (with 10mM glucose) Stock powder comes at 10mg. 
Dissolve all in 2.44ml of DMSO to 
make a 10mM stock and dilute this 
1:1000 by adding 10µl into 10ml of 1x 
KRB buffer with 10mM glucose 
IBMX 100µM (with 10mM glucose) Stock IBMX is 100mM. Dilute this 
1:1000 by adding 10µl into 10ml of 1x 
KRB buffer with 10mM glucose 
Table 2.6: Insulin secretion assay test agents. A simple guide to calculate test 
agent concentrations, used in insulin secretion assays. IBMX, 3-
isobutylmethylxanthine. 
 
Insulin secretion was then measured in each sample using an ultrasensitive insulin 
Elisa kit (MERCODIA, Cat: 10-1132-01) using the standard protocol. MIN6 cells were 
used in this insulin secretion assay as a control and were plated at the same density 
as 1.1B4 cells. 
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2.4.10. Apoptosis assay 
MIN6/1.1B4 cells were seeded into white 96-well sterile tissue culture treated 
microplates with clear bottoms (PerkinElmer, Cat: 6005181), at 10,000 cells/well in a 
total volume of 200µl of cell-type specific media, and incubated overnight at 37°C. 
Media was removed by inversion of the plate and 100µl of cytokine mix containing 
the following was added to respective triplicate wells: 1L-1β (50 U/ml), TNF-α (1000 
U/ml), INF-γ (1000 U/ml); diluted in media and incubated for 16 hours at 37°C. 
 
Caspase-Glo 3/7 reagent (Promega, Cat: G8090) was added at a 1:1 ratio of 
reagent:sample (100µl) to each well and incubated for 1 hour at room temperature 
before reading the luminescent signal generated on the luminometer. There were 
triplicate wells of each of the following: 
- Blank wells: had no cells but had cytokine mix added. These wells emitted 
background luminescence associated with Caspase-Glo reagent. This value 
was subtracted from experimental values. 
- Basal caspase activity: wells containing cells with media not containing 
cytokine mix.  
- Cytokine-stimulated caspase activity: wells containing cells with respective 
cytokine mix added. 
 
Two-sample Wilcoxon rank-sum (Mann-Whitney) non-parametric statistical tests, 
two-way ANOVA tests, and two-tailed unpaired parametric T-tests were performed 
on the data generated from these apoptosis assays.
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2.4.11. Single site-directed mutagenesis 
The QuikCHANGE II XL site-directed mutagenesis kit (Agilent Technologies, Cat: 
200521) was used to alter the BamHI site that was within the EIF2S3 insert in the 
pCMV-SPORT6 vector containing the full cDNA EIF2S3 sequence (Source 
Bioscience). This is the same vector that was used to make RNA probes for the in 
situ hybridization studies (Chapter 2.5). The BamHI site already within the EIF2S3 
cDNA had to be mutated so that the insert would not be cut in half during the BamHI 
digestion step. This BamHI site had one nucleotide substituted during this step 
without changing the amino acid, thus keeping the WT protein sequence intact and 
unaltered. Therefore when adding the BamHI enzyme at a later stage to cleave the 
EIF2S3 insert out of this pCMV-SPORT6 vector it would only cut at the ends of the 
insert yielding the full EIF2S3 sequence. The EIF2S3 insert had to have BamHI sites 
at either end, as the cloning site within the host LV-IRES vector that the inserts have 
to ligate into was within two BamHI sites. The primers used in this reaction to alter 
one base of the BamHI sequence (GAATCC) were as follows, with the altered 
nucleotide highlighted in red: 
 
BamHI_alter_F:  GCTCATGGTGAACATAGGCTCCCTGTCAACAGGAGG 
BamHI_alter_R:  CCTCCTGTTGACAGGGAGCCTATGTTCACCATGAGC 
 
The above primers were diluted to 125ng/μl and the vector to 10ng/μl. 1μl of this 
diluted vector was pipetted into a tube on ice and the following was added: 
1μl of each diluted primer 
1μl of dNTPs 
5μl of x10 buffer 
3μl Quikchange  
38μl of double distilled water   
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Lastly, 1μl of pfu enzyme (2.5 U/μl) was added to each well to total 50μl/well and the 
Thermocycler machine was set to run the following protocol: 
 
 
STAGE 1 STAGE 2 (x12)   STAGE 3 
95c 95c 60c 68c 68c 
1min 50secs 50secs 6mins * 7mins 
*This time length relates to 1 min per kb of DNA, reflecting the size of the vector 
containing the insert, which in this case was 5.815kb. 
 
Following the above PCR reaction, the wells were put on ice to cool slightly before 
1μl of Dpn I restriction enzyme was added into each well and mixed thoroughly with 
a pipette. The plate was then put into an incubator at 37°C for 1 hour to dissolve the 
parental supercoiled DNA.  
 
XL10 ultracompetent cells (provided in kit) were thawed on ice and 45μl of cells were 
aliquoted into labelled tubes. 2μl of β-mecaptoethanol (provided in kit) was added into 
each tube and left on ice for 10 mins whilst being flicked occasionally to mix. 2μl of 
the PCR product was pipetted into the respective tube, stirred with a pipette tip and 
left for approximately 30 mins on ice. During this time, S.O.C medium (Invitrogen, 
Cat: 15544034) was warmed to 42°C. 
 
After the 30 mins, the cells were heat shocked at exactly 42°C in a water bath for 
precisely 30 seconds and put back on ice immediately for 2 mins. Then 500μl of the 
pre-warmed S.O.C medium was pipetted into the tubes and shaken at 37°C for 1 
hour, during which time, ampicillin-resistant agar plates were warmed to 37°C.  
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The transformed cells were pipetted into the middle of their respective plate 
(250μl/plate) and a sterile spreader was used to equally spread them before 
incubation at 37°C overnight (not on a shaker). The following day ~4-6 colonies from 
each plate were picked using a pipette tip and dropped into ~3ml of ampicillin 
supplemented liquid broth (LB) in a 15ml falcon tube respectively. The tubes were 
incubated overnight at 37°C on a shaker and minipreps were carried out for each on 
the following day, using manufacturer’s instructions.  
 
Four primers were used to verify the full cDNA sequence of EIF2S3, (the EIF2S3_1R 
covered the beginning of the gene): 
 
 
EIF2S3_1F:  5’ GATCTTGTGGGAGCAGTACACC 3’ 
EIF2S3_2F:  5’ CCAAGAGACTTTACTTCAGAGCC 3’ 
EIF2S3_3F:  5’ CCGGGCTGACAGAATGGTGGGG 3’ 
EIF2S3_1R:  5’ CCGTTCAGCATAGTAGCCATC 3’  
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2.4.12. LV-IRES Vector digest  
The LV backboned host vector was obtained from the Immunology lab (ICH) (see 
Chapter 2.4.2 for details on LV vectors such as this). An unwanted insert was 
removed from this vector using the BamHI restriction enzyme (Promega, Cat: R6021) 
by adding the reagents listed in Table 2.7 to a sterile tube, briefly spinning down in a 
centrifuge and incubating at 37°C for <4 hours. 
 
 
Reagent Volume (μl) 
Nuclease-free water 83 
Restriction enzyme 10x Buffer E  10 
BSA (10μg/μl) 1 
Vector DNA (1680ng/μl) 3 
Mix by vortex at this stage 
BamHI enzyme (10U/μl) 3 
 Total volume = 100 μl 
 
Table 2.7: The volume of reagents used to digest the LV-IRES vector. Reagents 
were added into a sterile Eppendorf tube in the order listed. 
 
 
2.4.13. Alkaline Phosphatase treatment 
The linearized BamHI cut LV-IRES vector was dephosphorylated by treatment with 
calf intestinal alkaline phosphatase (CIAP) (Promega, Cat: M1821) to prevent the 
BamHI cut vector ends ligating back together. As per manufacturer’s instructions, the 
digested DNA was purified before dephosphorylation by ethanol precipitation: 10μl of 
sodium acetate (3M) and 250μl of 100% ethanol was added to the 100μl of digested 
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DNA, and centrifuged at 13,000rpm for 10 mins. The supernatant was removed and 
200μl of 70% ethanol was added and spun as before, to wash the pellet. The 
supernatant was removed and the pellet was allowed to air dry for >10 mins at room 
temperature. Nuclease-free water (43 μl) was added to resuspend the pellet, followed 
by 5μl of 10x CIAP buffer and 1μl of stock CIAP enzyme (Promega, Cat: M1821), and 
incubated at 37°C for 30 mins. A further 1μl of CIAP stock enzyme was added to 
make a final volume of 50μl, and was incubated at 37°C for a further 30 mins. 
  
2.4.14. Gel extraction  
The dephosphorylated cut vector was run over 2 wells on a 20-well 1% agarose gel 
at 100V for 1 hour before being excised using a scalpel under UV light. The weight of 
an empty Eppendorf tube was subtracted from the weight of the gel and tube together 
to give the weight of the gel. A QIAquick Gel Extraction Kit protocol (Qiagen, Cat: 
28704) was then followed as by manufacturer’s instructions to yield purified vector 
DNA, which was then stored at -20°C. 
 
2.4.15. Amplification of the EIF2S3 insert 
The full coding region of the EIF2S3_WT insert was amplified out of the original 
pCMV-SPORT6 plasmid (Source Bioscience, IRATp970H0941D, IMAGE ID: 
4419438). Primers were designed with the BamHI sequence flanking the EIF2S3 
coding region (highlighted in red):  
 
EIF2S3_BAMHI_F:   5’ GGACTCGGATCCATGGCGGGCGGAGAAGCTGG 3’ 
EIF2S3_BAMHI_R:   5' CGCTTAGGATCCTCAGTCATCATCTACTGTTGG 3' 
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An AccuPrime pfx Supermix (Invitrogen, Cat: 12344-040) containing a proofreading 
3’ to 5’ exonuclease activity with a higher fidelity than the pfu proof reading 
polymerase enzyme, was used in the PCR reaction. 
 
 
Reagent Volume (μl) 
10ng of DNA maxiprep (diluted stock to 
10ng/μl) 
1 
Accuprime pfx supermix (containing 
MgSO4, dNTPs and polymerase 
enzyme) 
22.5 
Forward and reverse primer (diluted 
100uM stock 1:10 to give 10uM) 
1 of each primer 
 Total volume: 25 
 
Table 2.8: Amplification of the EIF2S3 cDNA insert. Reagents and volumes used 
in the PCR reaction to amplify the EIF2S3 gene out of the pCMV-SPORT6 vector.  
 
The above PCR reaction was prepared on ice in a 96-well sequencing plate, put into 
a Thermocycler and run using the following protocol:  
 
Step1 (x1 cycle) 
95°C for 5 mins   
 
Step 2 (x35 cycles) 
95°C for 15 seconds 
60°C for 30 seconds  
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68°C for 2 mins (~1 min for every kb in insert: EIF2S3 = 1.419kb) 
 
Step 3 (x1 cycle) 
Cool to 4°C for >10 mins 
 
5μl was then run on a 1% agarose gel slowly at 90 V for 90 mins next to a 1kb DNA 
ladder (Hyperladder I, Bioline, Cat:33053), to verify that the EIF2S3 insert was the 
correct size and had been amplified.  
 
2.4.16. Polyadenylation 
The addition of adenine bases (a Poly(A) tail) on the 3’ end of the amplified 
EIF2S3_WT PCR product was necessary for ligation of the inserts into the pGEM-T 
Easy vector (TA-cloning). This was achieved using Terminal Transferase (New 
England Biolabs LTD (NEB), Cat: M0315S). Manufacturer’s instructions were 
followed: 
 
Adenine tailing reaction  
5μl 10X Terminal Transferase buffer (TdT)  
5μl 2.5mM CoCI2 solution (provided in kit) 
20μl EIF2S3 PCR product 
0.5μl 10mM dATP (from dNTP set, 100mM, Bioline, Cat: 39025) 
0.5μl Terminal Transferase (20units/μl) 
Deionized (nuclease-free) water up to 50μl total volume (19μl) 
 
Incubate at 37°C for 30 mins and then stop the reaction by heating the mix to 70°C in 
a heat block for 10 mins. The PCR product was then column purified using the 
QIAquick PCR Purification Kit (Qiagen, Cat: 28104). 
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2.4.17. TA-Cloning: Ligation of the cDNA EIF2S3_WT insert into the pGEM-T 
Easy vector 
The polyadenylated EIF2S3_WT PCR product was cloned into the pGEM-T Easy 
vector (pGEM-T Easy Vector System II, Promega Cat: A1380) using the following 
standard equation for ligation of insert into vector: 
 
ng of vector x kb size of insert         x         insert:vector molar ratio = ng of insert 
           kb size of vector   
 
The pGem-T Easy vector kit recommends to use 50ng of the vector at a 3:1 
insert:vector ratio. Therefore the following values were put into the above equation to 
calculate how many ng’s of insert (EIF2S3 PCR product) were needed in the ligation 
reaction: 
 
50ng of vector  x  1.419kb insert           x        3            =  70.95ng of insert  
                 3.0kb vector               1 
 
The following table (Table 2.9) presents the volumes of DNA and reagents that were 
pipetted into sterile 0.5ml tubes for the ligation of the EIF2S3_WT insert into the 
pGEM-T Easy vector. The reactions were mixed by pipetting and incubated at room 
temperature for 1 hour.  
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Reagent EIF2S3 WT 
ligation 
Positive control 
2X Rapid ligation buffer 
for T4 ligase 
5 5 
pGEM-T Easy vector 
*(50ng) 
1 1 
Respective EIF2S3 
insert PCR product 
*(70.95ng) 
1.48 (stock DNA 
= 48ng/μl) 
- 
Control insert DNA - 2 
T4 DNA ligase (3U/μl) 1 1 
Nuclease-free water to 
a final concentration of 
10μl 
1.52 1 
 
Table 2.9: EIF2S3 ligation into the pGEM-T Easy vector. The volumes of reagents 
used in the ligation of the EIF2S3 amplified insert into the pGEM-T Easy vector. All 
volumes are in μl. *The concentration of DNA needed in the final reaction to give a 
3:1 ratio of insert:vector.   
 
2.4.18. Transformation of pGEM-T Easy vector 
The two products from the ligation reactions above; EIF2S3_WT and the positive 
control, were transformed in duplicate, respectively, on LB agar/ampicillin/IPTG/X-
GAL plates with ampicillin. JM109 High Efficiency Competent Cells (supplied in the 
pGEM-T Easy vector II kit) were thawed on ice (5 mins) and mixed by gently flicking. 
2μl of each ligation reaction was pipetted into sterile 1.5ml tubes on ice (x2 for each 
ligation), and 50μl of the JM109 cells were added to each. The tubes were gently 
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flicked to mix and placed on ice for 20 mins. The cells were then heat-shocked for 45 
seconds in a heat block at exactly 42°C and immediately returned to ice for 2 mins. 
950μl room temperature S.O.C medium was added to each tube and incubated for 
1.5 hours at 37°C on a shaker (~150rpm). During the last 30 mins of this incubation, 
x6 LB agar plates containing ampicillin were spread with 100μl of 100μM IPTG and 
50μl of 20μg/μl X-GAL to enable blue/white staining, and incubated at 37°C (without 
shaking). 100μl of each transformation culture in duplicate was plated onto labelled 
LB agar/ampicillin/IPTG/X-GAL plates and incubated overnight (16 hours) at 37°C. 
(The positive control ligation was diluted 1:10 with S.O.C medium before 100μl was 
plated in duplicate.) 
 
The following day white colonies were picked from each ligation and incubated in 3ml 
of LB with ampicillin in 15ml falcon tubes overnight (~16 hours) at 37°C on a shaker. 
The x8 tubes were then amplified via miniprep following manufacturer’s instructions. 
An aliquot from the EIF2S3_WT pGEM-T Easy plasmid miniprep was sent to Source 
Bioscience for the complete cDNA EIF2S3 insert to be sequenced (using the same 
four primers listed in Chapter 2.4.11) to check for unwanted errors.  
 
JM109 competent E.Coli cells were used in the transformation of the EIF2S3 insert 
into LV-backboned vectors as these cells contain mutations in the genes recA1 and 
endA1. These mutations aid in minimizing recombination and ensuring plasmid 
stability, therefore these cells are a better choice than DH5 alpha E.Coli cells when 
transforming LV-backboned vectors especially, as they yield a high quality plasmid 
DNA (Sigma).   
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2.4.19. Enzyme digest to cut out inserts from p.GEM-T vector 
Upon sequence verification of the EIF2S3_WT insert within the pGEM-T Easy vector, 
the insert was digested with BamHI, using the following protocol: 
 
Reagent Volume (μl) 
Nuclease-free water 17.5 
Restriction enzyme 10x Buffer E  5 
BSA (10μg/μl) 0.5 
p.GEM-T vector containing insert 25 
Mix by vortex at this stage 
BamHI enzyme (10U/μl) 2 
 Total volume =  50μl 
 
Table 2.10: Enzyme digest reaction.  The volume of reagents used to digest the 
EIF2S3_WT insert out of the pGEM-T Easy vector using the BamHI restriction 
enzyme. Reagents were added into a sterile Eppendorf tube in the order listed. 
 
The above reagents were briefly spun down in the tube in a centrifuge and incubated 
at 37°C for <4 hours. These were all run on a 1 % agarose gel and purified by gel 
extraction as previously described, using the QIAquick Gel Extraction Kit (Qiagen, 
Cat: 28704).  
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2.4.20. Ligation of EIF2S3 into LV-IRES vector 
The EIF2S3_WT purified insert was ligated into the linearized dephosphorylated LV-
IRES vector using T4 DNA ligase and 100ng of the vector at a 3:1 ratio of insert:vector 
as per manufacturer’s instructions (Promega, Cat: M1801): 
 
100ng of vector  x  1.419 kb insert           x        3            =  40 ng of insert  
                 10.5 kb vector                  1 
 
The reaction was incubated overnight on a Thermocycler at 15°C for 16 hours. The 
ligation product was then transformed with JM109 cells overnight using the same 
method used in transforming the pGEM-T Easy vector (Chapter 2.4.18). Colonies 
were picked and minipreps were made. Aliquots of each miniprep (x6) from six 
different colonies were sent to Source Bioscience with one primer (EIF2S3_1R) to 
verify that the insert had ligated into the LV-IRES vector in the correct orientation. The 
miniprep containing the EIF2S3 insert in the correct orientation was then taken 
forward for multi-site-directed mutagenesis. 
 
2.4.21. Multi-site-directed mutagenesis 
The patient EIF2S3 (p.P432S) mutation was introduced into the EIF2S3_LV-IRES 
ligated vector, in addition to correcting the altered BamHI site (as discussed in section 
2.4.11) within the EIF2S3 insert sequence. This was carried out to yield the final 
EIF2S3 (p.P432S) mutant construct used in further studies. The two primers used in 
this reaction were: 
 
EIF2S3_P432S_F: GTTTTGACCAATTCAGTGTGCACAGAGG 
BamHI correct_F: GCTCATGGTGAACATAGGATCCCTGTCAACAGGAGG 
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The protocol for this multi-site-directed reaction differs to the single site-directed 
reaction and is described in Table 2.11.  
 
Reaction component For templates >5kb 
10x Quikchange Multi reaction buffer 2.5 μl 
Double-distilled water X μl to final volume of 25 μl 
QuikSolution 0–0.75 μl (titrate for each template) 
Ds-DNA template X μl of (100ng) 
Mutagenic primers X μl (112ng of EIF2S3_P432S_F 
primer, 144 ng of BamHI_correct_F 
primer)  
dNTP mix 1 μl 
Quikchange multi enzyme blend 1 μl 
 
Table 2.11: Multi-site directed mutagenesis. Both primers used in this reaction are 
forward primers only (one for each mutation introduced), the ng’s of these primers 
added are relative to the number of nucleotides in them e.g. 25 bases = 100ng of 
primer is needed in the reaction, therefore a primer with 36 bases = 144ng of primer 
needed. This is consistent with the multi-site-directed mutagenesis protocol 
instructions. 
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The reaction in Table 2.11 was run on the Thermocycler machine as follows: 
 
Segment Cycles  Temperature  Time  
1 1 95 1 min 
2 30 95 1 min 
55 1 min 
65 2 mins/kb of plasmid length  
(EIF2S3-LV-IRES = ~12kb) 
 
 
A single site-directed mutagenesis reaction using the described method (Chapter 
2.4.11) was performed on the EIF2S3-LV-IRES plasmid to revert the single nucleotide 
back to give the original BamHI site within the EIF2S3 insert. This yielded the exact 
original EIF2S3_WT cDNA sequence and thus the final EIF2S3_WT construct used 
in further studies. This reaction corrected the previously altered BamHI site within the 
EIF2S3 cDNA by using the following primer pair: 
 
BamHI correct_F: GCTCATGGTGAACATAGGATCCCTGTCAACAGGAGG  
BamHI correct_R: CCTCCTGTTGACAGGGATCCTATGTTCACCATGAGC 
 
Both PCR products from both the single and multi-site-directed mutagenesis 
reactions above were transformed in JM109 cells as previously described (Chapter 
2.4.18). Colonies were picked and minipreps were made. An aliquot of a miniprep 
from both EIF2S3_WT and EIF2S3 (p.P432S) constructs respectively was sent to 
Source Bioscience for sequencing with the same four primers as before (Chapter 
2.4.11). This was to verify the whole cDNA EIF2S3 insert sequence to check if the 
site-directed reactions above had introduced the correct bases and that no unwanted 
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errors had occurred. Upon verification that the sequences in both constructs were 
correct, maxipreps of these plasmids were then generated.  
These final constructs: EIF2S3_WT and EIF2S3 (p.P432S) in the LV-IRES vector, 
were constructed in order to be packaged into viable LV particles and transduced into 
1.1B4 cells using the previously described method (Chapter 2.4.3 – 2.4.4).
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Cloning flowchart 
 
 
 
Figure 2.2: A summary of the cloning process. The steps performed in cloning the 
EIF2S3 insert into the LV-IRES vector and yielding the two constructs: EIF2S3_WT 
and EIF2S3 (p.P432S) used in further studies. 
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2.4.22. Transfection of the EIF2S3 constructs 
Both 1.1B4 and MIN6 cells were seeded at 3 x 105 per well in a 6-well plate in their 
specific complete media (10% FBS and 5% penstrep) and incubated (Chapter 2.4.1). 
The LV-IRES empty vector, EIF2S3_WT and EIF2S3 (p.P432S) constructs were 
transfected into cells using both Fugene-6 as previously described (Chapter 2.3.4) 
and lipofectamine 2000 (Life Technologies Ltd, Cat: 11668027) transfecting agents 
respectively on separate occasions, using standard manufacturer protocols. When 
using lipofectamine, 4μg of DNA and 10μl of lipofectamine in a total of 250μl opti-
mem media (Thermo Fisher Scientific, Cat: 31985070) was added to each well. Media 
was changed 24 hours after transfection and cells were observed for GFP 48 and 72 
hours after transfection. 
 
2.4.23. Cell sorting 
Seventy-two hours after transfection, cells were trypsinised and suspended in 1ml of 
respective media containing 1.5% FBS in 15ml falcon tubes and transported on ice. 
The cells were put into a BD FACS Aria III cell sorter, which has four different lasers: 
405nm, 488nm, 561nm and 633nm. The 530/30 filter from the 488nm laser was used 
in detecting the green fluorescing cells from each population: empty vector, 
EIF2S3_WT and EIF2S3 (p.P432S) LV-IRES transfected cells, which were collected 
in 1ml of complete media in 15ml falcon tubes. These green fluorescing cells were 
then plated into culture plates for expansion.  
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2.5. In situ hybridization 
 
2.5.1. Linearizing plasmids 
Fully sequenced human purified cDNA clones containing the full coding sequence of 
their respective gene, were obtained from Source Bioscience 
(http://sourcebioscience.com/). They were digested with specific restriction enzymes 
(Promega) (see Table 2.12 for all clones and enzymes used) that did not cut within 
our gene of interest, via the following protocol: 
 10μg DNA (circular plasmid) 
 1  restriction enzyme buffer (10μl of the x10 stock) 
 20-50U restriction enzyme (5μl of the 10U/μl stock)   
 Make up to 100μl with double distilled water (ddH2O)   
The reactions were then incubated for 2 hours at the enzymes’ optimum temperature, 
which in each case was 37°C. 1μl of the original circular plasmid was run next to the 
linearized clone on a 1.5% agarose gel with 5μl of 1kb ladder. The linearized plasmids 
were cleaned using a QIAquick PCR purification kit (Qiagen, Cat: 28104). 
 
2.5.2. DIG probe transcription 
The purified linearized plasmids (Table 2.12) were labelled with digoxigenin (DIG), 
using 1μg of DNA, 2μl of DIG RNA labelling mix (stock at x10) (Roche, 11277073910), 
1μl of transcription buffer (stock X10), 1μl of protector RNA inhibitor (Roche, 
03335399001), 1μl of either T3, T7 or SP6 RNA polymerase (Roche), made up to a 
final volume of 20μl with RNase and DNase free water and incubated for 2 hours at 
37°C. 2μl of RNA probe was run for 5 mins at 150V on a 1% agarose gel to assess 
the efficiency of transcription. Good probes are usually ten-fold brighter than the DNA 
band in the 1kb ladder. The DIG probes were diluted with DEPC-water up to a total 
of 100μl and purified using spin columns (Chroma-spin, Clontech-100).  
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Gene 
Name 
Source 
Bioscience 
reference 
Plasmid Cloning 
site 
Restriction 
enzyme and 
polymerase 
used for 
sense probe 
Restriction 
enzyme and 
polymerase 
used for 
antisense 
probe 
EIF2S3 IRATp970H0941D 
IMAGE ID: 4419438 
pCMV-
SPORT6 
5s: SalI 
3s: NotI 
XhoI, SP6 AgeI, T7 
CTPS2 IRATp970A0631D 
IMAGE ID: 5268973 
p.BluescriptR 5s: SalI-
XhoI 
3s: BamHI 
KpnI, T7 EcoRI, T3 
RNPC3 IRATp970A029D 
IMAGE ID: 3873751 
pCMV-
SPORT6 
5s: SalI 
3s: NotI 
XhoI, SP6 AgeI, T7 
PRMT6 IRATp970A0595D 
IMAGE ID: 5212478 
pCMV-
SPORT6 
5s: EcoRV 
3s: NotI 
XhoI, SP6 AgeI, T7 
FASN IRATp970A1078D 
IMAGE ID: 6172538 
pCMV-
SPORT6 
5s: SalI 
3s: NotI 
XhoI, SP6 AgeI, T7 
APEX2 IRAUp969F1116D 
IMAGE ID: 3537317 
pOTB7 5s: EcoRI 
3s: XhoI 
BglII, SP6 EcoRI, T7 
 
 
Table 2.12: Details of IMAGE cDNA clones used in in situ experiments. 
Restriction enzymes that were used to linearize plasmids, deciphered from plasmid 
maps supplied with the respective IMAGE clone from Source Bioscience. The RNA 
polymerase used during transcription of sense and antisense probes.   
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2.5.3. Human embryonic sections 
Slides with sections of human embryonic tissue were selected at different stages of 
development: Carnegie stage (CS) 16, 19, 20, 23 and at late 8 post conception week 
(pcw) and prepared and obtained from the Human Developmental Biology Resource 
(HDBR). Slides were treated with RNAse as an extra control to avoid non-specific 
binding/hybridisation and were subject to the following steps: 
 
2.5.4. Pre-hybridisation treatment  
The sections were placed into solutions in different sterilized troughs (all equipment 
was RNAse-free), beginning with Histoclear solution (Agar Scientific), which helps 
preserve and clean wax from the tissue, followed by a series of washing steps with 
decreasing dilutions of ethanol to hydrate the tissue. Following this; 4% 
paraformaldehyde in 1x PBS (PFA) to ‘fix’ the sections, PBS to wash them, 
Proteinase K (PK) for precisely 8 mins to perforate the tissue, PFA to re-fix, a second 
PBS wash, 0.1M Triethanolamine with acetic anhydride to break up the bonds and 
make RNA accessible, a third PBS wash ending with a dehydration step with 
increasing ethanol concentrations and subsequent air drying on the bench. 
 
2.5.5. Hybridisation 
A solution of Hybmix, of which ingredients are listed below, RNAse inhibitor, tRNA 
and the EIF2S3 probe made earlier was added to each slide (100ul to each), then 
covered with a clean cover slip avoiding bubbles and placed into a humid chamber 
overnight at 65°C. 
Hybmix solution: 
50% formamide 
0.3M sodium chloride 
20mM Tris HCL at pH7.0 
5mM EDTA 
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10% Dextran sulphate 
1x Denhardt’s solution (a mixture of blocking agents) 
 
2.5.6. Post-hybridisation washing 
All following steps and solutions were at 65°C and not RNAse-free. The cover slips 
were removed from the slides which were placed into a rack, in a trough containing 
pre-warmed 2x saline-sodium citrate (SSC) (a hybridisation buffer) in a 65°C water 
bath. The following washes then took place: 
- Rack of slides was washed in fresh 2x SSC solution for 30 mins. 
- Washed with formamide twice for 30 mins.  
- Washed twice in 2x SSC for 30 mins. 
- Washed in 0.2x SSC for 30 mins. 
- The trough was then emptied and filled with 0.2x SSC and allowed to cool to 
room temperature. 
 
2.5.7. Antibody detection 
The slides were transferred into a rack and washed twice in buffer 1 (0.1MTris pH 
7.6, 0.15M sodium chloride), followed by a blocking step for 1 hour in buffer 1 
containing 10% fetal calf serum (FCS). After draining the slides, the antibody solution; 
anti-DIG fab antibody at 1:1000 in buffer 1, was added and covered with parafilm 
before being incubated in a humid chamber overnight at 4°C. The fragment antigen-
binding (Fab) fragment is the region on the antibody that binds to the antigen, which 
in this case is DIG. Therefore the anti-DIG fab antibody recognises and binds to the 
DIG-labelled probe that is bound to the respective RNA transcripts in the section. The 
following day the parafilm was removed and slides were washed in buffer 1. Finally 
the developing solution (polyvinyl alcohol (PVA), Nitro-blue-tetrazolium-chloride 
(NBT) and Bromo-chloro-indolyl-phosphate (BCIP) separating solution) (Roche) was 
added to each slide and allowed to develop, resulting in a purple colour change 
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reaction detectable by eye showing the presence of the anti-DIG antibody and thus 
where the RNA transcripts are located. 
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Chapter 3 
 
 
 
Novel lethal form of congenital hypopituitarism  
associated with the first recessive LHX4 mutation 
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3.1. Introduction 
Due to our laboratory screening patients on such a large scale, other hospitals across 
the world contact and send us DNA from patients with hypothalamo-pituitary related 
phenotypes for us to screen. One such case, was a hospital in Karachi, Pakistan 
where Dr Humayun, an endocrinologist from the Aga Khan University Hospital, sent 
us DNA from two male deceased siblings from a pedigree (Pedigree 1) that had had 
CPHD related symptoms with fatal consequences.  
 
3.1.1. Pedigree 1 
A non-consanguineous Pakistani pedigree consisted of three siblings (Pedigree 1, 
Figure 3.1); one female and two males. The first child, a daughter (IIIa), was born with 
a birth weight of 2.4kg and a birth length of 46cm (DNA not available). She had poor 
tone and respiratory effort with grunting, persistent hyponatraemia, mid-facial 
hypoplasia, small nose with depressed nasal bridge, antimongoloid slant of eyes and 
low set crumpled ears. She had no cleft of lip or palate. She was started on nasal 
continuous positive airway pressure followed by ventilation. The second child, a son 
(IIIb), was born with a birth weight of 2.44kg and a birth length of 51cm. He presented 
with poor tone and respiratory distress marked by grunting, upon which he was 
started on ventilation. Examination showed signs of panhypopituitarism, normal tone 
and reflexes, low set crumpled ears, small upturned nose with depressed nasal 
bridge, mid-facial hypoplasia, hypoplastic nipples and nails, micropenis (1.7cm) and 
absent scrotal rugae with undescended testes. His free thyroxine was 200μg/L, TSH 
0.01mU/L, basal cortisol 2.9μg/dL and ACTH was undetectable. The third child, a 
male (IIIc), was born with a birth weight of 2.6kg and a birth length of 37.5cm (Table 
3.1). He had poor tone, low blood glucose, respiratory distress with grunting, and was 
started on ventilation. Examination showed signs of panhypopituitarism, normal tone 
and reflexes, low set crumpled ears, small upturned nose with depressed nasal 
bridge, mid-facial hypoplasia, micropenis (1.5cm), absent scrotal rugae, and a 
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palpable right testis with a left undescended testis. Persistent hyponatraemia and 
intestinal perforation complicated the clinical phenotype. His free thyroxine was 
350μg/L, basal TSH 0.004mU/L, basal PRL <0.5μg/L, peak GH <0.05μg/L, basal 
cortisol <1.1μg/dL with an undetectable ACTH (Table 3.1). In spite of the rapid 
commencement of hydrocortisone and thyroxine, all three children died within the first 
week of life with what was presumed as fulminant sepsis, with klebsiella sepsis 
confirmed as the cause of death only in the first born male. 
 
 
Pedigree 1  
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Pedigree 1 harbouring the LHX4 (p.T126M) variant. The three affected 
sibling, female and two males, are represented by the fully shaded circle and squares 
respectively; the two affected brothers harboured the homozygous LHX4 (p.T126M) 
variant. The shapes containing a dot represent heterozygous asymptomatic carriers. 
Un-shaded shapes indicate normal control individuals, and shapes crossed with a 
diagonal line indicate that the individual is deceased.  
I 
II 
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a b c d 
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Patient  IIIa IIIb IIIc 
Sex Female Male Male 
GA 35 35 38 
Birth weight SDS (kg) -2.3 (2.4) -2.4 (2.44) -2 (2.6) 
Birth length SDS (cm) -2.2 (46) -0.02 (51) -1.8 (47.5)  
FT4 (ng/dL) (NR) - 0.20 (NR 0.93-1.7)  0.35 (NR 0.93-1.7)  
Basal TSH (mU/L) - 0.01 <0.01 
Basal Cortisol (μg/dL) - 2.9 <1.1 
ACTH - Undetectable Undetectable 
Peak GH (μg/L) - - <0.05 
Basal Prolactin (μg/L) - - <0.5 
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Other features - Antimongoloid slant of 
eyes 
- Persistent 
hyponatraemia 
- Poor muscle tone 
- Poor respiratory 
effort, grunting 
(started on ventilation) 
- CXR: atelectasis and 
RDS-like picture 
- Low set crumpled 
ears 
- Small upturned nose 
with depressed nasal 
bridge 
- Mid-facial hypoplasia 
- Poor muscle tone 
- Small phallus (1.7cm) and 
absent scrotal rugae 
- Undescended testes 
- Poor respiratory effort, 
grunting (started on 
ventilation) 
- CXR: atelectasis and RDS-
like picture 
- Low set crumpled ears 
- Small upturned nose with 
depressed nasal bridge 
- Mid-facial hypoplasia 
- Poor tone and reflexes 
- Small phallus (1.5cm) and 
absent scrotal rugae 
- Left undescended testis 
- Low blood glucose 
- Persistent hyponatraemia 
- Poor respiratory effort, 
grunting (started on 
ventilation) 
- CXR: atelectasis and 
RDS-like picture 
- Low set crumpled ears 
- Small upturned nose with 
depressed nasal bridge 
- Mid-facial hypoplasia 
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Table 3.1: Endocrinology and phenotypes of the three patients in Pedigree 1. *GA, gestational age; SDS, standard deviation score; 
NR, normal range; TSH, thyroid-stimulating hormone; ACTH, adrenocorticotropic hormone; GH, growth hormone; CXR, chest X-ray; 
RDS, respiratory distress syndrome.  
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MRI of patient IIIb from Pedigree 1 showed a complete absence of the anterior 
pituitary and an ectopic posterior pituitary (EPP) gland (Figure 3.2 C-D). A comparison 
between a normal control individual and patient IIIb MRI scans are presented in 
Figure 3.2 where a different position and size of the pituitary gland is noted in the 
patient. The two other patients; IIIa and IIIc did not have an MRI available. The three 
siblings were reported to have atelectasis of the lungs, with chest X-rays of patients 
IIIa and IIIb showing a ground-glass appearance (a hazy increased attenuation of the 
lungs) typical of hyaline membrane disease, which is now more commonly known as 
classical respiratory distress syndrome (RDS) (Figure 3.2 E-F). Chest X-ray images 
were not available for patient IIIc. 
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Figure 3.2: The MRI scan of patient IIIb and chest X-rays of patients IIIa and IIIb 
from Pedigree 1. (A-B) Taken from the Fipa patients database 
(www.fipapatients.org). (A) A sagittal MRI view of a normal control individual showing 
the correct size and position of both the anterior and posterior lobes of the pituitary 
gland. (B) A magnified image of the area of the brain highlighted by the white box in 
‘A’, however the image is taken from a different normal control individual. (C) A 
sagittal MRI view of patient IIIb showing complete absence of the AP and an EPP 
gland. (D) A magnified image of ‘C’ in the area highlighted by the white box. (E-F) 
Chest X-rays of patients IIIa and IIIb respectively, showing a ground-glass opacity 
typical of hyaline membrane disease, also known as classical RDS. AP, anterior 
pituitary; EPP, ectopic posterior pituitary; RDS, respiratory distress syndrome. 
115 
 
 
3.2. Results 
LHX4 is a member of the LIM/homeobox protein family which are multifunctional. 
Please refer to Chapter 1.3.6 for a detailed account of LHX4 and its past association 
with hypopituitarism. Heterozygous LHX4 mutations in humans are usually 
associated with variable and variably penetrant CPHD (Pfaeffle et al., 2008), making 
LHX4 a known causative gene and thus why it is routinely screened in our cohort of 
CPHD patients. The proband and his younger brother from Pedigree 1 sent to us from 
Pakistan were therefore screened for variants in the LHX4 gene by direct sequencing 
analysis (Chapter 2.1 – 2.2). 
 
 
3.2.1. Mutational analysis 
Direct sequencing analysis revealed a novel homozygous missense variant in exon 
3 of LHX4 (ENST00000263726), c.377C>T, p.T126M, in the two deceased brothers 
(Pedigree 1) (Figure 3.3 A). The variant was not present in 1000 Genomes, dbSNP, 
EVS or the ExAC Browser databases, with the latter including a total of >100,000 
control alleles of which >16,000 were of a South Asian background and thus more 
relevant to refer to for this variant in Pedigree 1. The mutated residue is located within 
a highly conserved region across multiple species as well as with other members of 
the LHX-family (Figure 3.3 B). Causative genes LHX3, HESX1, PROP1, POU1F1 and 
SOX3 were also screened for mutations in the patients in Pedigree 1, but were 
negative for mutations.  
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Figure 3.3: The electropherogram and conservation of the LHX4 (p.T126M) 
variant. (A) An electropherogram showing the homozygous missense variant, 
c.377C>T (p.T126M), in exon 3 of LHX4 in pedigree 1 (indicated by the arrow) with 
the WT sequence shown below the patient coding sequence. (B) The conservation 
of the LHX4 residue that is mutated. The threonine residue (represented by the green 
‘T’) at location p.T126 is highly conserved between multiple species and other 
members of the LHX-family of proteins. This residue is substituted by methionine in 
the proband and his sibling in pedigree 1. WT, wild-type. 
 
This detected LHX4 (p.T126M) variant is located within the LIM2 domain where 
previous reported mutations in LHX4 have been located. Other mutations have also 
been identified in the LIM1 and homeodomain, as well as along the whole protein 
(Figure 3.4). 
Patient 
WT 
B 
                                  LHX4 p.T126M 
Human:      R--Q--L--A--T--G--D--E--F 
Chimpanzee: R--Q--L--A--T--G--D--E--F 
Mouse:      R--Q--L--A--T--G--D--E--F 
Cow:        R--Q--L--A--T--G--D--E--F 
Dog:        R--Q--L--A--T--G--D--E--F 
Elephant:   R--Q--L--A--T--G--D--E--F 
Chicken:    R--Q--L--A--T--G--D--E--F 
Rabbit:     R--Q--L--A--T--G--D--E--F 
Xenopus:    R--Q--L--A--T--G--D--E--F 
Zebrafish:  R--Q--L--A--T--G--D--E--F 
Human LHX3: R--Q--L--A--T--G--D--E--F 
Human LHX6: R--Q--L--S--T--G--E--E--F 
Human LHX8: R--Q--L--S--T--G--E--E--F 
A 
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Figure 3.4: A schematic diagram of the LHX4 protein. Previously published exonic heterozygous mutations in LHX4 and the novel 
homozygous variant, T126M, located in the LIM2 domain (highlighted in red). The numbers depict the protein position of the mutated 
residue, and at what residue the domains begin and end respectively.  
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 3.2.2. Western blot analysis 
In the first instance, western blot analysis was performed on total protein extracted 
from cell lysates following transfection with wtLHX4, LHX4 (p.T126M) and LHX4 
(p.R84C) constructs respectively to investigate the amount of LHX4 protein that was 
being produced in each population. The known partial loss of function mutation LHX4 
(p.R84C) was used as a control in the transfection assays in this study, and therefore 
was also run on the western blot. This LHX4 (p.R84C) mutated protein is known to 
be of comparable size to wtLHX4 protein (Pfaeffle et al., 2008). Total protein was 
quantified using a BCA assay and a western blot was performed as described in 
Chapter 2.3.3, with GAPDH used as a control. Results indicated that protein extracted 
from LHX4 (p.T126M) transfected cells produced a protein product of comparable 
size to wtLHX4 and LHX4 (p.R84C) transfected cells (Figure 3.5).  
 
 
 
 
 
 
 
 
 
 
 
LHX4 
GAPDH 
EV wtLHX4 R84C T126M 
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Figure 3.5: LHX4 western blot analysis. Western blot analysis using an anti-LHX4 
antibody showing a specific band at 42kDa, indicative of LHX4, at the same significant 
intensity in wtLHX4, LHX4 (p.R84C) and LHX4 (p.T126M). An anti-GAPDH antibody 
was used to stain GAPDH as a control, which is shown in the specific band at 38kDa. 
‘EV’; empty vector, ‘wtLHX4’; wild-type LHX4.  
 
3.2.3. Protein prediction modelling 
Online prediction models Polyphen2 and SIFT were initially consulted for the LHX4 
(p.T126M) variant, showing a score of 1.000 on Polyphen2 termed ‘possibly 
damaging’ and a score of 0 on SIFT interpreted as ‘damaging’. An actual protein 
prediction model was created by our collaborator; Dr Jose Saldanha from the Division 
of Mathematical Biology, National Institute for Medical Research, Mill Hill, using the 
RasMol software (www.RasMol.Org) database. He is an expert in this field and 
interpreted the model to give the prediction discussed here. This was carried out in 
order to analyse what happens to the structure of the LHX4 protein when the p.T126M 
variant is introduced. The model showed that normally the threonine at position 126 
in LHX4 likely interacts with arginine at position 103 (Figure 3.6). Substitution of this 
threonine by methionine, as seen in the patients in Pedigree 1, is predicted to disrupt 
this interaction by affecting stability of the protein. Additionally, the threonine is on the 
surface within a turn of the protein structure (Figure 3.6), suggesting direct 
involvement in protein-protein interaction.  
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Figure 3.6: A protein prediction model of the LHX4 (p.T126M) variant. The 
RasMol software (www.RasMol.Org) database; a computer program commercially 
used for molecular visualization of protein models, was used to create the LHX4 
(p.T126M) protein model. The threonine at p.T126 is on the turn of the protein. The 
threonine interacts with an arginine residue at p.R103, labelled. This interaction is 
predicted to be disrupted when this threonine is substituted for methionine (p.M126) 
as seen in Pedigree 1. The yellow shapes signify beta-strands, thus p.R103 is in a 
beta strand. The light blue represents a turn region in the protein and therefore T126 
is on a turn. The dotted lines depict hydrogen-bonds and the red spheres represent 
water molecules. Thr; threonine, Arg; arginine. 
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3.2.4. Gene activation assays 
The LHX4 (p.T126M) variant identified in Pedigree 1 is located in the LIM2 domain; 
known to play a role in transactivation and protein-protein interaction. This knowledge 
led me to perform transactivation assays to investigate whether the p.T126M variant 
would affect the activation of known LHX4 downstream targets; αGSU and prolactin 
(Prl). In these assays, luciferase (Luc) was used as the reporter that was measured 
to compare activation of the mutant LHX4 (p.T126M) against the WT LHX4 (wtLHX4), 
at two different doses (Chapter 2.3.4). The constructs transfected into cells is 
illustrated in Figure 2.1. 
 
3.2.4.1. Non-parametric test: Part 1 (data refers to Figure 3.7 A and Appendix 1 
A) 
A two-sample Wilcoxon rank-sum (Mann-Whitney) test was used to test the 
hypothesis that the two independent samples (WT group and T126M group) come 
from populations with identical luciferase/protein (luciferase normalised to total 
protein values) distribution (in other words, to compare WT luciferase/protein values 
to T126M luciferase/protein values). There was no significant difference in 
luciferase/protein between WT LHX4 and T126M (p = 0.4015). 
 
Group (Cell population?) N Rank sum Expected 
WT 9 76 85.5 
T126M 9 95 85.5 
Combined 18 171 171 
 
Both wtLHX4 and LHX4 (p.T126M) similarly activated the αGSU-Luc reporter (Figure 
3.7 A), showing that the LHX4 (p.T126M) variant does not result in a change of 
function in the context of activating the αGSU-Luc promoter. Thereafter, the 
synergistic activity of wtLHX4 and LHX4 (p.T126M) with POU1F1, a known protein 
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partner of LHX4 (Pfaeffle et al., 2008) were compared respectively on the Prl 
promoter.  
 
Mann-Whitney tests were used to compare the normalised luciferase values (each 
raw measurement divided by the average EV for that particular assay). 
 
3.2.4.2. Non-parametric tests: Part 2 (data refers to Figure 3.7 B and Appendix 
1 B) 
A significant difference was found between LHX4 and lhx4 (p = 0.0003). 
Group (Cell population?) N Rank sum Expected 
LHX4 9 126 85.5 
lhx4 9 45 85.5 
Combined 18 171 171 
 
A significant difference was found between lhx4 and lhx4+pou1f1 (p = 0.0003). 
 
 Group (Cell population?) N Rank sum Expected 
lhx4 9 45 85.5 
lhx4+pou1f1 9 126 85.5 
Combined 18 171 171 
 
No evidence of a difference between lhx4 and t126m (p = 0.2332). 
 
Group (Cell population?) N Rank sum Expected 
lhx4 9 99 85.5 
t126m 9 72 85.5 
Combined 18 171 171 
 
There was evidence to suggest that T126M and lhx4 are significantly different (p = 
0.0007). 
 
Group (Cell population?) N Rank sum Expected 
T126M 9 124 85.5 
lhx4 9 47 85.5 
Combined 18 171 171 
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Evidence to suggest that there is a difference between lhx4 and t126m+pou1f1 (p = 
0.0003). 
 
Group (Cell population?) N Rank sum Expected 
lhx4 9 45 85.5 
t126m+pou1f1 9 126 85.5 
Combined 18 171 171 
 
No evidence to suggest a difference between LHX4 and T126M (p = 0.4529). 
 
Group (Cell population?) N Rank sum Expected 
LHX4 9 94 85.5 
T126M 9 77 85.5 
Combined 18 171 171 
 
Evidence of a difference between POU1F1 and pou1f1 (p = 0.0092). 
 
Group (Cell population?) N Rank sum Expected 
POU1F1 9 115 85.5 
pou1f1 9 56 85.5 
Combined 18 171 171 
 
Evidence of a difference between t126m and T126M (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
t126m 9 45 85.5 
T126M 9 126 85.5 
Combined 18 171 171 
 
Significant difference between t126m and t126m+pou1f1 (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
t126m 9 45 85.5 
t126m+pou1f1 9 126 85.5 
Combined 18 171 171 
 
No evidence to suggest a difference between lhx4+pou1f1 and t126m+pou1f1 (p = 
0.4015). 
 
Group (Cell population?) N Rank sum Expected 
lhx4+pou1f1 9 76 85.5 
t126m+pou1f1 9 95 85.5 
Combined 18 171 171 
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3.2.4.3. Non-parametric tests: Part 3 (data refers to Figure 3.7 C and Appendix 
1 C) 
Significant difference between LHX4 and lhx4 (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
LHX4 9 126 85.5 
lhx4 9 45 85.5 
Combined 18 171 171 
 
Significant difference between lhx4 and lhx4+pou1f1 (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
lhx4 9 45 85.5 
lhx4+pou1f1 9 126 85.5 
Combined 18 171 171 
 
Significant difference between lhx4 and r84c (p = 0.0013). 
 
Group (Cell population?) N Rank sum Expected 
lhx4 9 122 85.5 
r84c 9 49 85.5 
Combined 18 171 171 
 
Significant difference between lhx4 and lhx4+r84c (p = 0.0071). 
 
Group (Cell population?) N Rank sum Expected 
lhx4 9 55 85.5 
lhx4+r84c 9 116 85.5 
Combined 18 171 171 
 
Significant difference between lhx4 and r84c+pou1f1 (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
lhx4 9 45 85.5 
r84c+pou1f1 9 126 85.5 
Combined 18 171 171 
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Significant difference between LHX4 and R84C (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
LHX4 9 126 85.5 
R84C 9 45 85.5 
Combined 18 171 171 
 
Significant difference between lhx4+pou1f1 and lhx4+r84c (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
lhx4+pou1f1 9 126 85.5 
lhx4+r84c 9 45 85.5 
Combined 18 171 171 
 
Significant difference between lhx4+pou1f1 and r84c+pou1f1 (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
lhx4+pou1f1 9 126 85.5 
r84c+pou1f1 9 45 85.5 
Combined 18 171 171 
 
Significant difference between r84c and R84C (p = 0.0009). 
 
Group (Cell population?) N Rank sum Expected 
r84c 9 48 85.5 
R84C 9 123 85.5 
Combined 18 171 171 
 
Significant difference between r84c and lhx4+r84c (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
r84c 9 45 85.5 
lhx4+r84c 9 126 85.5 
Combined 18 171 171 
 
Significant difference between r84c and r84c+pou1f1 (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
r84c 9 45 85.5 
r84c+pou1f1 9 126 85.5 
Combined 18 171 171 
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Significant difference between pou1f1 and POU1F1 (p = 0.0017). 
 
Group (Cell population?) N Rank sum Expected 
pou1f1 9 50 85.5 
POU1F1 9 121 85.5 
Combined 18 171 171 
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3.2.4.4. Parametric tests: Two-tailed unpaired T-tests 
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Figure 3.7: Transient transfection gene activation assays in HEK293T cells 
using the LHX4 (p.T126M) variant. (A-C) Results are shown as the mean ± SD of 3 
independent experiments with each assay performed in triplicate. The average mean 
values from each triplicate assay 1, 2, 3 are shown in Appendix 1. The error bars 
represent the standard deviation (SD) of the mean. Two-tailed unpaired T-tests were 
the statistical tests used here. (A) Luciferase activity on the αGSU promoter following 
transfection with wtLHX4 and LHX4 (p.T126M) expression constructs respectively, 
co-transfected with the αGSU-Luc reporter construct. Luciferase activity was 
normalized to the amount of total protein and showed no significant difference 
between wtLHX4 and LHX4 (p.T126M). EV: empty vector was used as a negative 
control. (B) Luciferase activity on the Prl-Luc following transfection with wtLHX4, 
wtPOU1F1 and LHX4 (p.T126M). The lower dose (31.25ng/well) is indicated by the 
lower case lettering (lhx4, pou1f1) and the higher dose (62.5ng/well), which is the 
concentration consistent with previous studies, is indicated by the upper case lettering 
(LHX4, POU1F1). Luciferase activity was normalized to Renilla-luciferase activity. 
There was a significant increase in luciferase activity between wtLHX4 transfected 
alone, and wtLHX4 co-transfected with wtPOU1F1 on activating the Prl-Luc (p<0.05) 
indicated by *. In addition, there was significant difference in luciferase activity 
between LHX4 (p.T126M) alone, and LHX4 (p.T126M) co-transfected with 
wtPOU1F1 (p<0.01) indicated by **. (C) Luciferase activity on Prl-Luc following 
transfection with two doses, as described in ‘B’, of each expression construct: 
wtLHX4, wtPOU1F1 and LHX4 (p.R84C) alone, in addition to wtLHX4 and LHX4 
(p.R84C) (lower dose) co-transfected with wtPOU1F1 (lower dose). The significant 
increase in luciferase activity between wtLHX4 transfected alone, and wtLHX4 co-
transfected with wtPOU1F1 was replicated in this assay on activating the prolactin 
promoter but to a higher degree (p<0.001), indicated by ***. There was also a 
significant increase in activity between LHX4 (p.R84C) alone, and LHX4 (p.R84C) co-
transfected with wtPOU1F1 (p<0.01) indicated by **. There was a significant 
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difference in luciferase activity between wtLHX4 co-transfected with wtPOU1F1, and 
LHX4 (p.R84C) co-transfected with wtPOU1F1 (p<0.05), indicated by *. Luc, 
luciferase; Prl-Luc, prolactin-luciferase. 
 
When activating prolactin-luciferase (Prl-Luc), the individual constructs alone 
(wtLHX4 and LHX4 (p.T126M)) resulted in a dose-dependent increase in luciferase 
activity. When each of these constructs were co-transfected with wtPOU1F1, there 
was a significant increase in activity compared to transfection with LHX4 alone. 
Results are shown as the mean ± SD of 3 independent experiments with each assay 
performed in triplicate; wtLHX4 with wtPOU1F1, 4.44 ± 1.28 vs 30.01 ± 10.23; 
p=0.013 and LHX4 (p.T126M) with wtPOU1F1, 3.92 ± 1.01 vs 33.60 ± 9.95; p=0.007. 
However, there was no significant difference in synergistic transactivation of the Prl-
Luc reporter between wtLHX4 and LHX4 (p.T126M), co-transfected with and without 
wtPOU1F1 (Figure 3.7 B). The significant increase in activity between wtLHX4 
transfection alone and wtLHX4 co-transfection with wtPOU1F1 was replicated, 4.22 
± 1.43 vs 30.26 ± 3.73; p=0.0004 in another set of transfection assays that activated 
the Prl-Luc reporter (Figure 3.7 C). This is a higher significant difference in 
transactivation between wtLHX4, and wtLHX4 with wtPOU1F1, compared to what 
was observed the first time (p=0.0004 vs p=0.013) (Figure 3.7 B), showing variability 
between assays with a stronger transactivation in this final assay (Figure 3.7 C). In 
these final transfections, the known partial loss of function mutation, LHX4 c.250C>T, 
p.R84C (Pfaeffle et al., 2008), was used as a control. There was no significant 
difference in activation of the Prl-Luc reporter when transfecting the LHX4 (p.R84C), 
both alone and in the presence of wtLHX4, compared to wtLHX4 alone. Additionally, 
co-transfection of LHX4 (p.R84C) with wtPOU1F1 led to an increase in transcriptional 
activity compared to LHX4 (p.R84C) alone, 2.12 ± 0.45 vs 17.13 ± 3.44; p=0.002, 
however, activation was significantly lower than that achieved by co-expression of 
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wtLHX4 with wtPOU1F1, 30.26 ± 3.73 vs 17.13 ± 3.44; p=0.011 (Figure 3.7 C), 
demonstrating the reported partial loss of function of LHX4 (p.R84C). The use of this 
reported mutant construct, indicates that the assays performed in this study work well 
and that the results are a true representation. As the wtLHX4 and the LHX4 (p.T126M) 
showed similar positive activities, it is suggested that both are well expressed, thus 
complementing the western blot analysis (Figure 3.5).   
 
3.4. Discussion 
The homozygous LHX4 variant identified in the three siblings from Pedigree 1 causes 
a change in a highly conserved region of the LIM2 domain of the protein (Figure 3.3 
B), and has outcomes that parallel the Lhx4 homozygous null mutant mouse model 
(Li et al., 1994). This is the first homozygous LHX4 mutation to be described in 
humans in association with hypopituitarism, I therefore wished to further test the 
impact of the mutation on LHX4 function. Mutations affecting LIM domains have been 
known to affect transactivation as well as interaction of protein partners, however 
functional studies have been performed in a relatively small number of mutant LHX4 
proteins. Previous functional studies on the partial loss of function mutation, LHX4 
(p.R84C), showed reduced activation of the αGSU and TSHβ reporters and inactivity 
on the POU1F1 promoter reporter gene (Pfaeffle et al., 2008). Another study looked 
at the LHX4 (p.V101A) mutant which was completely unable to activate the POU1F1 
and FSHβ subunit gene promoters (Tajima et al., 2010). Additionally, the LHX4 
(p.V75I) mutation located in the LIM1 domain was associated with a partial 
impairment of the capacity to transactivate POU1F1 and αGSU, without any 
dominant-negative effects (Takagi et al., 2012).  
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As transactivation of both the αGSU-Luc and Prl-Luc promoters were not affected by 
LHX4 (p.T126M), it is suggested that gene activation is perhaps not the mechanism 
affected by this variant. It is understood that there are other promoters to explore in 
this context such as TSHβ, POU1F1 and FSHβ; however it cannot be certain that 
these are genuine physiological targets of LHX4 as they may be expressed at 
different developmental stages and at very particular doses. Thus the lower and 
higher doses used in the transactivation assays in these studies may not be mirroring 
the in vivo doses that occur in the body. In addition, LHX4 and POU1F1 may not be 
present in equal doses in vivo, as they have been in the analysis of these assays; the 
quantities of both proteins most likely vary within the biological system making it 
extremely difficult to mimic what occurs physiologically in in vitro studies. Essentially, 
the complete target gene set of LHX4 is unclear and many mechanisms taking place 
in vivo might underlie the defect associated with this mutation. Therefore 
controversially it cannot be ignored that the possibility of the LHX4 (p.T126M) 
substitution may be effecting an as yet undetermined function of the protein. It should 
also be noted that as this variant was identified via a Sanger sequencing approach, it 
cannot be excluded that another undetected genetic abnormality or deletion 
elsewhere in the genome may be contributing to the phenotype as only the known 
causative genes were screened in this Pedigree: LHX3, HESX1, PROP1, POU1F1 
and SOX3. 
 
Mutations located in the LHX4 homeodomain often cause a loss of DNA-binding, as 
seen in reported mutations p.L190R and p.A210P (Pfaeffle et al., 2008). A 
heterozygous frameshift mutation, p.T99Nfs*53, was previously identified in LIM2 of 
LHX4 in two brothers with GH and TSH deficiencies, pituitary hypoplasia and a poorly 
developed sella turcica. The youngest also had corpus callosal hypoplasia and an 
EPP. This mutation led to a loss of transcriptional activity on the POU1F1, PRL and 
GH promoters due to abolished DNA-binding, which was a result of complete 
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truncation of the homeodomain (Castinetti et al., 2008). As the p.T126M substitution 
is not located and does not affect transcription of the homeodomain, it is not predicted 
to affect DNA-binding. Therefore it would not be necessary to perform an experiment 
such as an electrophoretic mobility shift assay (EMSA) for example, which is a 
common affinity electrophoresis technique used to study protein–DNA or protein–
RNA interactions, as the homeodomain in our patients is intact and should have a 
normal DNA-binding ability.   
 
LIM domains are involved in protein-protein interaction, as observed in both LHX3 
and LHX4. Sloop et al. (Sloop et al., 2001) previously analysed the binding abilities 
of purified LHX3 protein (mutant and WT) with partners Ldb1/NLI and POU1F1. 
Through in vitro binding assays, they tested whether the LHX3 (p.Y111/116C) 
substitution, located in the LIM2 domain, disrupts structure and binding to putative 
partner proteins. Interaction of LHX3 (p.Y111/116C) with POU1F1 was reduced 
compared to wtLHX3, which may explain the reduction in the ability of LHX3 
(p.Y111/116C) to activate the Prl promoter in the presence of POU1F1 (Sloop et al., 
2001). Studies such as this led me to investigate the protein-protein interaction of 
LHX4 and POU1F1 and its synergistic ability to activate the Prl promoter. Despite no 
significant difference being apparent in these synergistic assays, the LHX4 (p.T126M) 
may be affecting other such interactions with partner proteins even though interaction 
with POU1F1 seems to be unaffected. One needs to bear in mind that the partners 
with which LHX4 interacts are largely unknown, therefore the LHX4 (p.T126M) 
mutation may affect interaction with a partner yet to be identified. Alternatively likely 
partners such as Ldb1 for example may demonstrate impaired complex formation and 
be a possible mechanism whereby LHX4 (p.T126M), especially in its homozygous 
state, leads to the phenotype seen in Pedigree 1. Furthermore, the RasMol protein 
prediction model concluded that the threonine that is substituted by methionine in 
Pedigree 1, is on the surface within a turn of the protein (Figure 3.6), suggesting an 
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involvement in protein-protein interaction. Moreover, online prediction models 
Polyphen2 and SIFT predict the p.T126M variant to be damaging (Table 3.2).  
 
Protein prediction 
model software used 
Website reference 
to software 
Score 
generated 
from model if 
applicable 
Result determined 
from model 
Polyphen2 genetics.bwh.harva
rd.edu/pph2/ 
1 Possibly damaging 
SIFT sift.jcvi.org/ 0 Damaging 
RasMol www.RasMol.Org N/A Predicted to alter 
stability and 
protein-protein 
interaction 
 
Table 3.2: Protein prediction models used for the LHX4 (p.T126M) variant. Two 
that generate a score reflecting the level of pathogenicity; Polyphen2 and SIFT, and 
one that illustrates a molecular model of the p.T126M variant; Rasmol. 
 
The p.T126M variant was present in both brothers (IIIb, IIIc) in Pedigree 1. 
Unfortunately the daughter’s (IIIa) DNA was not available; however, her clinical 
presentation suggests that it was highly likely that she carried the same homozygous 
variant in addition to her brothers. Previously, patients carrying heterozygous LHX4 
mutations have manifested variable CPHD incorporating GH +/- TSH, PRL, ACTH, 
LH and FSH deficiencies. Phenotypes have included dysmorphic features, a small 
AP, an EPP, a poorly developed sella turcica, Chiari malformation, respiratory 
distress syndrome and corpus callosal hypoplasia (Castinetti et al., 2008, Pfaeffle et 
al., 2008, Dateki et al., 2010, Tajima et al., 2007). Both brothers in Pedigree 1 
presented with severe panhypopituitarism (Table 3.1) and showed anterior pituitary 
atrophy and an EPP, similar to previously reported carriers of LHX4 mutations. One 
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such previous report describes a maternally inherited heterozygous 1.5-megabase 
microdeletion in 1q25.2-q25.3, which spans LHX4 (q25.2), in a CPHD patient with 
minor physical anomalies, suggestive of a midline defect, and heart failure (Filges et 
al., 2012). Additionally, a de novo interstitial deletion of chromosome 1q24.3q31.1, 
again incorporating LHX4, was defined by array-comparative genomic hybridization 
(array-CGH) in a patient with pituitary hormone deficiencies, severe cognitive 
impairment, bilateral cleft lip/palate and other associated abnormalities. The deletion 
of LHX4 was considered to be largely causative of the diminished growth and CPHD 
in this patient (Capra et al., 2014). The CPHD observed in Pedigree 1 is consistent 
with these previous data, however the fact that all three patients died supports the 
hypothesis that the presence of a homozygous LHX4 mutation elicits fatal 
consequences. 
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3.5. Conclusion 
To date, described LHX4 mutations have been heterozygous, and often variably 
penetrant with outcomes likely caused by haploinsufficiency (McCabe and Dattani, 
2014) (Figure 3.4). This is the first report describing a homozygous variant in a patient 
identified through Sanger sequencing. Exome sequencing was not performed in this 
pedigree. Given the lethality of recessive mutations in rodents (Li et al., 1994), the 
homozygous p.T126M variant is likely to be responsible for this pedigree’s lethal 
phenotype, although the presence of another genetic abnormality contributing to their 
fatal phenotype cannot be ruled out. All three siblings presented with respiratory 
distress due to atelectasis of the lungs, echoing the mouse model in which null 
mutants died within the first week of life from immature lungs that failed to inflate (Li 
et al., 1994). Based on the phenotypic characterization of this mutant, this previous 
study concludes that Lhx4 plays a critical role in the development of early postnatal 
respiratory control mechanisms and in the normal growth and maturation of the lung 
in the mouse, as this study also suggests in humans. However the etiology of how 
mutant Lhx4/LHX4 elicits this fatal lung phenotype is as yet unknown. The high 
conservation between murine Lhx4 and human LHX4 indicates the fundamental 
importance of this protein in maintaining life across species and that recessive 
mutations in Lhx4/LHX4 are lethal. 
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Chapter 4 
 
 
 
New candidate genes identified through exome sequencing and their 
expression profiles in a phenotype-related context 
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4.1. Introduction 
At Great Ormond Street Institute of Child Health (ICH) we have access to over 2000 
DNA samples from around the world, that have hypothalamo-pituitary related 
phenotypes in whom no genetic diagnosis has been made. Aside from screening the 
known causative genes in the quest to find the genotype responsible for certain CH 
patient phenotypes, an alternative strategy of exome sequencing is demonstrated in 
this study. Many pedigrees that are negative for mutations in the known 
hypopituitarism genes, and phenotypically unique pedigrees that do not have any 
obvious genes to be screened, have been put forward for exome sequencing, in 
collaboration with GOSgene, to potentially highlight regions of interest in the exome 
that can be investigated further. The phenotypically unique cohort includes 
consanguineous and non-consanguineous families with varying hypothalamo-
pituitary disorders that have unusual accompanying phenotypes that have not been 
described in collaboration with the CH spectrum in the literature before. This chapter 
describes seven different unrelated Pedigrees (Pedigrees 2-8) with unusual 
phenotypes of this nature, that have had novel variants in novel genes revealed 
through exome sequencing as potential targets for hypothalamo-pituitary related 
phenotypes. An example of how exome sequencing data is filtered is illustrated in 
Appendix 2.  How each exome sequencing project (Pedigrees 3-7) was filtered is 
displayed in Appendix 3, and a summary table of the phenotypes and identified 
variants of Pedigrees 2-7 is shown in Appendix 4. Albeit the final pedigree (Pedigree 
8) discussed in this chapter, these novel variants will be functionally investigated in 
future projects through various analyses that are specific to each gene and the 
pathway in which it is involved. In this study, expression analysis has been conducted 
for each of the genes in which potentially causative variants have been identified, 
focusing on the hypothalamo-pituitary axis in human embryonic development, and 
any related tissues relevant to the patient phenotype. Initially following identification 
of a novel gene, it is very important to establish an expression profile in the context 
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of the tissues affected in the pedigree. If no expression is apparent in these areas 
there is less evidence to say that the gene is contributing towards the phenotype. As 
well as their expression profile, an introduction to the potential function of each 
respective gene and the phenotype of the patients that harbour these potential 
pathogenic variants, is reviewed in this chapter. Each gene appears to be unique in 
terms of expression pattern, function and impact on the phenotype. Establishing the 
exact hypothalamo-pituitary expression as in these data, will potentially benefit and 
complement future functional studies enabling delineation of the role of the relevant 
gene in development and disease.  
 
A total of six potential novel CH candidate genes have been identified through exome 
sequencing in these seven different families (Pedigrees 2-8). These genes, that were 
found to be mutated in the patients from these pedigrees, are: CTPS2, RNPC3, 
PRMT6, FASN, APEX2 and EIF2S3. An antisense and sense DIG-labelled RNA 
probe was generated from IMAGE clones for each gene, and in situ hybridisation was 
performed on human embryonic tissue at different stages of development as 
described in Chapter 2.5. All control sense probes for the genes were negative for 
any mRNA transcript staining; presenting with no visible colour image under the 
microscope, thus confirming that the expression data generated from this study are 
reliable.  
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4.2. CTPS2 
4.2.1. Pedigree 2 
A 23 year old female patient of Afro-Caribbean non-consanguineous background 
presented with congenital panhypopituitarism; GH, TSH, ACTH, LH and FSH 
deficiencies. Her complex phenotype additionally included left microtia; an absent 
pinna, with severe conductive hearing loss, ciliary dyskinesia, complete situs inversus 
with dextrocardia, hypoplasia of the mandible, severe eczema, learning difficulties, 
left facial nerve palsy with left sided hemiparesis and learning difficulties (Pedigree 2, 
Figure 4.1).  
 
Pedigree 2 
 
 
Figure 4.1: Pedigree 2 with the patient harbouring the CTPS2 (p.F166L) variant. 
The Afro-Caribbean non-consanguineous Pedigree 2 with the affected daughter, 
indicated by the shaded circle and arrow, that harbours the heterozygous de novo 
CTPS2 (p.F166L) variant. The roman numerals on the left of the image refer to the 
generation within the pedigree. The unshaded square and circle represent that the 
parents are unaffected. 
 
4.2.2. Exome sequencing results: CTPS2 
A heterozygous missense de novo variant in CTPS2 (ENST00000443824), 
c.498C>A, p.F166L, was identified in this patient (Pedigree 2). This is in a highly 
conserved region across multiple species (Figure 4.2) and is not present on any 
II 
  
 I 
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control database, including 1000 Genomes, dbSNP, EVS or the ExAC Browser, with 
the latter including over >87,000 control alleles; with >52,421 alleles from an African 
origin, which is a more relevant control cohort to this patient.  
 
CTPS2 (p.F166L) 
Human:      A--F--R--Q--F--Q--F--K--A 
Mouse:      A--F--R--Q--F--Q--F--K--A 
Chimpanzee: A--F--R--Q--F--Q--F--K--A 
Cow:        A--F--R--Q--F--Q--F--K--A 
Dog:        A--F--R--Q--F--Q--F--K--A  
Chicken:    A--F--R--Q--F--Q--F--K--A  
Xenopus:    A--F--R--Q--F--Q--F--K--A 
 
Figure 4.2: Conservation of the substituted CTPS2 residue. The extent of 
conservation across multiple species of the substituted amino acid (highlighted in 
green), and the spanning protein sequence, in CTPS2.  
 
4.2.3. CTPS2 function 
The coding region of Cytidine 5'-Triphosphate Synthase II (CTPS2) is 1.761kb in 
length, comprising of 19 exons on the X chromosome. CTPS2 catalyses the 
amination of UTP to CTP with the concomitant deamination of glutamine to glutamate 
(Bearne et al., 2001). It is the rate-limiting enzyme in the synthesis of cytosine 
nucleotides which play an important role in various metabolic processes and provide 
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the precursors necessary for the synthesis of RNA and DNA. CTPS2, like its family 
member CTPS1, regulates intracellular CTP levels through interactions with the four 
ribonucleotide triphosphates (Endrizzi et al., 2004). A recent report describes a loss-
of-function homozygous mutation (rs145092287) in CTPS1 in a patient with a novel 
life-threatening immunodeficiency, characterized by an impaired capacity of activated 
T and B cells to proliferate in response to antigen receptor-mediated activation (Martin 
et al., 2014). This mutation affected a splice donor site producing a transcript lacking 
exon 18 of CTPS1, of which expression was absent from lysates derived from 
Epstein-Barr Virus (EBV)-transformed B and T cells from patients. Functional assays 
performed in this previous study restored normal T-cell proliferation in CTPS1-
deficient cells by expressing WT CTPS1 or by the addition of CTP, or its nucleoside 
precursor cytidine (Martin et al., 2014). CTPS2 may also be referred to as an 
oncogene, as cancer cells that exhibit increased cell proliferation also exhibit an 
increased activity of this encoded protein, making it a potential target for 
chemotherapy (www.ncbi.nlm.nih.gov). Previous studies have shown that a reduction 
in CTPS2 expression increases resistance of colorectal cancer cell lines to the drug 
5-fluorouracil (5FU). This was reflected in their study in vivo, where patients with low 
CTPS2 did not gain a survival benefit from 5FU treatment, while those with high 
expression did (Tan et al., 2011).  
Murine Ctps2 is expressed in multiple systems including the reproductive, respiratory, 
nervous, olfactory, auditory and visual systems with many more listed as having 
transcript staining (MGI). Human CTPS2 expression is highest in the prostate, ovarian 
follicles, testis, areas of the brain, lymph nodes, tonsils and the parathyroid gland as 
well as other areas of the body according to the Human Protein Atlas.  
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4.2.4. CTPS2 expression results 
The hypothalamo-pituitary axis of the brain has not previously been studied for 
CTPS2 in detail. Expression analysis conducted in this study show expression in the 
neural tube and Rathke’s pouch (the primordium of the anterior pituitary) at CS16 and 
CS19 (Figure 4.3A-B, D). In the diencephalon, telencephalon (Figure 4.3C), 
trigeminal ganglia at CS19 (Figure 4.3D), spinal cord and spinal ganglia at CS19 
(Figure 4.3E). In the developing neural retina of the eye at CS19 and at late 8 post 
conception week (pcw) (Figure 4.3F-G), and in the oesophagus and the lungs; 
bronchi at CS19 (Figure 4.3H-I). CTPS2 expression was also noted in parts of the 
developing ear; in the cochlea at CS23 and in the semi-circular canal and the utricle, 
which is one of the vestibular sensory organs at CS19 (Figure 4.4A-D). Due to the 
patient having dextrocardia, sections of the heart at CS19 were also analysed in this 
study, however they showed no significant transcript expression.  
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Figure 4.3: CTPS2 expression in the developing hypothalamic-pituitary axis, 
eyes and lungs during human embryogenesis. In situ hybridization using the 
antisense probe against the human CTPS2 mRNA transcript (hCTPS2) on human 
sections from different Carnegie stages (CS) during embryogenesis. Scale bars in 
each image depict 200µM. (A-E) Transverse sections, (F-G) sagittal sections, (H-I) 
transverse sections (A) CS16: expression is seen in the neural tube, Rathke’s pouch 
and the eye. (B) CS16: Rathke’s Pouch and the hypothalamus show high CTPS2 
expression. (C) CS19: expression in the telencephalon and diencephalon, (D) CS19: 
in the trigeminal ganglia and Rathke’s pouch. (E) CS19: expression is observed in 
the spinal cord and spinal ganglia, (F) CS19 a gradient of expression in the 
developing neural retina of the eye. (G) Late 8 post conception week (pcw): 
expression in the developing neural retina of the eye. (H-I) CS19: expression in the 
oesophagus and bronchi of the lungs. The black boxes in ‘A’ and ‘H’ reflect the section 
of the image that is magnified in ‘B’ and ‘I’ respectively. RP, Rathke’s pouch; Hyp, 
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hypothalamus; T, telencephalon; D, diencephalon; TG, trigeminal ganglia; S, spinal 
cord; SG, spinal ganglia; R, retina; B, bronchi; O, oesophagus. 
 
Figure 4.4: CTPS2 expression in the developing ear. In situ hybridization 
performed on human transverse sections using the antisense probe against the 
human CTPS2 mRNA transcript (hCTPS2). The scale bar in ‘A’ represents 500µM 
and the scale bars in ‘B-D’ depict 200µM. (A-C) CS19: expression is seen in the utricle 
(a vestibular sensory organ) and the semi-circular canal of the ear. The black boxes 
in ‘A’ are the sections of the image that are magnified in ‘B’ and ‘C’ respectively. (D) 
CS23: expression in the cochlea structure of the ear, highlighted by the arrowheads. 
U, utricle; SC, semi-circular canal; C, cochlea.
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4.3. RNPC3 and PRMT6 
4.3.1. Exome sequencing results of Pedigrees 3-6 
Exome sequencing revealed an area of homozygosity in four unrelated Turkish 
consanguineous pedigrees (Pedigrees 3-6, Figure 4.5) where the probands 
manifested a unique phenotype characterized by IGHD and primary ovarian failure in 
the affected females, with male patients manifesting IGHD. Six out of the seven 
affected individuals in Pedigrees 3-6; four females and two male patients, and the 
unaffected father of the female patient in pedigree 5, had exome sequencing 
performed (Figure 4.5). This area contained a novel homozygous missense variant in 
RNPC3 (ENST00000423855), c.1449A>T, p.L483F, and a novel homozygous 
missense variant in PRMT6 (ENST00000370078), c.1049C>G, p.P350R. The 
affected males have not been reported to have testicular problems, however limited 
detailed clinical information from these Turkish pedigrees are currently available. 
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Pedigree 3 
Pedigree 4 
Pedigree 5 
Pedigree 6 
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Figure 4.5: Pedigrees 3-6 harbouring the RNPC3 (p.L483F) and PRMT6 
(p.P350R) variants. Four unrelated pedigrees (Pedigrees 3-6) from Turkish origin. 
Shaded squares and circles indicate affected family members, squares for males, 
circles for females. Shapes joined by two lines indicate consanguinity between those 
individuals. The arrows and arrowhead highlight the probands in each pedigree. A 
diagonal line through a shape indicates that the individual is deceased. The roman 
numerals down the left hand side refer to the generation within that Pedigree. All 
affected individuals illustrated in these pedigrees had exome sequencing performed, 
with the exception of the affected male patient in Pedigree 5. In addition, exome 
sequencing was also performed in the unaffected father of the female patient in 
Pedigree 5. 
 
The novel missense substitution, RNPC3 (p.L483F), is highly conserved across 
multiple species (Figure 4.6A) and is not present on control databases; 1000 
Genomes, dbSNP, EVS or the ExAC Browser, with the latter including >111,000 
alleles; incorporating >67,000 from a European background which is where any 
Turkish control alleles would be categorized and thus are more relevant controls to 
Pedigrees 3-6. The novel PRMT6 (p.P350R) missense substitution is conserved 
across four species (Figure 4.6B) and is not present in homozygous form on control 
databases; 1000 Genomes, dbSNP, EVS or the ExAC Browser. However, a 
substitution of the Proline by a Threonine residue at position 350 is present in 
heterozygous form in two alleles from European origin on the ExAC Browser, out of 
a total of >66,000 control alleles; 60,174 of which were from the European cohort. 
The role of PRMT6 is discussed in section 4.3.4 of this chapter. 
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A) RNPC3 (p.L483F)  
Human:      A--A--K--A--L--K--E--A--N 
Mouse:      A--A--K--A--L--K--E--A--N 
Chimpanzee: A--A--K--A--L--K--E--A--N 
Cow:        A--A--K--A--L--K--E--A--N  
Dog:        A--A--K--A--L--K--E--A--N 
Chicken:    A--A--K--A--L--K--E--A--N 
 
B) PRMT6 (p.P350R)  
Human:      S--R--D--N--P--R--R--L--R 
Mouse:      S--P--D--N--P--R--R--L--R 
Chimpanzee: S--R--D--N--P--R--R--L--R 
Elephant:   A--R--D--N--P--R--R--L--R 
 
 
Figure 4.6: Conservation of the substituted RNPC3 and PRMT6 residues. The 
extent of conservation across multiple species of each substituted amino acid, (A) 
RNPC3 and (B) PRMT6 (highlighted in green), and the spanning protein sequences. 
Any spanning amino acid residues that differ from the normal human reference 
sequence are highlighted in red. 
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4.3.2. RNPC3 function 
There are two types of spliceosomes that catalyse splicing of pre-mRNAs: the major 
U2-type spliceosome removes U2-type introns (99% of pre-mRNA introns) and the 
minor U12-type spliceosome removes U12-type introns, which are rare with distinct 
splice consensus signals. Both the U2- and U12-type spliceosomes consist of several 
small nuclear RNAs (snRNAs) and associated proteins (Sharp and Burge, 1997) 
(Figure 4.7). The RNA-binding region (RNA recognition motifs [RRM]) containing 3 
(RNPC3) coding region is 1.554kb in length, incorporating 16 exons on chromosome 
1. RNPC3 encodes a 65K protein that is a component of the U12-type spliceosome. 
It contains two bipartite nuclear targeting sequences important for nuclear targeting 
for proteins, especially those functioning in the cell nucleus itself (Zhao et al., 2003). 
RNPC3 is located in the cell nucleus and is abundantly expressed in the kidney and 
pancreas (Zhao et al., 2003). This protein’s two RRM’s suggest that it may contact 
one of the small nuclear RNAs of the minor spliceosome (Zhao et al., 2003).  
Defects in the U12-type splicing; via mutations in the U4atac snRNA component of 
the minor spliceosome, have been reported to be associated with the complex 
disorder Taybi-Linder syndrome (also known as microcephalic osteodysplastic 
primordial dwarfism 1), a severe developmental disorder involving brain and skeletal 
abnormalities, and tragically unexplained postnatal death (Edery et al., 2011) (He et 
al., 2011). This is an example of how poorly spliced endogenous U12-dependent 
introns, but not U2-dependent, can specifically cause life-threatening complex 
disorders. Defective U12-type splicing, via a mutation in the tumour suppressor gene 
LKB1 intron, has also been linked to a hereditary intestinal polyposis condition, Peutz-
Jeghers syndrome, which is associated with increased cancer risk (Hastings et al., 
2005). 
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U2-type spliceosome and U12-type spliceosome 
 
Figure 4.7: A comparison of the steps during the formation of the U2- and U12-
type spliceosome. The U2-type major spliceosome forms at introns with a GU 
sequence at their 5’ end and an AG sequence at their 3’ end. The U12-type minor 
spliceosome forms at introns with an AU sequence at their 5’ and an AC sequence at 
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their 3’ end. Both the U2- and U12-type spliceosomes recognise an ‘A’ residue branch 
site in the intron. A series of different small nuclear RNA (snRNA) molecules e.g. U1, 
U2, U11, U12 etc, belonging to either the U2- or U12-type spliceosome, bind in 
succession to the intron to form the spliceosome complexes respectively, resulting in 
the cleavage and thus the splicing of introns. The U5 snRNA is the only common 
component between the U2- and U12-type spliceosome. This image was taken and 
adapted from Will CL, Luhrmann R. Biol. Chem. 2005 Aug; 386(8): 713-24.  
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Murine Rnpc3 is expressed in the nervous and olfactory systems (MGI) yet, to date, 
there is no murine model for Rnpc3 loss of function. However, a study using a 
zebrafish mutant model with an induced lethal point mutation in rnpc3 resulted in 
arrested development of the digestive organs. This phenotype arose from the 
formation of aberrant U11- and U12-containing snRNAs that impaired the efficiency 
of U12-type splicing. This zebrafish model provided a useful and specific model of 
aberrant U12-type splicing in vivo. Analysis of its transcriptome revealed that efficient 
mRNA processing is a critical process for the growth and proliferation of cells during 
vertebrate development (Markmiller et al., 2014).  
Biallelic mutations in RNPC3 have previously been described in three sisters with 
severe IGHD and pituitary hypoplasia, where anomalies were identified in U11/U12 
di-snRNP formation and the splicing of multiple U12-type introns in these patient cells 
(Argente et al., 2014). Through RNA sequencing (RNA seq) the authors identified a 
list of 21 genes with significantly decreased U12/U2 ratios in patient cells, as well as 
aberrant processing events including exon skipping and activation of cryptic U2-type 
splice sites (Argente et al., 2014). A subset of the 21 genes were found to encode 
proteins with relevant functions in pituitary development, such as SPCS2 and SPCS3 
that encode subunits of the signal peptidase complex, implicated in posttranslational 
processing of preprohormones such as preproghrelin to proghrelin (Argente et al., 
2014, Yin et al., 2009), thus themselves becoming candidates for the phenotype. 
 
 
 
 
 
153 
 
4.3.3. RNPC3 expression results 
Human expression analysis was performed on embryonic tissue from the 
hypothalamo-pituitary axis of the brain (Figure 4.9) in this study. Results showed high 
RNPC3 expression in the telencephalon, diencephalon (Figure 4.9A), trigeminal 
ganglia, hypothalamus and Rathke’s pouch at CS19 (Figure 4.9B-D). Furthermore, 
human embryonic ovarian sections were also requested from HDBR, however 
following staining of these sections it came to light that the tissue was not in fact fully 
ovarian, despite being referenced as so. Therefore the RNPC3 mRNA transcript 
staining is observed in the mesonephros (ducts that later develop into the kidney), 
and in what is possibly the fallopian tube (Figure 4.9 F-K), at 9pcw, in tissue that was 
originally thought to be ovarian. The ovary and mesonephros are attached to each 
other during early female embryonic development, and by the 10pcw stage the 
mesonephros have disappeared as the true kidney is formed (HDBR specialists). 
Unfortunately, the large bulk of the ovary was not present in the 9pcw sections 
acquired in this study, only its smaller counterpart was intact, as demonstrated in the 
comparison below of our section and an image of what it should have looked like 
following sectioning (Figure 4.8) (recent unpublished information from HDBR). There 
are two pairs of genital ducts present in both male and female embryos, the 
mesonephric (wolffian) and paramesonephric (müllerian). In female embryogenesis 
at 9pcw, the mesonephric ducts degenerate but the paramesonephric ducts, by the 
process of fusion that starts caudally and progresses cranially, form the uterovaginal 
canal. This canal later develops into the upper portion of the vagina and uterus, while 
their non-fused portions become fallopian tubes (Grechukhina et al., 2016). In recent 
talks with HDBR, colleagues said that in transverse sections through the lower body 
at 10pcw stage or later, it would be possible to distinguish between the fallopian tubes 
and paramesonephric ducts, however it remains ambiguous here at 9pcw as it is too 
early to tell these structures apart. Therefore I will now acquire sections from at least 
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10pcw from HDBR, with intact ovarian tissue, in order to clarify where the RNPC3 
transcript staining is located.   
 
 
Figure 4.8: Human embryonic tissue sections from the ovary and developing 
kidney. (A) A sagittal section of human embryonic tissue taken from an ovary and 
developing kidney at 9pcw. (B) The 9pcw sagittal section that our study acquired with 
the large section of ovarian tissue missing, that is present in (A). Each specific tissue 
is indicated by the arrows. The scale bar in the image represents 200µM. 
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Figure 4.9: RNPC3 expression in the developing hypothalamic-pituitary axis 
and the ovary during human embryogenesis. In situ hybridization using the 
antisense probe against the human RNPC3 mRNA transcript (hRNPC3) on human 
sections from CS19 and 9pcw during embryogenesis. The scale bars in ‘A-B’ 
represent 500µM and the scale bars in ‘C-K’ represent 200µM. (A-E) Transverse 
sections, (F-K) sagittal sections. (A-D) CS19: high hRNPC3 expression seen in the 
telencephalon, diencephalon, trigeminal ganglia and Rathke’s pouch. (E) CS19: 
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expression can be seen in the spinal cord and spinal ganglia. (F-J) 9pcw: expression 
is noted in the mesonephros of the premature kidney, indicated by the arrows labelled 
‘M’. (J-K) 9pcw: expression is observed in what may be the paramesonephric duct or 
the fallopian tube, indicated by the arrows labelled ‘FT’ in this case. This structure is 
difficult to determine at this early stage of development. The black boxes in (B), (G) 
and (J) indicate the area in the image that has been enlarged in the adjacent image 
respectively. T, telencephalon; D, diencephalon; TG, trigeminal ganglia; RP, Rathke’s 
pouch; Hyp, hypothalamus; S, spinal cord; SG, spinal ganglia; M, mesonephros; FT, 
fallopian tubes.
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4.3.4. PRMT6 function 
A homozygous missense variant in PRMT6, c.1049C>G, p.P350R, was identified in 
the same individuals from the four Turkish families (Pedigrees 3-6, Figure 4.5) that 
possess the RNPC3 (p.L483F) variant, in the same area of homozygosity. Variants 
RNPC3 (p.L483F) and PRMT6 (p.P350R) are evidently inherited from the same allele 
from both asymptomatic heterozygous parents. 
The coding region of Protein arginine methyltransferase 6 (PRMT6) is 1.128kb in 
length, consisting of only one exon on chromosome 1. It catalyses the sequential 
transfer of a methyl group from S-adenosyl-L-methionine to the side chain nitrogens 
of arginine residues within proteins, to form methylated arginine derivatives and S-
adenosyl-L-homocysteine. PRMT6 catalyses both the formation of Omega-N 
monomethylarginine and asymmetrical dimethylarginine (strongly) and specifically 
mediates the asymmetric dimethylation of Arg2 (R2) of histone H3 to yield its 
methylated form, giving it a specific tag for epigenetic transcriptional repression 
(Figure 4.10). PRMT6 forms a complex with and methylates DNA polymerase beta, 
and brings about the stimulation of polymerase activity by enhancing DNA binding 
and processivity (El-Andaloussi et al., 2006).  
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Figure 4.10:  PRMT6 transcriptional repression. A model of the transcriptional repression of Hox genes and Myc-dependent genes by PRMT6. 
Taken and adapted from Litt et al. (Litt et al., 2009). (A) Di and trimethyl of K4 is associated with the recruitment of MLL1 and WDR5 to chromatin 
and transcriptional activation. (B) PRMT6 recruitment and asymmetric dimethylation of R2 (Arg2) of H3 (H3R2) (denoted by the red circle labelled 
Me R2) results in the loss of the MLL complex, absence of H3 and K4 (H3K4) methylation (denoted by the green circle labelled Me K4), and 
decreased transcripts from target genes. The presence of asymmetrical dimethylation of H3R2 inhibited binding of the Ash2 (absent, small, or 
homeotic disc 2)/WDR5 (WD40 repeat-containing protein 5)/MLL (family methyltransferase complex) and methylation of H3K4. Brg1, BRM-
related gene 1; mSin3A, mammalian SIN3A; HDAC2, histone deacetylase 2; RpBP5, retinoblastoma binding protein 5.
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The Human Protein Atlas states that PRMT6 is variably expressed throughout the 
human body, with high expression in the kidney (renal tubules), pancreas (exocrine 
glandular cells), oral mucosa, testes (Leydig cells), breast (myoepithelial cells), 
thyroid gland, tonsils and bronchi (respiratory epithelial cells). Medium expression is 
seen in the ovary, fallopian tubes, cervix, placenta, salivary glands and the 
gastrointestinal tract (stomach, small intestine). In this study, human embryonic whole 
ovarian sections for in situ hybridisation studies were not able to be obtained as 
discussed earlier, therefore we have not yet looked at PRMT6 expression in the 
ovary.    
Murine Prmt6 is expressed in the nervous, olfactory and visual systems (MGI). A 
transgenic mouse model has been developed to ubiquitously express Prmt6 fused to 
the hormone-binding portion of the estrogen receptor (ER). Upon systemic treatment 
with tamoxifen, it becomes stabilized and translocates into the nucleus. Induced ER-
Prmt6 activation results in increased interleukin-6 (IL-6) levels, with expression 
regulated by the nuclear factor-kappa B (NF-κB) transcription factor and with Prmt6 
functioning as a coactivator of the pathway. Prmt6 is recruited to chromatin at 
selective NF-κB target promoters, where it likely impacts the histone code and/or 
methylates other chromatin-associated proteins to facilitate transcription (Di Lorenzo 
et al., 2014).  
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4.4. FASN and APEX2 
4.4.1. Pedigree 7 
A 19 year old male from a non-consanguineous family (Pedigree 7, Figure 4.11) 
presented at the age of 4 years with a unique complex phenotype characterized by 
panhypopituitarism; GH, TSH, ACTH, LH and FSH deficiencies, short stature, 
dysmorphic features, developmental delay, sensorineural deafness, 
hypoparathyroidism, retinal dystrophy, Reynaud’s syndrome, splenomegaly and 
aortic regurgitation. He failed to respond to high doses of recombinant human growth 
hormone (rhGH) with low IGF1 concentrations. He measures 128 cm at the age of 19 
years and is completely prepubertal. 
 
Pedigree 7 
 
 
 
 
Figure 4.11: Pedigree 7 with the patient harbouring the FASN (p.A2132V) and 
APEX2 (p.M422V) variants. The non-consanguineous Pedigree 7 with one affected 
male, indicated by the shaded square and arrow, that harbours both the heterozygous 
de novo FASN (p.A2132V) and the hemizygous APEX2 (p.M422V) variant. The latter 
variant was inherited from the mother, indicated by the circle containing a dot. The 
roman numerals on the left of the image refer to the generation within the pedigree. 
 
I 
  
a b 
a 
     
II 
161 
 
4.4.2. Exome sequencing results: FASN and APEX2 
A novel heterozygous missense de novo variant in FASN (ENST00000306749) 
located on chromosome 17, c.6395C>T, p.A2132V, has been identified in this 19 year 
old male with a unique phenotype (Pedigree 7), via exome sequencing. This variant 
is highly conserved across multiple species (Figure 4.12A) and is not present on 
control databases, including 1000 Genomes, dbSNP, EVS or the ExAC Browser 
which includes a total of >100,000 control alleles; >10,000 of which are from an 
African origin the same as the mother, and >64,500 alleles which are from a European 
origin (including a mix of controls from different European countries) the same as the 
father, who is white European. These sub-cohorts were individually referenced as 
they are more directly relevant to the patients’ ancestry. This patient also had a novel 
hemizygous missense variant in the APEX2 gene (ENST00000374987) located on 
the X chromosome, c.1264A>G, p.M422V, at a residue conserved in three other 
species; chimpanzee, dog and dolphin (Figure 4.12B). This variant was inherited from 
the heterozygous asymptomatic mother. Furthermore this variant (p.M422V) was 
identified once on control databases; in the ExAC browser in an African heterozygous 
individual out of a total of 86,652 alleles, of which 8405 were from an African origin 
the same as the mother. The role of APEX2 is discussed in section 4.4.5 in this 
chapter. 
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A) FASN (p.A2132V) 
Human:      V--E--A--V--A--H--I--L--G 
Mouse:      V--K--A--V--A--H--I--L--G 
Chimpanzee: V--E--A--V--A--H--I--L--G  
Chicken:    V--E--A--V--A--H--I--L--G 
Xenopus:    V--E--A--V--A--H--I--L--G  
Zebrafish   V--E--A--V--A--H--I--L--G 
 
B) APEX2 (p.M422V) 
Human:      M--S--A--L--M--T--P--K--T 
Chimpanzee: M--S--T--L--M--T--P--K--T  
Dog:        M--G--A--L--M--T--P--K--T  
Dolphin:    L--G--T--L--M--T--P--K--T 
 
Figure 4.12: Conservation of the substituted FASN and APEX2 residues. The 
extent of conservation across multiple species of each substituted amino acid 
(highlighted in green), and the spanning protein sequence, in both (A) FASN, and (B) 
APEX2. Any spanning amino acid residues that differ from the normal human 
reference sequence are highlighted in red.  
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4.4.3. FASN function 
The coding region of Fatty Acid Synthase (FASN) is 7.536kb in length comprising of 
43 exons on chromosome 17. FASN has long been identified as a crucial 
multienzyme composed of two identical 272 kDa polypeptides that have multiple 
functions in which substrates are transferred from one domain to another. More 
precisely, this complex enzyme essentially converts acetyl-CoA and malonyl-CoA into 
long-chain saturated fatty acids such as palmitate in the presence of NADPH, and 
has been reported to have as many as seven different catalytic activities (Wakil, 
1989). Recent studies in mice have shown that hepatocarcinogenesis, induced by 
AKT/c-Met, is fully inhibited by Fasn ablation. Therefore suppression of FASN might 
be highly detrimental for the growth of human hepatocellular carcinoma subsets (Hu 
et al., 2016). In addition, Shh signalling induces FASN, which mediates metabolic 
processes such as proliferating neural progenitors to support rapid growth, which can 
induce lipogenesis and aerobic glycolysis; pathways that are increased in 
medulloblastoma metabolism (Tech and Gershon, 2015). Fasn is highly active in adult 
neural stem and progenitor cells (NSPCs) and conditional deletion of Fasn in mouse 
NSPCs impairs adult neurogenesis (Knobloch et al., 2013). Other studies have shown 
that murine null mutant Fasn-/- embryos die before implantation, and Fasn+/- 
heterozygotes die at various stages of development in utero, suggesting haploid 
insufficiency (Chirala et al., 2003). 
Murine Fasn is expressed in the brain, parathyroids, liver and adrenal, as well as the 
high level of expression observed in adult NSPCs. It is expressed in numerous tissues 
including the limbs, the exocrine and endocrine systems, and the olfactory, 
reproductive, respiratory and connective tissue systems, to name a few (MGI). In 
humans, this multifunctional enzyme has been noted to be highly expressed in the 
glandular and adipocyte cells of the breast (Human Protein Atlas).  
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4.4.4. FASN expression results 
In this study, human embryonic expression in a hypothalamo-pituitary context, 
revealed high FASN expression in the hypothalamus, and in Rathke’s pouch at the 
early stage of CS16 (Figure 4.13A-C). At CS19, expression was noted in the spinal 
cord (Figure 4.13D), spinal ganglia and trigeminal ganglia (Figure 4.13E). However, 
despite expression being maintained in the diencephalon and telencephalon (Figure 
4.13F), there appeared to be no FASN transcript expression in Rathke’s pouch from 
this stage onwards in embryogenesis [shown by the lack of total expression in 
Rathke’s pouch at CS20 (Figure 4.13I)]. Specific FASN expression was observed in 
the retina of the eye at CS20 (Figure 4.13G-H). No specific expression was observed 
in the developing ear, heart or spleen for this gene.  
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Figure 4.13: FASN expression in the hypothalamo-pituitary axis and the eye in 
the developing human embryo. In situ hybridization using the antisense probe 
against the human FASN mRNA transcript (hFASN) on human transverse sections 
from CS16, CS19 and CS20. The scale bars in the images are as follows: 500µM in 
‘A’, 200µM in ‘B’, 100µM in ‘C’, 500µM in ‘D-G’ and 200µM in ‘H-I’. (A-B) CS16: high 
FASN expression in the hypothalamus. (C) CS16: expression in Rathke’s pouch. (D) 
CS19: expression seen in the spinal cord and spinal ganglia, (E) trigeminal ganglia 
and hypothalamus, (F) diencephalon and telencephalon. (G-H) CS20: expression in 
the retina of the eye, (I) Rathke’s pouch shows no FASN expression at CS20. The 
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black boxes in ‘A’ and ‘G’ indicate the area of the sections that are magnified in 
images ‘B’ and ‘H’ respectively. H, hypothalamus; RP, Rathke’s pouch; SG, spinal 
ganglia; S, spinal cord; TG, trigeminal ganglia; D, diencephalon; T, telencephalon; R, 
retina.  
 
4.4.5. APEX2 function 
The coding region of Apurinic/apyrimidinic (AP) endonuclease 2 (APEX2) is 1.557kb 
in length comprising of 6 exons, on the X chromosome. It is a member of the 
endonuclease family that initiates the repair of AP sites formed by spontaneous 
hydrolysis of the N-glycosylic bond, mutagen-induced base release, or damaged-
base excision caused by a DNA repair glycosylase (Hadi et al., 2002). Previous 
functional studies showed, through immunocytochemistry, that APEX2 localises to 
the mitochondria due to the gene having a mitochondrial targeting sequence on its N-
terminus (Tsuchimoto et al., 2001). These studies also showed evidence that APEX2 
participates in mitochondrial base excision repair (BER) as well as in nuclear BER 
(Tsuchimoto et al., 2001). Other studies revealed that Apex2-null mice exhibit a 
growth retardation phenotype (80% the size of WT littermates) with moderate 
dyshaematopoiesis and a severe defect in lymphopoiesis (Ide et al., 2004). In addition 
these mice showed significant accumulation of thymocytes and mitogen-stimulated 
splenocytes in G2/M phase compared to WT, which they concluded implicated 
APEX2 as an essential regulator of efficient cell cycle progression of proliferating 
lymphocytes (Ide et al., 2004). Despite the name, APEX2 exhibits weak AP 
endonuclease activity compared to its strong 3-5-prime exonuclease and 3-prime 
phosphodiesterase activities (Burkovics et al., 2006). According to the Human Protein 
Atlas, expression of the APEX2 transcript is located in the myocytes of the heart.  
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4.4.6. APEX2 expression results 
Human embryonic expression in this study interestingly revealed strong expression 
in areas of the developing oral cavity and throat as well as in the eye (Figure 4.14). 
At CS19 and 20, APEX2 expression was seen in the laryngeal pharynx, laryngeal 
inlet, in the palatine shelf and the developing tongue of the oral cavity (Figure 4.14A-
E, G-H), but is no longer expressed in these areas of the throat by CS23 (Figure 
4.14J). Expression in the eye at CS19 appears to be specifically in the lens and 
around the front of the eye where the cornea will form (Figure 4.14F). By CS23, 
expression in the eye has become more defined and stronger around the developing 
cornea; distinctively in the conjunctival sacs of the eye, whilst remaining in the lens 
(Figure 4.14K). APEX2 expression is also seen partially in the ear (Figure 4.15C-D), 
and in the gonads and the lining of the stomach (Figure 4.15B) in sections taken at 
CS19. Expression is also seen in the bronchi (Figure 4.15A, E-G), trachea (Figure 
4.15F, H) and oesophagus (Figure 4.15F) at CS19 and CS22. Intriguingly at CS23, 
there is highly defined expression along the midline raphe glial system, located 
between the raphe nuclei in the brain (Figure 4.15I-J). The raphe nuclei are a 
moderate-sized cluster of nuclei with the main function of releasing serotonin to the 
rest of the brain. Serotonergic neurons in the raphe nuclei, situated in the brainstem, 
densely innervate the olfactory bulb where they modulate olfactory information 
(Brunert and Tsuno, 2016).  
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Figure 4.14: APEX2 expression in the hypothalamo-pituitary axis, oral cavity 
and the eye in the developing human embryo. In situ hybridization using the 
antisense probe against the human APEX2 mRNA transcript (hAPEX2) on human 
transverse sections from CS19 and CS20. The scale bar in ‘A’ represents 500µM and 
the scale bars in ‘B-H’ represent 200µM. (A-B) CS19: high APEX2 expression in the 
oral cavity; LP, laryngeal pharynx; LI, laryngeal inlet; PS, palatine shelf. (C) CS19: 
expression is observed in the PS, however not in the hypothalamus or Rathke’s 
pouch. (D-E) CS19: high expression in the PS from a different transverse section, 
expression in the body of the tongue can be seen in ‘E’. (F) CS19: expression in the 
lens and the cornea of the eye (also visualised in ‘D’). (G-H) CS20: expression 
remains high in the PS and LI areas of the oral cavity. RP, Rathke’s pouch; Tn, 
tongue; C, cornea; L, lens. 
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Figure 4.15: APEX2 expression in developing human embryonic tissues. In situ 
hybridization using the antisense probe against the human APEX2 mRNA transcript 
(hAPEX2) on human transverse sections from CS19, CS22 and CS23. (A) CS19: 
high APEX2 expression in the bronchi of the lungs. The scale bars in the images are 
as follows: 200µM in ‘A’, 500µM in ‘B’, 200µM in ‘C-D’, 500µM in ‘E’, 200µM in ‘F-H’, 
500µM in ‘I-J’ and 200µM in ‘K’. (B) CS19: expression in the gonads and in the lining 
of the stomach. (C-D) CS19: expression in the ear; at the end of the utricle. (E-H) 
CS22: section of the torso showing APEX2 expression in multiple bronchi, trachea 
and the oesophagus, (H) CS22: high expression in the trachea (image taken from 
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image ‘E’ in the area highlighted by the black box). (I-J) CS23: defined line of APEX2 
transcript expression noted in the midline raphe glial system. There is no expression 
in the palatine shelf at this stage. (K) CS23: high expression in the cornea of the eye; 
in particular the conjunctival sacs at the sides of the eye. B, bronchi; G, gonads; S, 
stomach; U, utricle; T, trachea; O, oesophagus; MR, midline raphe glial system; R, 
raphe nuclei; PS, palatine shelf; CS, conjunctival sac. 
 
4.5. Discussion 
4.5.1. Pedigree 2: Discussion 
It should be noted that individuals from an African origin are known to have more 
genetic variation than those from the non-African population (Song et al., 2017). 
However as the CTPS2 (p.F166L) variant is de novo there is a reasonable body of 
evidence to suggest that this heterozygous variant is likely to be associated with the 
striking phenotype of the proband in Pedigree 2. The strong CTPS2 expression seen 
in the developing hypothalamus and Rathke’s pouch, indicates a role for this gene in 
the formation of the midline forebrain; specifically the pituitary gland, during 
embryogenesis. The expression data make CTPS2 a likely candidate in causing the 
panhypopituitarism seen in the patient carrying the CTPS2 (p.F166L) variant 
(Pedigree 2), and it would therefore be worth taking the gene forward to conduct 
functional studies in this respect. In addition, the high expression of this gene seen in 
the ear is a strong indication that the variant may be contributing to the abnormal 
formation of the ear, with severe hearing loss seen in the patient. Although CTPS2 is 
not expressed in the heart tissue specifically, this does not necessarily rule out a role 
for the gene in the phenotype of situs inversus with dextrocardia observed in the 
patient (Pedigree 2). Rather, this mutated gene may be involved in causing the 
asymmetry seen in the patient and thus would not be expressed in the heart tissue 
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itself. Looking at the phenotype, there are multiple signs of asymmetry diagnosed in 
the patient: the dextrocardia/situs inversus, left microtia, and the left-sided 
hemiparesis including left facial nerve palsy. Therefore it is proposed that CTPS2 
may well be involved in the determination of left-right asymmetry during development. 
Further functional studies need to be undertaken to delineate its role in human 
development. 
 
4.5.2. Pedigree 3-6: Discussion 
Due to the previously published data linking RNPC3 mutations to the phenotype of 
IGHD and pituitary hypoplasia, together with the expression profile elucidated in this 
study, the novel RNPC3 (p.L483F) variant is predicted to be responsible for the GHD 
observed in the patients in Pedigrees 3-6. Interestingly, and without intention, 
expression of RNPC3 was noted in the mesonephros of the premature kidney, and in 
what is potentially the paramesonephric duct or the fallopian tube in 9pcw embryonic 
tissue. The cause of the ovarian failure in these patients remains to be established, 
and future work will begin by looking at the expression of both RNPC3 and PRMT6 in 
>10pcw ovarian sections when tissue is available. Interestingly Markmiller et al report 
that four genes, including the orthologs of the two mutated in Pedigrees 3-6: col11A1, 
rnpc3, prmt6, and ntng1 (Markmiller et al., 2014), are contained within a region on 
chromosome 24 in the zebrafish. This region therefore appears to be syntenic to 
human chromosome 1, illustrating the close relationship between RNPC3 (1p21) and 
PRMT6 (1p13.3) in evolutionary terms. Thus evidently RNPC3 and PRMT6 are co-
located across species, not just in humans, therefore the two mutations, RNPC3 
(p.L483F) and PRMT6 (p.P350R), in Pedigrees 3-6 have co-segregated in all affected 
individuals. Due to all the patients in these consanguineous pedigrees having these 
variants, there is a strong possibility that these four pedigrees are distantly related as 
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they all originate from the same geographical isolated population in Turkey. However 
this is unknown and the families are therefore noted as unrelated. Therefore the co-
segregation of these two variants may be termed as a founder effect. Further work is 
required to clarify the pathogenesis of the ovarian failure, and to understand the 
pathogenesis of IGHD in relation to the role of RNPC3 in pituitary development and 
function. 
 
4.5.3. Pedigree 7: Discussion 
The proband in Pedigree 7 has a unique phenotype with a multi-system disorder. The 
exciting finding of a de novo variant in FASN suggests that this patient’s phenotype 
could at least in part be explained by a disorder of fatty acid synthesis. The role of the 
gene in NSPC proliferation could also suggest a role in hypothalamo-pituitary 
development, supported by the gene in the hypothalamus and developing pituitary. 
Further investigations are underway currently in this patient, and it is clear that the 
patient has consistently elevated fasting concentrations of triglycerides. APEX2 does 
not appear to be expressed in the hypothalamus or in Rathke’s pouch at any stage of 
embryogenesis, whereas FASN is strongly expressed in these areas at a very early 
stage during development (CS16). This indicates that it may be the FASN variant in 
this patient that may be causative of the panhypopituitarism. Additionally FASN is 
expressed in the retina, unlike APEX2, and again these data suggest a role for FASN 
in the aetiology of the retinal dystrophy rather than APEX2, which appears to be 
expressed in the conjunctival sacs near the lens of the eye. Previous studies have 
shown that hyperplastic parathyroids from patients with chronic renal failure strongly 
express fatty acid synthase, indicating that it may be a potential biological indicator of 
highly proliferating parathyroid cells (Alo et al., 1999). However our studies were 
unable to analyse whether parathyroids from a normal embryo express FASN. 
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Therefore we do not have enough evidence to conclude whether the FASN 
(p.A2132V) mutation is contributing to the hypoparathyroidism phenotype at this 
stage. 
The proband in Pedigree 7 has been reported to have had many recurrent episodes 
of choking, which may possibly be linked via some unknown mechanism to the 
APEX(M422V) mutation, given its expression in the developing larynx. APEX2 is also 
expressed in the developing ear (Figure 4.15 C-D) and therefore could be associated 
with the sensorineural hearing loss seen in the patient. It is unknown if the expression 
observed in the midline raphe glial system (Figure 4.15 I-J) is related to the phenotype 
in this patient. However due to serotonergic neurons, which derive from the raphe 
nuclei, densely innervating the olfactory bulb and modulating its information, the 
patients olfactory system should be monitored for any abnormalities, such as sense 
of smell and should perhaps be structurally analysed, if not done so with particular 
focus, by MRI. Given the presence of a de novo variant in a gene that is critical for 
embryonic survival (FASN), and a further variant in a gene that is on the X-
chromosome (APEX2), there is a possibility of a digenic explanation for the highly 
complex phenotype in the patient in Pedigree 7. However further in vivo/in vitro 
functional investigation would need to take place for any clear conclusions to be 
drawn. 
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4.6. Summary of expression profiles 
Expression of CTPS2, RNPC3 and FASN in Rathke’s pouch in the respective patients 
suggests that these three genes may be implicated in the early stages of embryonic 
development of the pituitary. The variants identified in these genes may be 
responsible for the endocrine deficits seen in the respective patients, through 
incomplete development of this primordium of the anterior pituitary in the embryo. 
Expression is used as a strong indicator as to where a gene is active, however 
mutations may have a very different effect on the structure and function of the protein 
in which it encodes, and may differ from each other in pathogenicity, affecting one or 
many other tissues in addition to that showing expression. Thus, certain mutations 
may cause a downstream target effect and have an ultimate end result elsewhere. 
The complex genetic cascades of different multifunctional pathways within the body 
are intertwined and linked directly and indirectly, highlighting the need for 
manipulation and exploitation of these pathways through functional assays that help 
show the significance of a mutation, and shed light on what each individual mutation 
does. In the pedigrees described in this study, we have identified a number of genetic 
variants of interest, and in initial preliminary studies, have explored the expression 
patterns of the novel candidate genes in human embryonic tissue. The expression 
patterns of the genes seem to match the specific phenotypes observed in the patients, 
and act as a guide to functional studies, building evidence towards whether a mutation 
in that gene should be pursued. Given that functional studies are not only difficult to 
perform but also very expensive, we believe that the use of expression studies as an 
initial screen is essential. The expression studies could be performed in murine 
embryos, but given our access to human embryonic sections as part of the HDBR 
resource, I have pursued the route of human gene expression at this stage.  
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4.7. EIF2S3/eIF2γ 
 
4.7.1. Exome sequencing of the X chromosome in Pedigree 8  
Exome sequencing of the X chromosome was performed in a single X-linked non-
consanguineous white European pedigree with GHD, severe hypothyroidism and an 
unusual pancreatic phenotype that fluctuates between hyperinsulinaemic 
hypoglycaemia and hyperglycaemia (Pedigree 8, Figure 5.1). At this time, the 
association of a pituitary and pancreatic phenotype had not been described in the 
literature previously, hence there was no clear defined known gene to screen in this 
unique family. Analysis revealed a novel hemizygous missense substitution in the 
EIF2S3 gene (ENST00000253039.8): ChrX_24091319 C/T, c.1294C>T, p.P432S, 
located at a highly conserved residue across multiple species (Figure 4.16) in the C-
terminal domain of unknown function. Protein prediction models predict this variant to 
be deleterious, Polyphen2: score 0.971, and SIFT: score 0, with SIFT inferring that 
this is most likely due to the loss of Proline, which is well known to be involved in 
protein folding. This variant was absent from control databases; 1000 Genomes, 
dbSNP, EVS and the ExAC Browser, with the latter incorporating a total of >87,000 
control alleles with >52,000 being from a European background and thus ethnically 
relevant to Pedigree 8. GOSgene used their own internal data sets of the X-
chromosome to filter for novel variants in Pedigree 8. The EIF2S3 (p.P432S) was the 
only variant identified that was considered to be a potential pathogenic cause of the 
disease seen in the patients. Therefore this gene was taken forward for functional 
analysis in this study (Chapter 5). 
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eIF2γ (p.P432S) 
Human:      V--L--T--N--P--V--C--T--E 
Mouse:      V--L--T--N--P--V--C--T--E  
Chimpanzee: V--L--T--N--P--V--C--T--E 
Cow:        V--L--T--N--P--V--C--T--E  
Dog:        V--L--T--N--P--V--C--T--E 
Chicken:    V--L--T--N--P--V--C--T--E 
Xenopus:    V--L--T--N--P--V--C--T--E  
Zebrafish   V--L--T--N--P--V--C--T--E  
 
Figure 4.16: Conservation of the substituted eIF2γ residue. The conservation 
across multiple species of the substituted amino acid (highlighted in green), and the 
spanning protein sequence, in eIF2γ.  
 
It has already been established that the murine EIF2S3 homologue, Eif2s3x on the X 
chromosome of the mouse, is highly expressed in the pancreas, hypothalamus and 
pituitary (MGI). However, human EIF2S3 expression studies have not been 
previously performed in depth in a hypothalamo-pituitary context. I therefore 
performed in situ hybridisation to analyse the gene expression profile of the EIF2S3 
gene in human embryonic tissue taken from the brain and the pancreas.   
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4.7.2. EIF2S3 expression results 
Human expression studies using the human EIF2S3 DIG-labelled antisense probe 
showed EIF2S3 mRNA transcript expression in the hypothalamus and Rathke’s 
pouch at CS20, and in the anterior and posterior areas of the pituitary (AP and PP) at 
CS23, however not throughout the whole pituitary tissue (Figure 4.17 A-B). 
Expression was observed in the progenitor cells of the nasal epithelium (Figure 4.17 
C), and in the retina of the eye at CS20 and 23 in the human fetus. At CS23 the retina 
is in the process of differentiating into different cell types, and the gradient of 
expression seen here appears to be within the developing inner nuclear layer, 
possibly in the developing ganglion cells (Figure 4.17 D). Expression seems to be 
excluded from the outer layer which is where cells that form the photoreceptors 
reside. The EIF2S3 transcript was also present in the pancreas of a 13-week old fetus 
in the exocrine component and Islets of Langerhans, in the cells that will become beta 
cells (Figure 4.17 E-F). The EIF2S3 DIG-labelled sense probe was negative for 
staining, in the areas in which the antisense probe stained positive, indicating that the 
expression profile generated from the antisense probe in this study is reliable. 
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Figure 4.17: Human EIF2S3 expression in the hypothalamo-pituitary axis, eye 
and pancreas in the developing human embryo. In situ hybridization using the 
antisense probe against the human EIF2S3 mRNA transcript (hEIF2S3) on human 
sections. Expression is representative of two embryos. The scale bars in the images 
are as follows: 200µM in ‘A’, 100µM in ‘B-C’, 200µM in ‘D’ and 100 in ‘E-F’. (A-C) 
Transverse sections of the brain, (A) mRNA EIF2S3 transcripts were localised to the 
ventral hypothalamus and Rathke’s pouch (CS20). (B) EIF2S3 expression was seen 
in the AP and PP although not throughout the whole pituitary tissue (CS23). (C) 
Defined EIF2S3 transcripts were seen in progenitor cells in the nasal epithelium 
(CS23). (D) Sagittal section of the eye. EIF2S3 transcripts were localised in the retina 
(CS23). (E-F) Sagittal sections from a pancreas obtained from a 13 week old fetus, 
expressing the EIF2S3 transcript in the exocrine component, in the Islets of 
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Langerhans and in the progenitors of beta cells; ‘E’; X5 magnification, ‘F’; X10 
magnification. Abbreviations: Hyp, hypothalamus; RP, Rathke’s pouch; AP, anterior 
pituitary; PP, posterior pituitary; NE, nasal epithelium; R, retina.  
 
The expression profile performed in this study demonstrates the involvement of 
EIF2S3 in early hypothalamo-pituitary and pancreatic development. These data 
support the hypothesis that the EIF2S3 mutation identified in Pedigree 8 may be 
implicated in the phenotype observed in the patients, given the expression pattern of 
the gene in the relevant tissues. Therefore, after establishing this expression profile, 
this gene was taken forward and functionally assessed in this investigation in an 
attempt to understand its biological role, with particular focus on these tissues. 
Chapter 5 of this thesis investigates the role of EIF2S3 and the effect of the p.P432S 
variant using a variety of assays. 
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Chapter 5 
 
 
 
A Novel Mutation in Eukaryotic Translation Initiation Factor 2 Subunit 3 
(EIF2S3) Associated with Severe Hypoglycaemia and X-Linked 
Hypopituitarism 
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5.1 Introduction 
As discussed in Chapter 4 many novel potential candidate genes for hypopituitarism 
and related phenotypes have recently been identified through exome sequencing, in 
collaboration with GOSgene, of specific pedigrees with unique phenotypes. One such 
pedigree is Pedigree 8 (Figure 5.1), a non-consanguineous white European pedigree 
with affected male monozygotic (identical) twin brothers (IIId,e). Patients IIId and IIIe 
have severe short stature and GHD, central hypothyroidism, hyperinsulinism causing 
hypoglycaemia and a small AP on MRI. They have maternal twin cousins; one male, 
one female, with the male manifesting a similar phenotype (IIIc). The exome 
sequencing performed on this single X-linked pedigree (Pedigree 8), revealed a novel 
hemizygous variant in the EIF2S3 gene: ChrX_24091319 C/T, c.1294C>T, p.P432S, 
which segregates fully within the affected members of the family (Figure 5.1). The 
EIF2S3 (p.P432S) variant was inherited from the heterozygous mothers who had 
presented with secondary amenorrhea. 
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Pedigree 8 
 
 
 
Figure 5.1: Pedigree 8 harbouring the EIF2S3 (p.P432S) variant. This pedigree 
consists of three affected individuals that are hemizygous for the EIF2S3 (p.P432S) 
variant, represented by the black shaded squares labelled with ‘EIF2S3 p.P432S’. 
Patients IIId and IIIe are monozygotic twins represented. The circles containing a dot 
highlight the females that carry the variant in heterozygous form. Un-shaded 
squares/circles represent males and females that were negative for the variant 
respectively. The roman numerals on the left of the image depict the generation within 
the pedigree. The letters ‘a’ – ‘e’ distinguish between each individual within that 
generation, which are referred to in the text. 
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5.1.1. Patients in Pedigree 8 
5.1.1.1. The three affected males 
The three males, IIIc, IIId, IIIe, presented with severe recurrent hypoglycaemia, short 
stature and GHD (Figure 5.2), with a low IGF1 and low IGFBP3 concentration (Table 
5.1). They have a unique pancreatic phenotype which fluctuates between 
hyperinsulinaemic hypoglycaemia and hyperglycaemia (Table 5.2). They were 
treated up to the age of 7 years with Diazoxide, and their blood glucose was 
adequately controlled during this time. To date, the cortisol and prolactin 
concentrations have been normal. Additional features in the three boys include 
intestinal lymphonodular hyperplasia and eosinophilic infiltration. MRI of the brain 
revealed a small AP, a normal posterior pituitary and stalk, and a thin corpus 
callosum, with patients IIIc and IIId also having generalised white matter loss, and IIIc 
having ventricular asymmetry (Figure 5.3). Endocrine values for the three patients are 
presented in Tables 5.1 and 5.2. 
 
5.1.1.2. Patient IIIc 
Patient IIIc was the first born of twins via emergency caesarean at 38 weeks 
gestation, with a birth weight of 2.1kg. He presented with poor feeding and 
hypoglycaemia 18 hours after birth. Aside from the clinical phenotypes described 
above he presented with congenital heart disease; total anomalous pulmonary 
venous return, in which the four veins that take blood from the lungs to the heart do 
not attach normally to the left atrium. He also presented with a gastro-oesophageal 
reflux which required a Nissen’s procedure with a complication of dumping syndrome. 
He has IGHD but is having his FT4 and TSH closely monitored, and is currently too 
young to have his gonadotrophins tested as he has not yet reached pubertal age. He 
had a blunted testosterone response to a 3-day HCG test, however he was only 3 
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years of age when this test was performed (Table 5.2). He has global developmental 
delay, behavioural problems and has hepatomegaly. His mother presented with 
secondary amenorrhoea. 
 
5.1.1.3. Twin brothers: patients IIId and IIIe 
The monozygotic twin brothers were born via caesarean at 34 weeks gestation, 
patient IIId had a birth weight of 2.15kg, and patient IIIe a birth weight of 1.93kg. Aside 
from the clinical phenotypes described in the above section (5.1.1.1), they developed 
central hypothyroidism at the age of 2 years and were treated with thyroxine (Table 
5.1). They both presented with hypoglycaemia with seizures at this age, and had a 
microphallus, which increased in size following GH treatment. Patient IIId had small 
pea-sized testes that were initially undescended, however they did descend 
spontaneously. His twin brother, IIIe, had normal descended testes on initial 
examination. The twins had feeding difficulties and poor weight gain, which may have 
been partly due to their dairy free diet, however their feeding is now normal. By the 
age of 4 years the brothers had delayed speech development, and by 6 years they 
had mild conductive hearing loss, global developmental delay, behavioural and 
learning difficulties. A microarray performed in both boys was normal. Patient IIId 
presented with behavioural difficulties, although not as severe as his twin brother 
(IIIe), however he often had episodes of twitching, possibly related to his 
hypoglycaemia. Patient IIId also had hepatomegaly, myopia and a squint, and now 
wears glasses. Both brothers underwent surgery at the age of 4 years to have their 
tonsils removed due to recurrent tonsillitis, their adenoids were removed due to 
recurrent upper respiratory infections and upper airway obstruction, and grommets 
were inserted due to glue ear. Their palates appeared normal on examination. At the 
age of 10 years the brothers had a glucose tolerance test which showed impaired 
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glucose tolerance; the glucose concentrations fluctuated between hypoglycaemia 
and hyperglycaemia. Table 5.3 shows these test results for patient IIId. They have 
recently reached pubertal age and have had their gonadotrophin secretion tested, 
which appears reasonably normal (Table 5.2). Patient IIId had a blunted testosterone 
response to a 3-day HCG test, with his brother IIIe having a borderline testosterone 
response (Table 5.2).  
Their mother had osteoporosis due to secondary amenorrhoea, with menarche at 13 
years and periods stopping at 16 years, after which she received oestrogen 
supplementation (CycloProgynova). In later life she had a hysterectomy. An MRI 
performed on the mother was reported to be normal. Their mother had a height of 
162.9cm and their father a height of 169cm, with a mid-parental height of -0.34 SDS. 
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Patient Birth 
weight 
kg (SDS) 
(gestation) 
Age at 
presentation 
years 
Height at 
presentation 
cm (SDS) 
Peak GH to 
provocation 
µg/L 
IGF1 
ng/ml 
(NR) 
IGFBP3 
mg/L 
(NR) 
Most 
recent 
cortisol 
nmol/L 
FT4 (pre-
treatment) 
pmol/L 
(NR) 
TSH (pre-
treatment) 
mU/L 
PRL 
mU/L 
(NR)  
IIIc  2.1 (-2.8) 
(38/40) 
 1.13 58.8  
(-6.7)  
<0.1 on 
profile 
 <25  <0.5 315 12.6  
(12 - 22) 
Not treated 
5 360  
(40 - 555) 
IIId  2.15 (-0.3) 
(34/40) 
 2.2 71.5  
(-4.4)  
 1.1 9  
(20 - 158) 
 0.67  
(1.2 - 3.7) 
183 11.4  
(12 - 22) 
2.9 225 
(40 - 555) 
IIIe  1.93 (-1.5) 
(34/40) 
 2.2 69.5  
(-5.2) 
 0.7 10  
(20 - 158) 
 1.2 
(1.2 - 3.7) 
 241 11.3  
(12 - 22) 
3.4 114 
(40 - 555) 
 
Table 5.1: Clinical data from the three affected males in Pedigree 8; IIIc, IIId, IIIe. Patients presented with GH deficiency, and low 
IGF1 and IGFBP3 concentrations. Their cortisol and prolactin concentrations were normal. The twin brothers, IIId and IIIe, developed 
central hypothyroidism and were treated with thyroxine. SDS, standard deviation score; NR, normal range. 
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Patient Peak LH 
IU/L 
(GnRH at age 
12) 
Peak FSH 
IU/L 
(GnRH at 
age 12) 
Peak 
testosterone 
to 3 day HCG 
nmol/L 
(age in years) 
Most recent 
height 
SDS 
(age in years) 
Glucose 
mmol/L 
(age in 
years) 
Insulin 
mU/L 
(age in years) 
HC 
SDS 
(age in 
years) 
Diazoxide 
treatment 
(age in years) 
IIIc N/A N/A  0.992  
(3) 
 -1.03  
(7) 
 3.3  
(0.25) 
 5.9  
(0.25) 
-3.3 
 (2.4)  
0.75 - 6.8 
IIId 6.3 4.0  1.99  
(12) 
 -2.04 
(12.1) 
3.4 
(2.2) 
6.8 
(2.2) 
 N/A 2.5 - 6.7 
IIIe 8.1  3.4  3.64  
(12) 
 -2.23  
(12.1) 
3.2 
(2.2) 
4.9 
 (2.2)  
 N/A 2.5 - 6.7 
 
Table 5.2: Clinical data following gonadotrophin tests from the three affected males in Pedigree 8, IIIc, IIId, IIIe. Values following 
a gonadotrophin secretion test and a 3-day HCG test. HCG, human chorionic gonadotrophin; SDS, standard deviation score; HC, head 
circumference.  
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Glucose tolerance test of patient IIId off Diazoxide 
Time 
(mins) 
-75 0 30 60 90 120 150 180 210 240 270 300 
Glucose 
(mmol/L) 
3.6 3.2 10.2 12.1 8.8 8.4 7.8 6.2 5.5 5.5 4.0 2.7 
Insulin 
(mU/L) 
5.6 4.9 21.2 21.3 19.5 22 22 20.5 19.4 16.1 10.7 5.5 
 
Table 5.3: Glucose tolerance test in patient IIId. A prolonged glucose tolerance test was performed on patient IIId at the age of 10 
years, off Diazoxide treatment. At 0 mins the patient had a high basal glucose with detectable insulin. Glucose increased over time and 
after 2 hours (120 mins) the patient had a high blood glucose above the normal range. Glucose then decreased and by 5 hours (300 
mins) the patient was hypoglycaemic with a detectable insulin. 
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Growth charts 
 
Figure 5.2: The growth charts from the three affected males from Pedigree 8, IIIc, IIId, IIIe. The labelled red arrows indicate when 
GH treatment was commenced in the three boys respectively.  
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190 
 
MRI scans 
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Figure 5.3: The MRI scans from the three affected males, IIIc, IIId, IIIe. A-C: The patients have a small AP with an otherwise 
structurally normal pituitary gland, and a thin corpus callosum, indicated by the labelled white arrows respectively. A (i-ii) Sagittal images 
of patient IIIc showing generalised white matter loss, a small AP and a thin CC. A (iii) A coronal image of patient IIIc showing a small AP 
and ventricular asymmetry with the right ventricle being larger than the left. B (i) A sagittal image of patient IIId showing generalised 
white matter loss, a small AP and a thin CC. B (ii) A coronal image of patient IIId showing a small AP. C (i) A sagittal image of patient 
IIIe showing a small AP and a thin CC. C (ii) A coronal image of patient IIIe showing a small AP. CC, corpus callosum; AP, anterior 
pituitary; WML, white matter loss; VA, ventricular asymmetry.
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5.1.2. EIF2S3 
The Eukaryotic translation initiation factor 2 subunit 3 protein (EIF2S3) gene is located 
on the X chromosome at position p22.11 (ChrX: 24091319), and is 52kDa in size 
comprising 472 amino acids. eIF2 is a heterotrimeric G protein, also known as a 
guanine nucleotide-binding protein, composed of three subunits; alpha, beta and 
gamma, with EIF2S3 coding for the eIF2γ subunit protein (USCN Life Sciences). This 
is the largest subunit of this heterotrimeric guanosine triphosphate (GTP)-binding 
protein, containing all three consensus GTP-binding elements (guanine nucleotide 
binding domains) (Kimball, 1999) (Figure 5.4). When these domains are mutated, the 
binding of GTP/GDP to eIF2γ is greatly decreased, suggesting that it is this subunit 
that contains the primary GTP-binding element (Naranda et al., 1995).  
 
 
Figure 5.4: Domain structure of human eIF2 α-, β-, and γ-subunits. Taken and 
adapted from Kimball SR 1999 (Kimball, 1999). The number of amino acids in each 
eIF2 subunit is shown to the right and just below the open boxes representing the 
polypeptide chains. Known phosphorylation sites are represented by a `P' above the 
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boxes with the residue number shown below it. Polylysine domains are shown as grey 
boxes, guanine nucleotide binding domains are shown as black boxes, and the 
putative `zinc finger' motif in eIF2β is shown as a box with cross hatching. The eIF2B 
and eIF5 binding domains in eIF2β are denoted by black lines beneath the eIF2β 
polypeptide. This figure has been modified from the original by the addition of the 
GTP-binding domain and the residue positions corresponding, with each guanine 
nucleotide binding region within the GTP-binding domain. In addition the location of 
the variant identified in this study has been added; indicated by the red arrow labelled 
‘p.P432S’. 
 
eIF2 functions in the early steps of protein synthesis by forming a ternary complex 
with GTP and initiator methionyl-tRNA (Met-tRNAi), in which cross-linking analysis 
has implicated the N-terminus of eIF2γ in the binding of the latter (Kimball, 1999). 
This process mediates the association of Met-tRNAi to the peptidyl-tRNA site, known 
as the ‘P’ site, on the 40S ribosomal subunit (Pain, 1996). Prior to this ternary complex 
binding to the 40S ribosomal subunit, another initiation factor (eIF3) binds to the 
ribosome first, whose role is to keep the ribosomal subunits, 40S and 60S, separate 
from each other at this early stage, thus allowing the ternary complex to associate 
with the 40S ribosomal subunit (Hershey, 2015). Following binding of eIF3 and the 
eIF2-GTP-Met-tRNAi ternary complex, a third initiation factor binds (eIF4) to the 
ribosomal subunit, which guides the whole complex to the 5′ end of mRNA where it 
binds to form the 43S pre-initiation complex (Flynn and Proud, 1996). This then scans 
mRNA to select the AUG start codon for protein synthesis (Figure 5.5) by using 
perfect complementarity with the anticodon of initiator tRNA to recognise the AUG 
(Hinnebusch, 2011).  
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eIF5 binds to eIF2β and stimulates the hydrolysis of GTP; which is thought to be a 
very important step in this start site selection (Huang et al., 1997). The resultant eIF2-
GDP inactive binary complex is then released from the ribosome (Figure 5.5). It is 
unclear where the GTPase activity that is responsible for catalysing this GTP-
hydrolysis comes from, but it has been proposed to be eIF5 or the β- or γ-subunits of 
eIF2. It is apparent, however, that eIF5 can only stimulate GTP-hydrolysis when eIF2 
is bound in its ternary complex (with GTP and Met-tRNAi) to the 40S ribosome 
(Kimball, 1999), which shows how highly specific this action is.  
 
eIF2 is then recycled and can participate in another round of translation initiation, only 
when the GDP is exchanged for GTP. It has been suggested that eIF2 transfer to the 
60S ribosomal subunit, which in itself is bound to the 80S initiation complex, is 
important for recycling as eIF2 has been found to be associated with this structure 
(Chakrabarti and Maitra, 1992). However, it is the interaction with another translation 
initiation factor, eIF2B, that is directly involved in the recycling process of eIF2 ternary 
complex formation (Figure 5.5) (Kimball, 1999).  
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Figure 5.5: Eukaryotic initiation factor 2 (eIF2): The role of eIF2 in the initiation 
of mRNA translation. Taken from Kimball SR et al. 1999.  
  
The eIF2B protein has been implicated in leukoencephalopathy, which essentially 
involves a neurological condition termed vanishing white matter (VHM), or childhood 
ataxia with central nervous system hypomyelination (CACH) (van der Knaap et al., 
2002). The GDP/GTP exchange reaction is therefore catalysed by eIF2B to reform 
the eIF2-GTP-Met-tRNAi ternary complex (Pavitt and Proud, 2009).  
Studies have shown that phosphorylation of eIF2α regulates eIF2B activity (Pavitt et 
al., 1998), but the actual interaction between these two proteins, eIF2 and eIF2B, 
occurs via eIF2β (Kimball et al., 1998). Therefore it is proposed that a structural 
change occurs from the phosphorylation of eIF2α that alters the structure of eIF2β in 
order to bind to eIF2B. The phosphorylation of eIF2α is a highly conserved signal 
implicated in the cellular adaption to numerous stresses, such as viral infection, 
apoptosis, cell transformation and amino acid limitation. Additionally it has been 
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shown that the sole phosphorylation of eIF2α in the mediobasal hypothalamus is 
sufﬁcient to regulate food intake (Maurin et al., 2014). Previous studies have shown 
that inhibition of the phosphorylated eIF2α signalling in the liver leads to a decrease 
in hepatic glucose production, and in addition impairs insulin-stimulated muscle and 
adipose tissue insulin sensitivity. The authors concluded that the hepatic endoplasmic 
reticulum-stress eIF2α signalling pathway affects hepatic glucose production, without 
altering hepatic insulin sensitivity (Birkenfeld et al., 2011). This association of protein 
synthesis and glucose production via eIF2α signalling, suggests that impairments in 
other subunits of eIF2 such as the EIF2S3 (p.P432S) variant may potentially be 
contributing to the glucose dysregulation seen in Pedigree 8. As described, eIF2B 
and eIF2 are protein partners that critically need to bind in order to permit translation 
initiation, which is a vital process routinely carried out in vivo. Insulin rapidly activates 
protein synthesis by activating components of the translational machinery including 
eIFs and eukaryotic elongation factors (eEFs), and interestingly it is insulin that 
indirectly regulates eIF2B activity and thus the recruitment of Met-tRNAi to the 40S 
subunit (Figure 5.6) (Kimball, 1999). 
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Figure 5.6: Formation of the eIF2 ternary complex stimulated by insulin. Taken 
from Proud CG (Proud, 2006). Insulin binds to its receptor on the cell membrane and 
signals through PI3K and PKB to phosphorylate GSK3, causing its inactivation. This 
allows eIF2B to dephosphorylate which promotes its GDP/GTP exchange activity and 
thus in turn the formation of the ternary complex; eIF2-GTP- Met-tRNAi. PI3K, 
phosphatidylinositol-4,5-bisphosphate 3-kinase; PKB, protein kinase B; GSK3, 
glycogen synthase kinase 3; eIF2B, eukaryotic initiation factor 2B. 
 
Therefore as mutations in eIF2B have been shown to cause such drastic phenotypes, 
this suggests that a mutation in eIF2, such as p.P432S in eIF2γ, may also do the 
same through disruption of translation initiation, and thus give rise to the complex 
phenotype observed in the hypopituitary related disease seen in our patients. Further 
evidence to support this theory is that patients IIIc and IIId from Pedigree 8 in this 
study had generalised white matter loss, in addition to previous reported patients with 
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EIF2S3 patients that had global reduction in white matter on MRI in a recent study by 
Moortgat et al, later discussed in this chapter. As white matter loss is a main 
phenotypic finding in patients with eIF2B mutations, this suggests how mutations in 
these protein partners may yield a potential phenotypic overlap. 
Despite the translation initiation role of eIF2 which takes place in the cytoplasm, 
studies by Ting et al have shown that eIF2 localises to the nucleus. In this previous 
study five polypeptides, three of which were the α-, β- and γ- subunits of eIF2, were 
found to interact with DNA-dependent protein kinase (DNA-PK), and stabilize 
formation of a complex containing DNA, DNA-PK and ‘Ku’ (a DNA binding protein). 
They found that eIF2β was phosphorylated by DNA-PK. These analyses suggest that 
eIF2 may also have a physiological role in DNA repair through its interaction with 
DNA-PK, in addition to its role in translation initiation (Ting et al., 1998).   
A missense substitution in the highly conserved GTP-binding (G) domain of EIF2S3, 
p.I222T, has been previously described in three male individuals in the same pedigree 
with clinical features including; moderate-to-severe intellectual disability (ID), 
microcephaly, short stature, epilepsy and facial dysmorphic features (Borck et al., 
2012). Each affected individual had unique additional features consisting of cleft 
lip/palate and behavioural problems, generalised seizures, and postpubertal 
microgenitalism and obesity respectively. Two of the three patients had GHD, 
however no endocrine values or details of diagnosis were given by the authors, thus 
it was not the main phenotypic focus of their study. Therefore, due to the authors 
focusing on the neurological phenotype, they may have overlooked a more detailed 
pituitary phenotype in the patients. Through analysis of the homologous archaeal 
aIF2γ complex, which can functionally replace eIF2γ in binding Met-tRNAi to the 
ribosome and scanning (Dmitriev et al., 2011), this mutation lies within a hydrophobic 
cleft on the backside of the GTP-binding domain which forms the binding site for 
aIF2β. Functional studies involved the corresponding yeast eIF2γ residue being 
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mutated, p.V281T/p.V281K, which substantially impaired/abolished, respectively, 
eIF2β binding to eIF2γ. Overexpression of eIF2β partially restored eIF2γ binding to 
the mutants (Baumann, 1999). This group also showed that the equivalent mutation 
in yeast eIF2γ also impaired translation start codon selection, of which the method is 
discussed in the future work section, 5.4.2, of this chapter. As stated, EIF2S3 is 
located at Xp22.11, which is interestingly part of a region to which a rare X-linked ID 
disorder designated as MEHMO syndrome has previously been mapped by linkage 
analysis (Xp21.1-p22.13) (Steinmuller et al., 1998). MEHMO syndrome patients have 
a life expectancy of less than two years and the disorder is characterized by mental 
retardation, epileptic seizures, hypogonadism and hypogenitalism, microcephaly, and 
obesity, in which all are present in at least one affected individual from the family 
reported by Borck et al.  
Very recently, two novel hemizygous variants in EIF2S3 have been reported in three 
males from two unrelated pedigrees, two brothers and one unrelated male, that were 
inherited from their heterozygous mothers; a missense substitution p.I259M and a 
frameshift p.I465Sfs*4 (Moortgat et al., 2016). Contrastingly, these mutations are 
located within the C-terminal domain, as the p.P432S variant is, and are not within 
the GTP binding domain; as was the case with the p.I222T mutation reported in the 
previous study by Borck et al. These patients had a similar phenotype to the 
previously reported patient, in that they had severe ID, microcephaly, GHD and 
epilepsy with various unique additional features such as spastic quadriplegia, delayed 
puberty and genital abnormalities. However they also had hypoglycaemia (Moortgat 
et al., 2016), as observed in Pedigree 8, although the underlying pathogenesis for the 
hypoglycaemia was not clear in the patients described in their study. Unfortunately 
two unrelated patients from this recent report died, one at 17yrs from severe 
respiratory distress and multi-organ failure, and the other at 12 months from 
multisystemic failure. Moortgat et al. created a morpholino (MO)-based zebrafish 
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eif2s3, the human EIF2S3 ortholog which shares 80.2% protein identity, knock down 
model, which they concluded recapitulated the human microcephaly and short stature 
phenotype, thus supporting the pathogenicity of their EIF2S3 variants identified. 
Injected embryos and uninjected controls were analysed at 0, 1, 2, and 3 days post 
fertilization (dpf) for survival, motility, and morphology. In addition, 30 morphants and 
30 controls were selected at 2 dpf for head width measurements. Their results 
showed that eif2s3 morphants exhibited hypomotility and morphological deficits at 2 
dpf and were shorter with a curved tail. These morphants also had a statistically 
significant reduction in head size (Kruskal–Wallis Test, P<0.0001) with small eyes 
compared with control MO-injected embryos. Following the establishment of the 
knock down phenotype, they then performed rescue experiments by co-injection of 
eif2s3 MO with 500 pg/egg of either WT zebrafish eif2s3 RNA or human EIF2S3 RNA, 
which partially restored the morphant phenotype. The authors also noted that there 
were no significant differences between the standard control MO and the uninjected 
embryos, and therefore concluded that the absence of total rescue was likely due to 
non-specific, or off-target effects of antisense technologies (Moortgat et al., 2016). 
These data, in addition to the phenotype of the patients manifesting both GHD and 
hypoglycaemia, support the hypothesis that the EIF2S3 (p.P432S) is causative of the 
unique phenotype observed in Pedigree 8. Both previous reports describing EIF2S3 
mutations have had phenotypic focus on ID with microcephaly, of which the former is 
not prominent and the latter is not present in our patients. The males in Pedigree 8 
differ vastly from these previous cases in having a much more severe hypopituitarism 
but a milder neurological phenotype. Therefore the EIF2S3 (p.P432S) may have a 
different effect in vivo to previous EIF2S3 mutations, giving rise to this different 
phenotype. 
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5.2. Results 
5.2.1. Cohort screening 
Upon identification of the EIF2S3 (p.P432S) variant in Pedigree 8, I initially screened 
a cohort of patients within our database to see if any additional EIF2S3 variants were 
present in other pedigrees. The full coding region of EIF2S3 was analysed by PCR 
and direct sequencing analysis (Chapter 2.2) in 103 patients with variable 
hypopituitary-related phenotypes to identify any further EIF2S3 variants in other 
patients in our cohort. The phenotype of patients ranged from mild to severe with and 
without structural midline brain defects on MRI: 16 had GHD with no details of further 
anterior pituitary deficiencies, 37 had SOD, 4 had HH/KS and 46 had variable MPHD. 
However no further variants were identified in the EIF2S3 gene in any of these 
patients. No other eukaryotic initiation factors were screened for mutations in this 
cohort, only EIF2S3.  
 
5.2.2. EIF2S3 knock down 
The expression pattern of EIF2S3/eIF2γ in the pituitary, hypothalamus and the 
pancreas, and the unusual phenotype of the patients in Pedigree 8 led me to further 
investigate the role of EIF2S3 in human development. An EIF2S3 KO study on a 
human hybrid pancreatic beta cell line using a viable LV transduction approach was 
carried out in this study, with subsequent insulin secretion and apoptosis assays 
(Chapter 2.4), to compare insulin secretion and cell death in EIF2S3 KO cells 
compared to controls respectively. These assays were performed to help characterize 
the functional role of this initiation factor of protein synthesis (EIF2S3/eIF2γ), and its 
importance in sustaining cell viability.   
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The four different silencing, and the one non-silencing control, pGIPZ LV-backboned 
plasmids described in Chapter 2.4.2 were packaged into viable LV particles (Chapter 
2.4.3) and, via transduction (Chapter 2.4.4), used to introduce EIF2S3-targeted 
shRNA cassettes into 1.1B4 human pancreatic cells in order to knock down the 
EIF2S3 gene. These plasmids also encoded GFP and a puromycin resistance gene. 
Forty-eight hours after transduction was carried out on the 1.1B4 cells, the cells 
appeared to fluoresce green under the microscope, indicative of GFP expression and 
thus successfully transduced cells. These cells were then under puromycin selection, 
which killed the non-transduced cells therefore allowing for the expansion of 
transduced ones. This method of a stable knock down was used over a transient 
transfection method, so that a KO cell line could be grown and aliquots could be 
frozen over a longer time scale in order to be used in multiple assays and at a later 
date. Transient transfection wears off quicker and shRNA cassettes would have only 
interfered with the gene, and thus knocked it down, for only a fraction of the time that 
a LV vector permits. Following expansion of each cell population, RNA was extracted 
from cells, reverse transcribed and a qPCR was performed (Chapter 2.4.5 – 2.4.7) to 
verify which of the four EIF2S3 shRNA cassette-containing pGIPZ plasmids was the 
most efficient in knocking down the gene. Initially a pilot qPCR assay was carried out 
on RNA derived from non-transduced WT 1.1B4 cells, to determine the most suitable 
dilution of cDNA to use, without using any cDNA samples from transduced cell 
populations. Following transduction using Clone 4, through visual observation the 
cells appeared to not survive for very long and cell viability looked extremely low, 
which would explain why very little RNA was able to be extracted (Chapter 2, Table 
2.1). 
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5.2.3. qPCR analysis 
The qPCR pilot assay concluded that the 1:5 dilution of stock cDNA began 
exponential expression of the genes tested at an appropriate cycle number (20 
cycles) on the StepOne qPCR software. Therefore a 1:5 dilution of cDNA was used 
in further qPCR assays for the different 1.1B4 cell populations that had been 
transduced with the different shRNA-containing constructs described: Scrambled 
non-silencing clone, Clone 1, Clone 2, Clone 3 and Clone 4 shRNA respectively, in 
addition to the non-transduced cells used as a control in all assays (WT 1.1B4 cells). 
 
Results from the qPCR showed that Clone 4 was the most successful construct in 
knocking down the EIF2S3 gene. Clone 4 had a Relative Quantification (RQ) of 0.186 
with a 95% Confidence Interval ranging between 0.127 - 0.274, when compared to 
non-transduced cells (RQ: 1, CI: 0.89 – 1.124) (Figure 5.7, Table 5.4), indicating that 
approximately 82% of EIF2S3 was knocked down. Clone 1-3 were not as efficient in 
silencing the EIF2S3 gene and only appeared to achieve a range between 15-40% 
knock down in the cells.  
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Figure 5.7: qPCR EIF2S3 expression results in cDNA populations. Histogram 
showing the relative quantification of EIF2S3 expression, against GAPDH, β-ACTIN 
and HPRT housekeeping genes in cDNA derived from transduced 1.1B4 cells, 
compared to non-transduced cells. Five different cDNA populations were derived 
from cells transduced with different shRNA cassette-containing constructs: 
Scrambled non-silencing and Clone 1, Clone 2, Clone 3, Clone 4 silencing. All were 
normalised to non-transduced cells.   
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cDNA population 
 
Relative 
Quantification 
(RQ) 
 
95% Confidence Interval 
RQ Minimum RQ Maximum 
Non-transduced 1 0.89 1.124 
Scrambled 1.019 0.913 1.137 
Clone 1 0.638 0.444 0.915 
Clone 2 0.85 0.601 1.201 
Clone 3 0.752 0.66 0.856 
Clone 4 0.186 0.127 0.274 
 
Table 5.4: qPCR EIF2S3 expression results in cDNA populations. qPCR Relative 
Quantification (RQ) values for EIF2S3 expression against GAPDH, β-ACTIN and 
HPRT compared to non-transduced cDNA, with a 95% confidence interval range: 
minimum RQ and maximum RQ, for all five cDNA populations. 
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5.2.4. Western Blot Analysis 
Following transduction as described, protein was extracted from cell lysates and a 
bicinchoninic acid assay (BCA) was performed to quantify the total concentration of 
protein in each sample (Table 5.5), in order to perform western blot analysis to detect 
eIF2γ protein (Chapter 2.4.8). A polyclonal anti-EIF2S3 antibody was used for the 
detection of eIF2γ in the different protein populations. A pilot western blot assay was 
performed on protein derived from HeLa cells, which were suggested to be used as 
a positive control by the antibody manufacturer, and non-transduced 1.1B4 cells 
respectively, at three different concentrations (Figure 5.8). This was to test the 
specificity of the antibody and to determine the optimal protein concentration to load 
into wells to obtain a clear eIF2γ band. 
 
BCA concentrations:  
Protein lysate Total protein 
lysate 
concentration 
(µg/ml) 
Total protein 
lysate 
concentration 
(µg/µL) 
Total protein 
yield (µg/µL) 
HeLa (control) 696.667 0.697 209.1 
1.1B4 WT NT 1339.313 1.339 401.7 
Scrambled 1313.125 1.313 393.9 
Clone 1 1173.375 1.173 351.9 
Clone 2 1287.625 1.288 386.4 
Clone 3 1173.375 1.173 386.4 
Clone 4  134.375 0.134 26.8 
Table 5.5: BCA assay quantification. Total protein lysate concentrations 
determined by a bicinchoninic acid assay (BCA) using a luminometer. WT, wild-type; 
NT, non-transduced. 
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The pilot western blot analysis showed strong unspecific binding of the primary anti-
EIF2S3 antibody in both cell populations, HeLa and non-transduced protein, at all 
three total protein concentrations (5µg, 10µg and 30µg). Additionally, a band just 
above the 55kDa protein ladder band, at approximately 57kDa, was present on the 
blot (Figure 5.8), however I did not believe this to be specific to eIF2γ and therefore 
did not perform a western blot on the extracted protein from Clones 1-4.  
 
Figure 5.8: Western blot analysis using the anti-EIF2S3 primary antibody. (A-B) 
Western blot membrane with WT human 1.1B4 cells and HeLa control protein lysate, 
each at three different concentrations; 5µg, 10µg and 30µg. Images A and B were 
taken from the same membrane. (A) An anti-EIF2S3 primary antibody was used to 
stain eIF2γ at 52kDa, however there was no significant band on the membrane at this 
size. (B) An anti-GAPDH primary antibody was used to stain GAPDH (37kDa) 
indicated by the arrows. WT, wild-type. 
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5.2.5. Insulin secretion ELISA assay 
As mentioned, the patients in Pedigree 8 had hyperinsulinism that caused 
hypoglycaemia. Due to this pancreatic phenotype observed in the patients, 1.1B4 
cells (PHE) were chosen for this study as they are human pancreatic beta cells that 
have been reported to secrete insulin (McCluskey et al., 2011). Upon establishing a 
human EIF2S3 KO cell line that had been verified by qPCR, I wanted to measure 
insulin secretion in these cells and compare it to WT cells, to see if there was a 
significant difference between the two. Initially, I wanted to confirm the insulin 
producing properties in this cell line myself as well as optimise the ultrasensitive 
insulin ELISA assay, before attempting to measure insulin secretion in the EIF2S3 
KO 1.1B4 cell line. Therefore a pilot assay was performed using non-transduced WT 
1.1B4 cells. 
Firstly, 10mM glucose alone was added to the cells, secondly Forskolin (10µM) was 
added in isolation to the cells, as it has been shown to stimulate insulin secretion in 
cell lines e.g. MIN6 cells (Luther et al., 2006). Thirdly, Forskolin (10µM) in combination 
with a phosphodiesterase inhibitor, IBMX (100µM), in a high glucose concentration 
(10mM) was added. IBMX is known to inhibit the breakdown of cAMP and thus further 
increase insulin secretion to a higher final concentration that can be more easily 
detectable (Al-Majed et al., 2004). However after subjecting the 1.1B4 cells to these 
treatments, the cells did not release any insulin above the background/lowest 
standard (Calibrator 0) from the ELISA kit. In further attempts, these test agent 
concentrations used as treatments on the cells were increased by 10 fold; 100mM 
glucose, 100µM Forskolin (in 100mM glucose), and 100µm Forksolin with 1000µM 
IBMX (in 100mM glucose), and yet still did not stimulate any insulin release from the 
human 1.1B4 cells.  
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At this later stage, I acquired MIN6 cells that were negative for mycoplasma from 
Professor Peter Jones, Kings College London, which up until this point had not been 
available. The original test agents made using the 10mM glucose KRB buffer used 
on the 1.1B4 cells (Chapter 2, Table 2.6) were then used to treat these MIN6 cells, 
with simultaneous treatment of 1.1B4 cells, and the solutions from all wells in the plate 
were collected and analysed for insulin secretion. The treatments successfully 
stimulated the MIN6 cells to release insulin (Figure 5.9), however the 1.1B4 remained 
unresponsive and had undetectable insulin secretion levels. 
 
The MIN6 cells secreted insulin after being incubated with three different treatments: 
10mM glucose, 10µM Forskolin (in 10mM glucose), and 10µM Forskolin with 100µM 
IBMX (in 10mM glucose) respectively, with the latter treatment combination being the 
most efficient at stimulating insulin secretion. The human 1.1B4 cells did not secrete 
insulin at a level above the ‘Calibrator 0’ standard after incubation with the same 
treatments.  
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Figure 5.9: Insulin secretion assay in MIN6 cells. Graph showing the mean insulin 
secretion from MIN6 cells in a well from a 6-well plate after incubation with forskolin, 
and forskolin in combination with IBMX. The error bars represent the standard 
deviation of the mean. IBMX, 3-isobutylmethylxanthine. 
 
 
These data suggest that these hybrid human 1.1B4 cells are not secreting insulin, as 
previously described in studies in Professor Peter Flatt’s laboratory. Through helpful 
discussion with a collaborator, namely Professor Peter Jones from Kings College 
London, we hypothesised that the beta insulin-secreting cells in this hybrid may have 
been overtaken by rapid growth of the PANC-1 epithelial cells, and therefore no 
detectable measure of insulin can derive from this cell line as a whole. This revelation 
meant that we were unable to measure the effect of EIF2S3 knock down on insulin 
secretion. 
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5.2.6. Apoptosis Caspase 3/7 Assay 
As mentioned in section 5.2.2, during culturing the cells transduced with the Clone 4 
shRNA cassette-containing construct were challenging to sustain and expand 
compared to the other cell lines (cells transduced with Clones 1-3). This may be due 
to a reduction in cell viability as a result of the highest percentage loss of normal 
EIF2S3, shown by qPCR (Figure 5.7). This led to the hypothesis that there is 
increased apoptosis in these cells due to the lack of eIF2γ protein. Therefore Clone 
4 was analysed for cell viability compared to WT 1.1B4 cells through conducting a 
cell apoptosis assay that measured caspase 3/7 activity in the cell, with and without 
the addition of a cytokine mix, which is known to stimulate caspase activity (Chapter 
2.4.10).  
Initially, a pilot apoptosis assay was performed using both MIN6 and 1.1B4 WT non-
transduced cells. After treatment with cytokines, both cell lines showed an increase 
in caspase 3/7 compared to the cells untreated with cytokines; termed basal caspase 
activity (Figure 5.10).  
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Figure 5.10: A pilot apoptosis assay performed on WT untransduced MIN6 and 
1.1B4 cells. Cells were seeded 24 hours before a 16 hour incubation with a cytokine 
mix. Results are shown as the mean ± SD from an assay performed in triplicate. There 
was a highly significant difference in caspase activity, measured as luciferase activity 
on a luminometer, in the cytokine-treated cells compared to basal activity in each cell 
line respectively; MIN6 cells (1070.33 ± 33.56 versus (vs) 116 ± 8.66) p=0.0006, 
1.1B4 cells (2354.67 ± 40.7 vs 601.33 ± 62 p=0.0001). The error bars represent the 
standard deviation (SD) of the mean. WT, wild-type. 
 
After establishing a working apoptosis assay, caspase activity in the human EIF2S3 
KO 1.1B4 cell population (Clone 4) was compared with 1.1B4 cells transduced with 
the scrambled non-silencing (NS) shRNA control construct, and the non-transduced 
(NT) cells respectively.  
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5.2.6.1. Non-parametric tests 
 
Significant difference between Clone 4 cyto and Clone 4 basal (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
Clone 4 cyto 9 126 85.5 
Clone 4 basal 9 45 85.5 
Combined 18 171 171 
 
Significant difference between NS cyto and NS basal (p = 0.0379). 
 
Group (Cell population?) N Rank sum Expected 
NS cyto 9 109 85.5 
NS basal 9 62 85.5 
Combined 18 171 171 
 
 
Significant difference between NT cyto and NT basal (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
NT cyto 9 126 85.5 
NT basal 9 45 85.5 
Combined 18 171 171 
 
Significant difference between Clone 4 basal and NS basal (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
Clone 4 basal 9 126 85.5 
NS basal 9 45 85.5 
Combined 18 171 171 
 
Significant difference between Clone 4 basal and NT basal (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
Clone 4 basal 9 126 85.5 
NT basal 9 45 85.5 
Combined 18 171 171 
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Significant difference between Clone 4 cyto and NS cyto (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
Clone 4 cyto 9 126 85.5 
NS cyto 9 45 85.5 
Combined 18 171 171 
 
 
Significant difference between Clone 4 cyto and NT cyto (p = 0.0003). 
 
Group (Cell population?) N Rank sum Expected 
Clone 4 cyto 9 126 85.5 
NT cyto 9 45 85.5 
Combined 18 171 171 
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5.2.6.2. Two-way ANOVA test 
 
This test was applied to the data to analyse whether there was a significant effect of 
cytokine treatment on caspase activity (represented through luciferase values) 
between the different cell populations: Clone 4, NS and NT. The data calculations are 
presented in Appendix 5B. 
 
Table 1. Normalised to blank mean measurements by group 
 Treatment group  
Cell line cyto basal Total 
Clone 4 2288.33 1202.67 1745.50 
NS 467.78 257.44 362.61 
NT 757.89 225.33 491.61 
Total 1171.33 561.81 866.57 
 
 
Table 2. ANOVA; group1: cell line and group2: treatment 
Number of obs = 54 R-squared = 0.9483   
Root MSE = 177.663 Adjusted R-squared = 
0.9429 
  
      
Source Partial SS df MS F Prob>F 
      
Model 27786935 5 5557386.9 176.07 <0.001 
      
group1 21007560 2 10503780 332.77 <0.001 
group2 5015423.1 1 5015423.1 158.90 <0.001 
group1#group2 1763951.3 2 881975.63 27.94 <0.001 
      
Residual 1515084.7 48 31564.264   
Total 29302019 53 552868.29   
 
 
There was a significant interaction between the two variable groups; cell populations, 
and with or without cytokine treatment (F(2, 48) = 27.94, p < 0.001) (Table 3), 
suggesting that the cytokine treatment has a different effect on caspase activity within 
each cell population. 
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5.2.6.3. Parametric tests: Two-tailed unpaired T-test  
 
Figure 5.11: Apoptosis assay comparing caspase activity in EIF2S3 KO cells 
compared to controls, with and without cytokine treatment. Results from an 
apoptosis assay shown as the mean ± SD of 3 independent experiments with each 
assay performed in triplicate, on NT 1.1B4 cells, NS shRNA transduced 1.1B4 cells 
and EIF2S3 knock-down (Clone 4) 1.1B4 cells. The average mean values from each 
triplicate assay 1, 2, 3 are shown in Appendix 5A. Caspase activity is measured as 
luciferase values on a luminometer. Caspase activity is significantly higher after 
cytokine treatment compared to the basal caspase activity in the Clone 4 (2288 ± 
358.31 versus (vs) 1203 ± 63.52 p=0.0067) and NT (758 ± 84.06 vs 230 ± 59.76 
p=0.0009) cell populations respectively. Basal caspase activity is significantly higher 
in Clone 4 compared with NS (1203 ± 63.52 vs 258 ± 100.49 p=0.00016; displayed 
in orange) and NT (1203 ± 63.52 vs 230 ± 59.76 p=0.00004; displayed in blue) 
respectively. Clone 4 cells treated with cytokine mix have a significantly higher 
caspase activity compared with NS (2288 ± 358.31 vs 468 ± 261.10 p=0.002; 
displayed in green) and NT (2288 ± 358.31 vs 758 ± 84.06 p=0.002; displayed in red) 
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cytokine-treated cell populations respectively. The error bars represent the standard 
deviation (SD) of the mean. NS, scrambled non-silencing; NT, non-transduced. 
 
In line with the pilot assay, there was significantly higher caspase activity in both the 
Clone 4 and NT populations after the addition of cytokines, compared to basal. The 
NS population did not reach a statistically significant difference in caspase activity 
after the addition of cytokines. There was significantly higher caspase activity in Clone 
4 compared to the two control populations, NS and NT, both after the addition of 
cytokines and in basal activity respectively (Figure 5.11).  
 
5.2.7. The EIF2S3 (p.P432S) mutant 
A KO cell line with significant reduction in EIF2S3 expression following transduction 
with Clone 4, showing a higher caspase activity (Figure 5.11) and thus increased 
apoptosis compared with WT cells, had now been established. I wanted to look at the 
effect of the specific mutation, EIF2S3 (p.P432S), that was identified in the patients 
in Pedigree 8. Therefore the EIF2S3_WT and mutant EIF2S3 (p.P432S) inserts were 
cloned into an LV-IRES (LV-backboned) vector, from their original pCMV-SPORT6, 
in order to be packaged into viable LV particles and transduced into cells using the 
same method (Chapter 2.4.3 – 2.4.4). The cloning procedure is illustrated in Figure 
2.2. 
The cloning site within the LV-IRES vector, that the inserts would have to ligate into, 
was within two BamHI sites. Therefore by site-directed mutagenesis (Chapter 2.4.11) 
the BamHI site already within EIF2S3 cDNA had to be mutated so that the insert 
would not be cut in half during the BamHI digestion step. This BamHI site had one 
nucleotide substituted without changing the amino acid, thus keeping the WT protein 
218 
 
sequence intact and unaltered. The EIF2S3_WT insert was then amplified out of the 
pCMV-SPORT6 IMAGE clone vector by PCR, with the BamHI sequence on each end, 
using specific primers (Chapter 2.4.15) (Figure 5.12).  
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Amplification of EIF2S3 insert 
  
 
Figure 5.12: Amplification of the EIF2S3 cDNA insert. Image showing the EIF2S3 
WT PCR product that was amplified from the pCMV-SPORT6 plasmid using specific 
primers, run on a 1% agarose gel next to different 1kb ladders. The arrows indicate 
the length of the ladder bands either side of the insert DNA band. The length of the 
EIF2S3 insert corresponds to the correct length for EIF2S3 cDNA; 1.4kb. 1kb ladders; 
Hyperladder I (Bioline) and GeneRuler 1kb plus (Thermo Scientific) respectively. 
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The PCR EIF2S3 insert product was then purified through gel extraction (Chapter 
2.4.14) and cloned into a pGEM-T Easy vector by TA-cloning (Chapter 2.4.16 – 
2.4.17). The host LV-IRES vector was digested with BamHI enzyme and treated with 
alkaline phosphatase (Chapter 2.4.12 – 2.4.13), and the EIF2S3 purified insert was 
cut out of the pGEM-T Easy vector, also with BamHI (Chapter 2.4.19), before the two 
were ligated (Chapter 2.4.20). Site-directed mutagenesis was then performed to 
revert the single nucleotide back to its original BamHI site within the insert, to yield 
the exact original EIF2S3_WT cDNA sequence and thus the final EIF2S3_WT 
construct. Alongside this, multi-site-directed mutagenesis (Chapter 2.4.21) was 
performed on another aliquot of LV-IRES_EIF2S3_WT ligated vector, to insert the 
p.P432S missense variant into the EIF2S3_WT sequence. This method 
simultaneously reverted the single altered nucleotide back to the original BamHI site 
at the same time, thus yielding the final EIF2S3 (p.P432S) mutant construct.  
Unfortunately, despite many attempts, the plasmids would not package into enough 
viable LV particles to be used in transduction assays. This LV packaging method 
appeared to work better for the shRNA cassette-containing pGIPZ plasmids used in 
the knockout studies. Therefore the EIF2S3_WT and EIF2S3 (p.P432S) mutant 
constructs were transiently transfected into cells rather than transduced. 
However, despite several attempts to transfect both 1.1B4 and MIN6 cells using both 
Fugene-6 and lipofectamine transfecting agent methods respectively (Chapter 
2.4.22), there were not enough green fluorescing cells visualised following 
transfection to be able to proceed to functional assays, only ~5% green cells were 
present at 48 hours after transfection. Seventy-two hours after transfection, this 
percentage rose to ~15% and cell sorting was performed to sort the green-fluorescing 
cells from the non-fluorescing cells (Chapter 2.4.23). However not enough cells were 
able to be expanded within the timeframe following the cell sort, before the green cells 
became normal again and transient transfection had worn off. If RNA had been 
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extracted from these cells with such a low green fluorescing overall percentage and 
analysed by qPCR, there would not have been enough RNA derived from transfected 
cells that were exhibiting EIF2S3_WT and mutant expression respectively, as ~85% 
of them would be expressing endogenous EIF2S3 only. Therefore, if the constructs 
were not being expressed to a high enough degree, the subsequent assays, such as 
insulin secretion (only able to be performed in MIN6 cells) and apoptosis assays, 
would not reflect the true effect of the EIF2S3 (p.P432S) mutant. 
 
5.3. Discussion 
5.3.1. Cell line choice and insulin secretion assay 
I wanted to functionally investigate the involvement of eIF2γ in an insulin secretory 
context by manufacturing an EIF2S3/eIF2γ knockout cell line (Chapter 2.4), to assess 
the role of eIF2γ protein in insulin secretion in the pancreas. Initially MIN6 cells were 
considered as a sensible choice of cell line as they have been extensively and 
routinely used in different laboratories, especially by Professor Peter Jones’ group in 
the Diabetes and Nutritional Sciences Division at Kings College London. Additionally, 
since the phenotype of the patients encompassed a pancreatic phenotype, the fact 
that these cells are pancreatic beta cells derived from transgenic mice (insulinomas) 
suggested that they were ideal in investigating the role of eIF2γ on pancreatic 
function, such as insulin secretion from these cells. However, unfortunately, all 
original stocks of MIN6 cells at Kings College were found to be highly infected with 
mycoplasma and were initially unable to be used in functional studies. Furthermore, 
MIN6 cells are not commercially available, thus making another cell line choice 
inevitable. At this stage, there were no other common pancreatic beta cell lines to 
choose from that had been as widely used as MIN6 cells in practice. Therefore, I 
thought it best to research possible human cell lines of a similar nature as opposed 
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to mouse or other species, as this would be more relevant and may reflect a more 
accurate representation of what may occur in a human pancreas if EIF2S3 was 
knocked out. Consequently human 1.1B4 pancreatic cells (PHE) were chosen; which 
are a hybrid cell line formed from the electrofusion of a primary culture of human 
pancreatic islets with PANC-1, in which the latter are human pancreatic ductal 
carcinoma cells. 1.1B4 cells have been reported to secrete insulin and have been 
extensively characterized through previous studies in Professor Peter Flatt’s 
laboratory in Northern Ireland (Vasu et al., 2013, McCluskey et al., 2011, Guo-Parke 
et al., 2012), specifically involving insulin secretion assays. This cell line is formally 
identified by PHE to have applications in the study of pancreatic cell biology, which 
may be stimulated to become pure insulin-secreting cells, supporting this cell line as 
a suitable choice for this study. An extra benefit of this cell line is that it is commercially 
available and had been analysed before dispatch for mycoplasma, as well as on 
arrival in our laboratory; with testing being negative on both occasions. Therefore, I 
decided to perform a stable knockdown of the EIF2S3 gene through the packaging of 
lentivirus and subsequent transduction (Chapter 2.4) in 1.1B4 cells. Interestingly, the 
patients in Pedigree 8 initially presented with hyperinsulinism which contributed to 
their hypoglycaemia, with later reduction in insulin secretion and glucose impairment 
in the three affected boys. It is therefore difficult to predict the effect of EIF2S3 knock-
down and also the EIF2S3 p.P432S variant on insulin secretion. However one 
hypothesis would be that as it is known that insulin promotes protein synthesis 
through the activation of eIF2B (Proud, 2006) (Figure 5.4), perhaps when eIF2γ is 
faulty as proposed in the patients carrying the EIF2S3 (p.P432S), there is an increase 
in the feedback loop mechanism that normally occurs within the cell, that promotes 
insulin secretion. Therefore the patients may be producing too much insulin, which is 
reflected in their hyperinsulinism phenotype, as not enough eIF2B is being promoted 
to stimulate formation of the ternary complex, due to the p.P432S variant in their 
eIF2γ. Therefore their pancreatic beta cells continue to stimulate more insulin release 
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to promote the protein synthesis pathway. Finding a human cell line that actually 
secreted insulin would have been ideal, however it has to be pointed out that even if 
this was possible, measuring endogenous insulin secretion in vitro may not have 
reflected physiological levels. Other factors may influence insulin secretion at different 
times, and as the dose of in vivo promoters and inhibitors of such pathways are 
unknown, in vitro analysis has its limitations as to whether it is reflecting what is 
actually occurring within the cell.       
 
5.3.2. EIF2S3 expression 
The human expression profile generated in this study is consistent with the tissues 
that are affected in the patients in Pedigree 8. Initial studies showed EIF2S3 
expression in the hypothalamo-pituitary axis, essentially in the developing 
hypothalamus and Rathke’s pouch at CS20, equivalent to 49 days into development. 
Transcripts were also noted in the AP and PP, however not throughout the whole of 
the pituitary tissue at CS23, equivalent to 56 days into development (Figure 4.16A-
B). These findings suggest that the phenotype in Pedigree 8 could stem from either 
the hypothalamus or the pituitary gland. Further studies investigated expression in 
the human pancreas due to the presence of a pancreatic phenotype in Pedigree 8. 
EIF2S3 expression was noted in specific cells in the pancreatic tissue of a 13-week 
old foetus (Figure 4.16E-F). Professor Tom Jacques, a pathologist at GOSH, was 
consulted with respect to the specific aspects of pancreas expression. He concluded 
that it appears to be in the exocrine component and in the Islets of Langerhans. It is 
likely that the expression is observed in those regions that contain beta cell 
progenitors. Expression was also observed in the nasal epithelium (Figure 4.16C) 
and areas of the eye (Figure 4.16D); however the patients had no overt eye 
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phenotype. Nevertheless, it will be important to monitor the affected males in the long-
term with respect to the development of an eye phenotype. 
 
5.3.3. EIF2S3/eIF2γ 
The EIF2S3 (p.P432S) variant segregates fully with the affected patients and the 
maternal ancestral line within the three generations of Pedigree 8, descending from 
the heterozygous asymptomatic grandmother (Figure 5.1). This variant is not located 
in any of the three known GTP-binding regions, but rather in the C-terminal domain 
of the eIF2γ (Figure 5.4), a region of unknown function. Based on the discovery of the 
EIF2S3 (p.P432S) variant in Pedigree 8 and the human expression profile of EIF2S3, 
an EIF2S3 KO human cell line was generated using a LV transduction approach, to 
investigate the role of EIF2S3/eIF2γ. Unfortunately, the EIF2S3 knock-down cell 
population was unable to be verified at the protein level, as a reliable antibody was 
unavailable, as indicated by the western blots performed in this study. Moreover, 
there are no previously published studies reporting the use of any human anti-EIF2S3 
antibody in the literature and therefore no reliable data demonstrating that an antibody 
specific to eIF2γ exists. Further work using the anti-EIF2S3 antibody, may perform 
immunostaining on human embryonic sections of the brain, to further clarify whether 
this particular antibody is functional in a different experimental assay to western blot 
analysis.  
Aside from the studies described earlier in yeast and zebrafish performed in previous 
studies (Borck et al., 2012, Moortgat et al., 2016), there has not been any other 
functional work performed that investigates the role of human EIF2S3/eIF2γ, and no 
further mutations have been identified in EIF2S3, making it difficult to plan functional 
assays in this highly unexplored area. Previous work has shown that murine Eif2s3y 
suppresses the pluripotency state of murine embryonic stem cells, and promotes their 
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proliferation (Li et al., 2016). In mice, Eif2s3y on the Y chromosome is homologous 
to Eif2s3x on the X chromosome. However, it should be made clear that there is no 
human EIF2S3Y gene, and thus no EIF2S3 homologue on the Y chromosome exists 
as it does in the mouse. Instead, EIF2S3 has a homologue on chromosome 12 
namely EIF2S3L which encodes the eukaryotic translation initiation factor 2 subunit 
3-like protein. During spermatogenesis when meiosis in males is occurring, genes on 
the X chromosome are silenced, a process termed meiotic sex chromosome 
inactivation (MSCI) (McKee and Handel, 1993). As several essential housekeeping 
genes are located in the X chromosome, mammals have evolved to give rise to 
duplicated retroposed copies of genes with important functions, and have integrated 
them into autosomal locations. These gene copies, termed retrogenes, are only 
expressed at the time that their X-encoded parental genes are inactivated and thus 
are only expressed in the germ line in the testes during meiosis (Shiao et al., 2007, 
Betran et al., 2002, Turner, 2015). The EIF2S3L gene on chromosome 12 is only 
expressed in the testes, and therefore strongly suggests that EIF2S3 is one of these 
essential genes on the X chromosome, as it has this retrogene copy in the autosome. 
This relates to the apoptosis data in this study, which showed higher cell death in the 
EIF2S3 KO cells compared to controls, thus suggesting that the presence of EIF2S3 
is critical for cell proliferation and maintenance.  
Yamauchi et al. have shown that spermatogenesis can occur in male mice with the Y 
chromosome contribution limited to only two genes: Sry, the testis determining factor, 
and Eif2s3y, the latter being the murine Y chromosome homologue of Eif2s3x 
(Yamauchi et al., 2014). Further studies by this group replaced Sry and Eif2s3y 
through transgenic activation of their homologues Sox9; which in mice is on 
chromosome 11 as opposed to the X chromosome in humans, and Eif2s3x on the X 
chromosome, and showed that spermatogenesis and reproduction still occurred in 
the mice. Thus the presence of just these two specific genes were able to substitute 
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the Y chromosome in mice (Yamauchi et al., 2016). This study demonstrates the 
critical role of Eif2s3x in reproduction, which complements the findings in this study 
of the high cell death observed in cells lacking EIF2S3. Due to eIF2γ being an initiation 
factor, it plays an essential key role in initiating protein synthesis within the cell 
(Yatime et al., 2007). Therefore in its absence, this fundamental pathway of protein 
synthesis may not be able to be achieved to a high enough standard to maintain cell 
survival. The highly significant difference in apoptosis observed between the EIF2S3 
KO population and control cells observed in my studies, supports this hypothesis. In 
line with these findings, the EIF2S3 (p.P432S) variant in our patients is therefore 
predicted to be a partial loss of function mutation, which is not deleterious enough for 
the patients to die but is pathogenic enough for them to manifest the disorder 
described. However further functional analysis is necessary to show the significance 
of the variant and the mechanism affected. The recent publication by Moortgat et al 
supports my observations by reporting pedigrees with certain similar phenotypic 
features, who are carrying what are described as pathogenic EIF2S3 mutations, in 
which two out of the three male patients died. My study has unique and novel aspects, 
firstly the human embryonic expression data presented here had not previously been 
analysed in depth in a hypothalamo-pituitary and pancreatic context in the literature. 
As discussed, Pedigree 8 still has a unique phenotype for a family harbouring an 
EIF2S3 variant, as the patients elicit a more severe hypopituitary phenotype, but a 
milder neurological phenotype compared to previous reports. Intellectual disability 
with the presence of microcephaly and epilepsy has been the main phenotypic focus 
in previous patients up until now. All previous reported patients had a thin corpus 
callosum on MRI; also observed in our patients. However three previously reported 
patients also had enlarged lateral ventricles (Borck et al., 2012); not present in 
Pedigree 8. In contrast, our patients have a small anterior pituitary on MRI as opposed 
to a normal structural pituitary and stalk in Moortgat et al’s study, and no mention of 
any structurally abnormal pituitary in Borck et al’s publication. Both previous reports 
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describe patients with GHD, however the authors did not provide any endocrine 
values; Borck et al simply stated that low growth hormone levels were observed in 
the two brothers, and treatment with GH resulted in some catch-up growth in one of 
them (Borck et al., 2012). The patients in Pedigree 8 have GHD and TSHD, 
suggesting that the EIF2S3 (p.P432S) variant may be affecting protein synthesis in 
both the somatotrophs and thyrotrophs, as opposed to previous EIF2S3 variants that 
suggest affects in only the somatotroph cells of the pituitary. The mechanism causing 
this is unknown although a proline to serine substitution is likely to affect protein 
folding, and thus be detrimental to the protein structure of eIF2γ. As we know it is 
expressed in the pituitary, it may be decreasing the occurrence of protein synthesis 
to a higher degree than previous mutations (thus causing the severe short stature), 
which extends across more cell types such as in the thyrotrophs. Patients in both 
pedigrees in Moortgat et al’s study had hypoglycaemia, however again there were no 
endocrine values presented. The microcephaly and ID observed in these patients 
may be primary, or secondary to brain damage caused by the hypoglycaemia. With 
this in mind, it cannot be ruled out that the microcepahly and ID in the patients 
described by Borck et al may in part have been a consequence of previous 
hypoglycaemia that went undetected. Although our patients in Pedigree 8 are similar 
to this report in having hypoglycaemia, they remain unique in having an unusual 
pancreatic phenotype that fluctuates between hyperinsulinaemic hypoglycaemia and 
hyperglycaemia, which has not been previously reported. Therefore this glucose 
dysregulation seen in our patients suggests a critical role for EIF2S3 in pancreatic 
function, as well as in hypothalamo-pituitary function. A comparison of the patient 
phenotypes described in the two previously published studies, and the patients in this 
study, are presented in Appendix 6. Finally, aside from the expression findings and 
clinical aspects, the EIF2S3 (p.P432S) remains completely novel, is in a highly 
conserved region of the gene, and has never appeared in a patient nor in a control 
individual before. The two previously reported EIF2S3 mutations, p.I259M and 
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p.I465Sfs*4 both lie within the C-terminal domain, and were concluded to be 
pathogenic following zebrafish morpholino studies (Moortgat et al., 2016). This 
suggests that our p.P432S variant, also lying within the C-terminus, may also be 
pathogenic, however causing a different phenotype. A clear defined role for the C-
terminal domain in eIF2γ remains to be established. As discussed, the variant is most 
likely to affect protein folding and therefore structure. Therefore the mechanism 
affected would potentially be protein-protein interaction, thus the binding ability of 
eIF2γ to other subunits and proteins would be altered, which in turn would influence 
protein synthesis.  
Unfortunately this study did not have time to delve into other avenues of investigating 
what the overexpression of EIF2S3 WT and the p.P432S mutant would do to a human 
or mouse pancreatic cell. If sufficient transfection had been achieved in 1.1B4 or MIN6 
cells in this study, and both inserts were being expressed at sufficient levels (validated 
by qPCR), then cells would have been analysed for cell death using the caspase 
assay protocol, and analysed for insulin secretion using the ELISA method. Insulin 
secretion could only be measured using the MIN6 cell line, since the 1.1B4 cells did 
not secrete insulin, as discussed (Figure 5.9). Therefore functional assays still need 
to be performed to clarify whether the p.P432S variant is pathogenic and how it is 
contributing towards the phenotype in Pedigree 8. 
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5.4. Future work investigating the function of eIF2γ 
5.4.1. Transfection assays 
Given more time, there are other approaches that can be applied to attempt a higher 
transfection efficiency of the EIF2S3_WT and EIF2S3 (p.P432S) constructs. These 
include non-viral physical methods such as electroporation, microinjection, 
impalefection, hydrostatic pressure or lipofection. I would most likely begin with 
electroporation in the next instance on 1.1B4 or MIN6 cells as this is the next most 
common method used on hard-to-transfect cells. This technology creates small pores 
in cell membranes in which constructs can enter, by applying an electrical pulse. 
Nucleofector technology (Lonza) is a new improved version of electroporation in 
which high transfection efficiencies may be reached using lower substrate amounts, 
with only a moderate impact on cell viability. However, attempting transfection with 
the current Fugene or lipofectamine method on an alternative pancreatic beta cell 
line, to see if they are more efficient in incorporating the plasmid into their genome, is 
a potential option. 
The EIF2S3 insert was cloned into the LV-IRES plasmid specifically in order to be 
packaged into a viable lentivirus. The fact that this was not possible for various 
unknown reasons suggests that there may be a better plasmid into which the WT and 
mutant EIF2S3 can be cloned, that may be more suitable for the transfection method 
as opposed to being chosen for transduction. In addition, given the fact that LV-IRES 
EIF2S3 constructs did not elucidate successful LV packaging as anticipated, one 
cannot rule out the possibility that there may be other underlying faults with this 
plasmid that may affect other methods, thus making it a poor choice with which to 
continue to attempt transfection. Re-cloning the inserts into a different plasmid that 
expresses GFP, or cloning GFP into the original pCMV-SPORT6 plasmid that already 
contained the EIF2S3 cDNA, would yield alternative constructs to the LV-IRES vector 
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which can then be transfected into cells. Alternatively, co-transfecting GFP with the 
pCMV-SPORT6 containing the EIF2S3 cDNA is another route that can be taken.  
 
5.4.2. Luciferase assays 
As mentioned previously, ribosomes typically initiate translation at an AUG start 
codon. Mutations that weaken Met-tRNAi binding to eIF2 or stimulate eIF2 GTPase 
activity have been found to enhance initiation at a UUG codon and confer a 
suppressor of initiation (Sui−) phenotype (Hinnebusch, 2011). In the previous study 
describing the p.I222T mutation in a patient with ID, the authors conducted an 
experiment showing that cells that express WT eIF2γ show a greatly reduced 
expression of firefly luciferase reporter with a UUG start codon than Renilla-luciferase 
with an AUG codon, producing a low UUG/AUG initiation ratio (Borck et al., 2012), 
which is consistent with what happens in vivo usually with the AUG codon being 
selected. When the p.V281T/p.V281K yeast equivalent mutations were analysed by 
Borck et al in their study, there was an increased UUG/AUG initiation ratio by 2-3 fold. 
Overexpression of eIF2β in the presence of p.V281T/p.V281K mutations, 
partially/fully respectively, restored the WT ratio in cells expressing the eIF2γ mutants 
(Borck et al., 2012). Therefore this complex start codon selection assay may be 
exploited to investigate the p.P432S variant, which may possibly allow further 
investigation of the p.P432S variant and reveal whether a defect in AUG start codon 
selection is the mechanism that is affected. Interestingly, the investigators who 
performed these assays stated that they were unable to express recombinant forms 
of mammalian eIF2γ, and were only able to mutate the corresponding Val281 residue 
in yeast eIF2γ for functional analysis. The authors do not elaborate on the problems 
they faced with expressing mammalian eIF2γ, indicating that they may have had the 
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same challenges in which I have been confronted with, e.g. with limited transfection 
efficiency.  
Insulin rapidly activates protein synthesis by activating eIF2B GDP/GTP exchange, 
thus promoting formation of the ternary complex; eIF2γ-GTP- Met-tRNAi. Therefore if 
successful transfection of our EIF2S3_WT and EIF2S3 (p.P432S) constructs can be 
achieved via any of the methods or cell lines discussed (section 5.4.1) then insulin 
could be used as a stimulant in the luciferase assays analysing UUG/AUG start 
codons. When these cells are expressing eIF2γ WT and eIF2γ mutant protein, firefly 
luciferase with the UUG start codon and Renilla-luciferase with the AUG start codon 
can then be measured directly from lysates following the Dual-Luciferase reporter 
assay system protocol (Promega). Basal activity can be initially analysed with the 
naturally occurring insulin in the cells, which would stimulate eIF2 activity 
endogenously. Insulin-stimulated activity generated by applying insulin into adjacent 
wells in the assay plate could essentially be measured simultaneously. The 
comparison of start codon selection in this context can then be compared between 
WT and mutant populations to observe the UUG/AUG start codon selection ratio in 
both cell populations at basal level, as well as after the addition of insulin. The latter 
will analyse whether the addition of insulin increases start codon selection in the 
mutant cells in a similar fashion to WT cells.    
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5.4.3. Binding assays 
In addition, co-transfecting constructs containing the genes encoding the eIF2α and 
β subunits (EIF2S1 and EIF2S2), with the eIF2γ WT and p.P432S variant constructs 
respectively, using a pull-down co-immunoprecipitation method with a His-tag, could 
essentially look for specific binding qualities of the individual subunits; α, β, γ, and 
also compare differences between the eIF2γ WT with the p.P432S variant. Previous 
studies by Borck et al describe a similar method that looked at the yeast equivalent 
residue to the human eIF2γ (p.I222T) variant that they identified (Borck et al., 2012). 
Given that the p.P432S variant is not in a known GTP-binding domain of eIF2γ, unlike 
the p.I222T variant, some would say that p.P432S may possibly not affect binding at 
all. However given the rudimentary knowledge about the C-terminal domain, and that 
the variant is predicted to alter protein folding and structure, it is beneficial to study 
effects on protein-protein interaction for significant binding differences between the 
WT and p.P432S proteins, in combination with the published p.I222T mutation (Borck 
et al., 2012) which can be used as a control. Conducting this assay may further clarify 
the role of the C-terminus in human eIF2γ. 
There are other initiation factors involved in the promotion of protein synthesis in 
similar ways to eIF2, such as eIF3 which is comprised of 13 subunits and participates 
in the majority of steps leading to translation initiation (des Georges et al., 2015). One 
of these roles, as mentioned in section 5.1.2., is to bind to the 40S ribosomal subunit 
in order to keep the 40S and 60S subunits separate from each other, which allows 
the association of the ternary complex with the 40S ribosomal subunit (Hershey, 
2015). Previous studies that sought to identify which components directly contacted 
residues in the eIF3 core, uncovered a direct bridge link between the globular domain 
of eIF3d to the eIF2α (des Georges et al., 2015). This is just an example of how the 
initiation factors may work together to initiate protein synthesis. Therefore binding 
assays may uncover subtle differences between the eIF2γ WT and the p.P432S 
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variant in respect to its ability to bind to closely related protein partners as well as 
more distant and unknown proteins in other pathways. 
 
5.4.4. Mouse-models 
In vitro studies are useful for characterising a gene and a particular variant within it to 
investigate how it may be contributing to a particular disease, but only to a certain 
extent. Alternatively, in vivo investigation using animal models would provide better 
analysis of the actual biology of a given disease in ways that in vitro assays are unable 
to. Coincidentally, it has just come to light that Dr James Turner’s research group at 
the Francis Crick Institute has attempted to create a CRISPR-generated Eif2s3x (the 
EIF2S3 mouse homologue) knock-out (KO) mouse. The CRISPR-Cas9 technique is 
namely the clustered regularly interspaced short palindromic repeats (CRISPR)-
Cas9, which refers to the immune system in bacteria. This naturally occurring process 
in prokaryotes has been manipulated and developed into a gene editing technique 
that can target particular sequences of DNA to inactivate whole genes or to edit them 
(Wiedenheft et al., 2009, Doudna and Charpentier, 2014). It can alter as little as one 
base pair, enabling specific gene variants identified in patients to be inserted into 
organisms (Walsh and Hochedlinger, 2013). Following the inactivation of Eif2s3x in 
the mouse via CRISPR-Cas9, Dr Turner’s group were unable to create mutant XY 
embryonic stem (ES) cell clones in the Eif2s3x KO mice (unpublished data), 
suggesting that Eif2s3x is critical for ES maintenance. Then, after injecting mouse 
zygotes, despite consistently recovering male and female mutants at the blastocyst 
stage, no mutants were recovered at birth, including female heterozygous mutants. 
Therefore the male mutants die consistent with the XY ES cells, and it appears that 
the targeting strategy that they performed was so efficient that it was able to kill both 
alleles in the females, again causing lethality. This is supported by their analysis of 
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XX blastocysts from which they failed to recover any WT alleles. These data are 
consistent with the findings in my study as the EIF2S3 KO 1.1B4 cell line had a highly 
significant increased cell death compared to controls, mirroring Dr Turner’s findings 
in unsustained life in Eif2s3x KO mice. We plan on collaborating with Dr Turner on 
this project and investigating Eif2s3x KO mice in the context of the pituitary and 
pancreas respectively. In addition, there may also be the possibility of creating an 
Eif2s3x (p.P432S) mutant mouse model using the CRISPR-Cas9 method. This will 
enable the analysis of any in vivo consequences of the p.P432S variant, with 
particular focus on the tissues affected in the patient. Initially the growth of the Eif2s3x 
KO and the Eif2s3x (p.P432S) mutant mouse models can be analysed. This will be 
followed by dissection of the hypothalamus, pituitary and pancreas, which can be 
visualised structurally for comparison with a WT mouse. The number, distribution and 
localisation of molecular markers, such as Sox2, Sox3, Lhx3, Lhx4 and Prop1 for 
example, may be analysed in both the hypothalamus and the pituitary at different 
stages of development. This will be implemented by fluorescent antibody staining, to 
see if there is a reduction in Sox2 positive cells in the mutant compared to the WT 
mouse for example. With these available working murine antibodies, this technique 
could look at co-expression of the known molecular markers in specific cell types of 
the pituitary, such as the somatotroph cells to see if there is correlation with hormone 
deficiencies that are seen in the patient. The pancreas in these mutants can also be 
investigated in a similar way to observe the appearance, number, distribution and 
localisation of pancreatic islets and their beta cells. Furthermore, molecular markers 
specific to the developing pancreas can be analysed, such as Ins1, Pdx1, NeuroD1, 
Ngn3 and MafA for example. In addition, insulin secreted from the beta cells and 
glucagon secreted from the alpha cells can be measured to look at different aspects 
and cell types of the pancreas in vivo.  
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Chapter 6  
 
 
 
General Discussion 
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6.1. Summary of findings 
In this study I have demonstrated both a Sanger sequencing and an exome 
sequencing approach to uncover novel variants and candidate genes in patients with 
congenital hypopituitarism (CH) and related phenotypes. The former was achieved 
by screening Pedigree 1 for LHX4 and identifying the first novel homozygous 
mutation, LHX4 (p.T126M), in two siblings with a lethal form of hypopituitarism 
(Gregory et al., 2015b). The latter was achieved by submitting seven unrelated 
pedigrees to GOSgene for exome sequencing and identifying novel variants in the 
following novel genes: CTPS2 (p.F166L) in Pedigree 2, RNPC3 (p.L483F) and 
PRMT6 (p.P350R) in Pedigrees 3-6, FASN (p.A2132V) and APEX2 (p.M422V) in 
Pedigree 7, and eIF2γ (p.P432S) in Pedigree 8. An EIF2S3 KO human cell line was 
established in this study, using an shRNA LV technique, which showed a significantly 
higher level of caspase activity compared to controls. This increased apoptosis in the 
KO cells suggests that EIF2S3 is crucial in sustaining cell viability. Although detailed 
functional analysis of the p.P432S variant was not completed within the timeframe of 
this study, these data, together with the hypothalamo-pituitary and pancreatic 
expression profile established in this study, suggest that p.P432S may cause a partial 
loss of function leading to a moderately severe phenotype. Molecular modelling 
together with the functional study of genes and the effect of particular mutations is 
extremely important to enable conclusions to be drawn about how certain phenotypes 
arise. However despite functional analysis performed in certain studies, often it is not 
possible to characterise the mechanisms affected by particular mutations through in 
vitro studies. This was the case when analysing the LHX4 (p.T126M) homozygous 
variant in this study, in which transactivation of αGSU and PRL were not affected. As 
discussed, despite there being more target genes to analyse in this assay such as 
TSHβ, POU1F1 and FSHβ, it is not certain that these are genuine physiological 
targets of LHX4. Therefore, although I was not able to show how the p.T126M 
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mutation altered LHX4 function, the molecular modelling together with the strong 
genetic evidence, animal conservation, and previous studies performed in mice, 
strongly suggests pathogenicity of this homozygous variant. Therefore even though 
it is ideal to show functional significance of a variant, it is not always possible, and 
sometimes it is more valuable to accumulate all the facts, including segregation within 
the family, molecular modelling and previous studies, in order to hypothesise whether 
a particular mutation is pathogenic or not. The molecular basis of congenital 
hypopituitarism remains to be established in the majority of the families in our large 
cohort of >2000 CH patients. This indicates that there is a significant number of novel 
genes and regions of interest that are yet to be discovered, and both scientists and 
clinicians can collaborate and identify these novel mechanisms in order to understand 
more about the embryogenesis and development of the hypothalamo-pituitary axis. 
 
6.2. Future Work 
The expression profiles of CTPS2, RNPC3, PRMT6, FASN and APEX2 have been 
analysed and discussed in Chapter 4. The variants identified in these genes in 
Pedigrees 2-7 will be functionally analysed in future studies using appropriate assays. 
Clinical investigation is essential and needs to take place regularly for all patients 
described in this study, to further characterise their phenotypes, and to get a clear 
picture of how their disorders are manifesting and changing with age. We would like 
to make murine transgenic models for all of these genes, as well as models 
harbouring the actual variants, using the CRISPR-Cas9 method. These in vivo 
models can then be compared to the normal mice for phenotypic differences, ranging 
from their size and the presence of other physical manifestations, through to 
molecular markers and hormone levels. The expression of RNPC3 analysed in this 
study, together with the previous report by Argente et al describing RNPC3 mutations 
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associated with IGHD, led me to hypothesise that the RNPC3 (p.L483F) variant is 
responsible for the GHD observed in the patients in Pedigrees 3-6. However 
functional analysis is needed to confirm this and to characterise the actual mechanism 
that is affected in these patients by either or both of the variants in RNPC3 and 
PRMT6 respectively. Additionally, the ovarian phenotype remains unexplained, and 
may be due to either the RNPC3 or the PRMT6 variant. We have already begun to 
create mouse models for Rnpc3 and Prmt6 with our collaborators at The Francis Crick 
Institute, London. Dr Karine Rizzoti and colleagues will knock out the Rnpc3 and 
Prmt6 separately in the mouse, as well as simultaneously, to try to characterise the 
role of each gene in the developing mouse. If these mutants do not survive, then a 
conditional knock out of each gene in the pituitary gland of the mouse will be 
generated. In addition the Rnpc3 (p.L483F) and Prmt6 (p.P350R) variants will be 
introduced separately and in combination with each other to create a mouse model 
reflective of the patients’ genotype (Pedigrees 3-6). Currently this group are analysing 
expression of both Rnpc3 and Prmt6 in embryonic murine hypothalamo-pituitary axis 
tissue as well as the ovaries, which can then be compared with the human expression 
profile performed in this study. We have obtained fibroblast cells from one of the 
affected female patients in Turkey that harbour the homozygous variants in RNPC3 
and PRMT6, and their unaffected sister that has a normal genotype. The RNA in 
these cells will be extracted and sequenced in a technique referred to as RNA-seq, 
also known as whole transcriptome shotgun sequencing. Transcriptomics can look at 
all parts of the transcript including mRNAs, non-coding RNAs and small RNAs, to 
enable analysis of the transcriptional structure of genes and their splicing patterns. In 
the RNA-seq technique, a population of RNA is converted into a library of cDNA 
fragments and then sequenced in a high-throughput manner to obtain short 
sequences, with reads typically 30-40 bp long. These can then be aligned to a 
reference sequence, or assembled to form a genome-scale transcription map that 
consists of both the transcriptional structure and the level of expression for each gene 
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(Wang et al., 2009). This method was carried out in the previous study by Argente et 
al in a lab in Finland which quantified the splicing efficiency and intron retention of 
U12-type introns with respect to U2-type introns per gene, and normalized by gene 
expression. The authors established 21 genes with significantly decreased U12/U2 
ratios in patient cells compared to controls (Argente et al., 2014). Therefore we plan 
on sending the patient fibroblast cells to Finland for RNA-seq, as this lab have 
experience in analysing the data in this context using this complex technique. The 
U12/U2 ratio in their optimised assay can then be measured and the gene expression 
of known U12-spliced genes can be analysed. This scrutiny of the transcript 
containing the RNPC3 (p.L483F) and PRMT6 (p.P350R) variants can potentially 
uncover any defects in the mRNA processing of the minor spliceosome that are giving 
rise to the tissue-specific consequences seen in the patient. For example, in the 
somatotroph cells of the pituitary, that may be causing the IGHD seen in Pedigrees 
3-6. In addition to analysing gene expression of the known U12-spliced genes 
associated with IGHD, previously identified by the authors, they could also analyse 
gene expression of U12-spliced genes known to be associated with the ovary. This 
can look for splicing abnormalities that may be giving rise to the ovarian failure seen 
in the patient. Furthermore the authors may be able to look back at their RNA 
sequencing data from the patients with the bilallelic RNPC3 mutations (Argente et al., 
2014), to look at splicing in ovarian-specific genes. The authors would most likely not 
have analysed these specific genes previously, due to their patients not having been 
diagnosed with ovarian failure, and thus were not considered relevant to the study. 
The mouse models together with the RNA sequencing results will help pinpoint the 
mechanism affected in the patients in Pedigree 3-7. Human ovarian embryonic tissue 
at >10pcw stage will be obtained from HDBR to analyse RNPC3 and PRMT6 
expression in the ovary. This will establish whether expression is apparent in the 
developing fallopian tube or related structures of the female reproductive system, or 
alternatively in the paramesonephric duct, as discussed in Chapter 4. Furthermore, 
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RNPC3 expression analysis of the developing pituitary will be repeated, as the 
Rathke’s pouch tissue in this study was damaged and despite results hinting at 
positive RNPC3 staining in this area (Figure 4.9 A-C), in situ hybridisation needs to 
be repeated for this to be concluded. 
To investigate the role of CTPS2 further we would like to generate a conditional Ctps2 
mouse knock out in the hypothalamo-pituitary axis, which will help characterize the 
role of Ctps2 in the context of this region. Furthermore, a Ctps2(F166L) mouse model, 
reflecting the genotype of the patient would be beneficial, to recapitulate the effect of 
the variant in the mouse. Additionally, it may be possible to collaborate with Martin E 
et al to perform functional assays based on their analysis of the CTPS1 gene (Martin 
et al., 2014). CTP formation depends on enzymes CTPS1 and CTPS2, whose 
respective roles remain unknown (Kassel et al., 2010). However the activity of these 
CTP synthases is thought to be a potentially important step for DNA synthesis in 
lymphocytes (van den Berg et al., 1995). This previous report identified a loss of 
function homozygous mutation (rs145092287) in CTPS1 that caused a novel and life-
threatening immunodeficiency. This disease was characterized by an impaired 
capacity of activated T and B cells to proliferate in response to antigen receptor-
mediated activation (Martin et al., 2014), previously discussed in Chapter 4.2.3. The 
splice mutation identified in this patient was found to have decreased ERK1/2 
phosphorylation, and CD25 and CD69 upregulation in CTPS1-deficient T-cells 
compared to controls. Firstly, fibroblast cells from the patient harbouring the CTPS2 
(p.F166L) in Pedigree 2 can be obtained and CTPS2 expression can be compared 
with control cells. In addition, based on the functional assays described in this 
previous study, and with the help of the immunology lab here at the ICH, proximal T-
cell activation signals, and late responses, may be investigated in fibroblast cells 
obtained from the patient, and compared to controls. Furthermore, B cells could be 
activated in these cells, with anti-BCR and CpG, and IL-4 and CD40L for example, 
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and monitored for the upregulation of CTPS2, using similar optimised previously 
performed methods that monitored CTPS1 upregulation. These data may give critical 
insights into the impact of the mutation on protein function. However, these assays 
obviously have particular focus on immune cells, and as our patient in Pedigree 2 has 
not been diagnosed with an immunodeficiency, they may not reveal the mechanism 
affected by the CTPS2 (p.F166L). Although, the immune system of this patient may 
need to be further investigated. It cannot be completely ruled out that immune cells 
specifically in the pituitary and related tissues where CTPS2 expression was identified 
(Figure 4.3), may be affected and indirectly contribute to the phenotype. However, 
the complex phenotype of the patient in Pedigree 2 is likely due to an as yet 
undetermined mechanism, unrelated to immune cells, initiated by the p.F166L 
missense substitution in CTPS2. In this case, the mouse model may be able to shed 
light on the underlying mechanism, hence it may be wise to begin with this in vivo 
study in the first instance.  
Finally, based on the expression profiles of both FASN and APEX2 in Chapter 4 of 
this study, it is hypothesised that the unique phenotype observed in the patient from 
Pedigree 7 is most likely to be hypothalamic. This hypothesis is based on the high 
FASN transcript expression observed in the hypothalamus in several stages during 
embryogenesis. This is opposed to only partial expression noted in Rathke’s pouch 
at the early stage of CS16, in which transcripts are otherwise absent from the 
developing pituitary gland (Figures 4.11). APEX2 transcript expression was 
completely absent in the developing hypothalamus and pituitary at all stages 
analysed. Recent clinical investigation of the patient identified an increased 
concentration of triglycerides, which will now be routinely monitored. The patient is 
due to have metabolic tests performed as an inpatient to analyse his fat metabolism, 
as well as an oral glucose tolerance test and diagnostic fast, which may show an 
abnormal impact on insulin secretion. His elevated triglyceride concentration 
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suggests a potential association of the phenotype with defective fatty acid synthesis 
due to the FASN mutation. These data together with the fact that FASN (p.A2132V) 
is a de novo variant, indicate that it is most likely to be mutated FASN that is giving 
rise to the phenotype seen in the patient (Pedigree 7). In addition, loss of Fasn in 
murine models generated in previous studies have a more severe phenotype 
compared to the Apex2 mouse models (discussed in Chapter 4.4.3 and 4.4.5). The 
conditional Fasn murine knock out in NSPCs impairs adult neurogenesis (Knobloch 
et al., 2013). Murine null mutant Fasn-/- embryos die before implantation, with Fasn+/- 
heterozygotes dying at various stages of development in utero, suggesting that Fasn 
haploinsufficiency is incompatible with survival (Chirala et al., 2003). Apex2-null mice 
exhibit a growth retardation phenotype, with moderate dyshaematopoiesis, a severe 
defect in lymphopoiesis, and an accumulation of thymocytes and mitogen-stimulated 
splenocytes in G2/M phase. The authors concluded that APEX2 was implicated as 
an essential regulator of efficient cell cycle progression of proliferating lymphocytes 
(Ide et al., 2004). Therefore, firstly, we plan on collaborating with Dr Sally Camper in 
Michigan in making a hypothalamic conditional Fasn knock out mouse. In addition we 
hope to generate a Fasn (p.A2132V) mouse model specific to the variant identified in 
the patient. These mice can then be phenotypically analysed in different ways such 
as in size, presence of other phenotypic features, and hormone levels, and compared 
to controls. We have recently obtained skin fibroblasts from the patient, and in 
collaboration with Professor Peter Clayton at ICH and Professor Robert Semple at 
Addenbrooks, we plan to investigate the lipid pathway in more detail. We will also 
measure the FAS levels in these patient cells, which will indicate whether the 
increased triglycerides are directly associated with increased FAS, which would 
suggest that the mutation identified is a dominant activating mutation. It cannot be 
ruled out that the APEX2 (p.M422V) variant is contributing to the hypothalamo-
pituitary phenotype observed in the patient. Alternatively this variant may potentially 
be responsible for the phenotype seen in other tissues, such as the sensorineural 
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hearing loss, which is echoed by the APEX2 expression noted in the utricle of the 
developing ear (Figures 4.13 C-D) as discussed in Chapter 4.4.6. Further expression 
studies will entail obtaining human embryonic tissue from the spleen to analyse 
expression of APEX2, as well as FASN, due to the patient from Pedigree 7 having 
splenomegaly. This condition may stem from the APEX2 (p.M422V) variant, 
especially as Apex2-null mice display an accumulation of splenocytes (white blood 
cells situated in the spleen). Discussions about generating an Apex2 (p.M422V) 
mouse model will possibly take place at a later stage after the Fasn (p.A2132V) has 
been investigated.  
 
6.3. Genetic screening methods 
Obviously every study has its limitations, for example human error when screening 
for variants in known causative genes. As every nucleotide is analysed by eye 
following direct sequencing analysis, crucial variants may be overlooked occasionally, 
perhaps missing the pathogenic mutation that is causing the disease phenotype. 
Despite being the more expensive option, whole exome sequencing (WES) can 
overcome this hurdle to an extent by picking up all potential variants in the coding 
region of a patient in the analysis. However, some may argue that the Sanger 
sequencing approach may actually result in being more costly, depending on the 
number of genes needed to be screened and number of patients in whom screening 
was to be performed. Thus using a lot of manpower in the analysis of just a handful 
of genes. Multi-gene panel tests are a step up from individual gene screening that 
enable the sequencing of several known causative genes simultaneously, providing 
a method to identify mutations using both a rapid and cost effective strategy. 
However, panel testing still only looks at a limited number of known genes, when 
there may be a multitude that have previously been implicated in the literature to 
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cause that specific disorder, such as in HH for example. In such cases where the list 
of potential mutated known genes is so large, any, or more than one gene, could be 
mutated in any given patient thus making it difficult to choose which of the genes to 
put on the panel test. Therefore WES is most likely to be the most efficient option for 
patients such as these, as both known, implicated and novel candidate genes may 
be assessed instantaneously. A limitation of WES however can be the filtering 
process, in which human error may occasionally overlook a pathogenic mutation by 
analysing the data in the wrong context. For example, if the database parameters are 
set to search the exome for de novo variants, and the data are not additionally 
analysed separately using parameters set to look for variants of autosomal dominant 
inheritance, then a heterozygous mutation may be overlooked. Therefore in this study 
the genetic data for each family submitted to GOSgene for exome sequencing was 
analysed using all alternative parameters, so as to be sure not to miss any potentially 
pathogenic mutations (Appendix 2). A general overview of the filtering process for 
exome sequencing data used by GOSgene is shown in Appendix 2. Therefore I am 
confident that the variants identified and discussed in the pedigrees in this study are 
the most likely candidates generated through the filtering process, and that all other 
polymorphic and benign variants have been disregarded, thus leaving the only 
potential variants that are likely contributing to the phenotype e.g. RNPC3 (p.L483F) 
and PRMT6 (p.P350R) in Pedigrees 3-6. However, future work will need to investigate 
the role of these genes in the pituitary and related tissues, and the effects of the 
variants on their function, to help show significance of these variants before any 
conclusions about their contribution towards the phenotype is made. Furthermore, 
exome sequencing only considers variants in the coding region, and splicing variants 
up to two bases into the intron at either end of the exon. Therefore the presence of 
an additional intronic variant in any of the pedigrees described cannot be completely 
ruled out, despite it being an unlikely occurrence. Additionally epigenetics is another 
factor that may influence the severity of a phenotype, which again also cannot be 
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ruled out in an individual. Epigenetics refers to modifications in heritable genetic 
information other than changes in the DNA sequence, such as DNA methylation and 
histone modification that alter gene expression (Holliday, 1989). Whole genome 
sequencing (WGS) would be the most beneficial and efficient option for the 
identification of variants if there were unlimited resources. This method can 
interrogate all parts of the genome potentially revealing single-nucleotide variants 
(SNVs), indels, structural variants (SVs) and copy number variants (CNVs) in both 
the ~1% part of the protein coding sequences, and the remaining ~99% of the non-
coding sequence (Ng and Kirkness, 2010). The 100,000 genomes project launched 
by Genomics England in 2012, aims to sequence 100,000 whole genomes of patients 
and their families with rare diseases and cancer by 2017 
(www.genomicsengland.co.uk). The genomic sequence data can be matched with 
patient medical records, and interpreted in order to investigate the cause, diagnosis 
and treatment of disease. This large resource of genomic data will build a platform in 
characterising rare diseases and cancers, which will benefit future generations and 
many different areas of research. We have contributed to a percentage of this project 
by providing DNA from certain unique families with pituitary disorders, and hope that 
this will shed light on some of the extremely rare cases in our cohort. Despite these 
patients submitted for WGS, either via the 100,000 genomes project or elsewhere, 
this remains an option only for the analysis of a very small number of unique 
pedigrees, as it is impossible to perform for all of the pedigrees within our large cohort. 
Therefore WES remains the preferred choice as it costs significantly less than WGS 
due to it being confined to just the cDNA. Although WES constitutes such a low 
percentage of the entire genome due to this, it still contains the majority of pathogenic 
mutations identified to date (Rabbani et al., 2014).  
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6.4. Control databases 
Control databases that are referred to when verifying a novel genetic variant can often 
be a concern. These databases can sometimes be ambiguous and lack information 
regarding the control samples themselves. They often fail to provide information as 
to how the individuals that were screened were classified as controls, and the criteria 
that was used for this. Nevertheless, they often state the number of controls within 
each ethnicity, enabling more relevant comparisons between DNA samples of similar 
ancestry. However, there are limitations here too, as individual control sub-cohorts 
are often small in number, and often do not define the descent of their controls 
sufficiently; such as when termed as ‘European’, which may consist of a multitude of 
ethnic backgrounds. Genotypes of Turkish descent will differ drastically from those of 
Swedish descent for example, and websites often generalise these as the same 
group and fail to subcategorize it. Prior to the ExAC browser 
(www.exac.broadinstitute.org) becoming one of the main control reference 
databases, control cohorts were also very limited in their number of patients too, for 
example in the 1000genomes database (www.1000genomes.org). One thousand 
individuals is not a very large number when verifying whether a variant is potentially 
pathogenic or not purely based on its absence from a database containing this 
number of patients. Prior to referring to databases, studies used to simply screen 
~100 individual patients from the same ethnic origin as the patient that possessed the 
variant. Despite the direct ethnicity match, this is still a rather small number to be used 
as evidence to make rational conclusions regarding pathogenicity. It is interesting to 
consider how many times a novel variant in the literature has been concluded as 
potentially pathogenic and/or had unnecessary functional analysis performed on in 
the past, purely based on this referral to a small number of controls. The accumulation 
of samples in the ExAC browser has improved the variant verification process by 
increasing the number of control samples to ~100,000 alleles, in which all 
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polymorphisms present in samples are listed along with their frequency within this 
population. The additional information of whether a particular variant is present in 
heterozygous, homozygous or hemizygous form is also apparent. If one has identified 
a homozygous variant for example, the fact that it is only present in heterozygous 
form in a control patient indicates that it could be recessive and may be worth pursuing 
functionally. The importance of indicating the sex of the control individual by 
distinguishing whether a variant on an X-linked gene is heterozygous or hemizygous 
(on the male X chromosome) for example, and not just stating the presence of the 
variant ‘on one patient allele’, is obviously also vital in deciphering whether a variant 
is worth pursuing. For example, if the ExAC browser purely stated that the APEX2 
(p.M422V) variant was present and did not mention that it had been identified in 
heterozygous form, then I would not have been sure that it had not been found in 
hemizygous form in a male control individual, as it is in the patient in Pedigree 7. 
Other control databases have not always had this information, which raises the 
question of how many novel homozygous variants have been excluded as being 
pathogenic, due to the database not stating whether it was heterozygous or not. Even 
though in my opinion the ExAC database is one of the best control databases 
commercially accessible, it still has an element of ambiguity that is similar to most 
other control databases. The large cohort of controls has been compiled from smaller 
cohorts of individuals that have been sequenced as part of various disease-specific 
and population genetic studies, where individuals affected by severe paediatric 
diseases have been excluded (www.exac.broadinstitute.org). Despite the removal of 
these patients with severe diseases, these cohorts are still derived from the general 
population that may suffer from a range of common polygenic diseases, and so 
cannot truly be termed as normal controls. This is a similar case to the National Heart 
Lung and Blood Institute (NHLBI) database, consisting of 6,500 subjects 
(www.nhlbi.nih.gov/), which GOSgene use as a control resource. The NHLBI collects 
the genotypes of patients with common diseases, therefore in my opinion it is not 
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completely impossible that one of the many variants that give rise to one of these 
common diseases may also be associated with a rarer disease when present in 
isolation. Even though the research area of the different groups that have contributed 
to the ExAC database are listed on their website, there is no detailed clinical 
information available for each sample. Therefore one cannot be sure that a certain 
‘control’ sample does not have a mild undetected or developing phenotype that is 
linked to the disease in the patient being studied. Thus, some may say that this would 
not be a true comparison to controls. Therefore discretion needs to be drawn upon 
here, for example if the variant in the patient appears once or twice in the ExAC 
database, it may still be worth pursuing with functional studies. Hence why GOSgene 
set parameters for variants to have an occurrence rate of <0.5% in control databases, 
when analysing exome sequencing data. 
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6.5. Variable penetrance 
Variable penetrance is when a heterozygous mutation is inherited from an 
asymptomatic parent but yet its presence in the progeny causes a disease phenotype. 
This has been reported to be the case in many publications and the concept has long 
been a subject of controversy, where many people firmly believe that such a variant 
cannot possibly be pathogenic simply due to its presence in the normal parent. This 
belief is that there must be another mutation so far undetected elsewhere in the 
genome that is working alongside such a variant to elicit the phenotype; termed 
digenic inheritance. However, this may not always be the case, and the argument 
against the sceptics is that in many publications the researchers have demonstrated 
that the mutation may lead to functional compromise, and has implications for 
pathogenicity that specifically fit with the patient phenotype. This suggests that 
perhaps a specific level of gene expression or dosage of the protein is needed for the 
phenotype to occur, and thus infers that each individual is different in this way, even 
when within the same family. Also, it cannot be ruled out that there may be another 
variant present in the parent, which influences gene dosage or has a positive effect 
that counteracts the pathogenic mutation, in which the child does not possess. From 
a wider perspective, variable penetrance casts an element of doubt on referring to 
control databases when validating a variant as potentially pathogenic or not. As 
mentioned, the presence of an identified patient variant in the same state (e.g. 
heterozygous) on a control database, often rules it out for further analysis. However, 
what if a heterozygous variant with variable penetrance is present in one of these 
control samples as it is in an asymptomatic parent? Therefore the same concept as 
previously mentioned applies; despite the presence of a variant amongst controls, it 
is the frequency of it that is crucial. This decision is the fine line between whether we 
may find the reason for a patient’s disorder, or whether it remains a mystery. 
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6.6. Human embryonic sections 
Human embryonic sections were analysed for expression in this study due to our 
unique access to the HDBR, rather than mouse embryonic sections. Even though the 
latter are more routinely used in other laboratories as they are more readily available, 
expression of a murine gene does not directly relate to human expression. Species 
may obviously differ from one another in terms of gene expression. Therefore I chose 
to analyse expression in normal human embryos in a hypothalamo-pituitary context, 
which had not been analysed by any other laboratory up until now. Essentially five 
different stages that span embryonic development were available: CS16, CS19, 
CS20 and CS23, equivalent to 39, 46, 49 and 56 days into development respectively 
(www.ehd.org/virtual-human-embryo/), and late 8pcw. Carefully processed 
hypothalamo-pituitary sections were obtained at these stages to observe specific 
expression, in addition to other sections of tissues affected in the respective patient 
who harboured the variant in the gene being analysed. As one can imagine, 
sectioning embryos is an intricate process, and maintaining the integrity of the tissues 
can be challenging (unpublished, HDBR), especially in smaller tissues such as the 
pituitary and the ovary. This delicate process with these precious embryos makes the 
success of both the sectioning and the expression assay vital, as human embryos are 
in short supply. There is little room for error in this field, and if the section is cut 
incorrectly or is damaged in the process, there is no rapid replacement at hand. 
Furthermore, human embryos more often than not peel off and do not stick down onto 
the slide as accurately as mouse embryos do (unpublished, HDBR), meaning that 
expression cannot always be visualised in some areas of the section with absolute 
precision. I found this a problem at times in this study as many of the sections 
obtained from HDBR had been damaged and were peeling off in this way, with some 
of the smaller structures of the brain not intact. For example, when looking at RNPC3, 
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although expression could be noted, areas of Rathke’s pouch tissue had been lost 
and I was not able to repeat the experiment using an alternative sample.  
 
6.7. Genetic counselling  
Genetic counselling was given to all the pedigrees discussed in this study after 
identification of the respective genetic variants. Genetic counselling refers to how 
families are advised about the consequences of an inherited disorder, and the 
probability of developing a disorder or passing it on to future generations. Often 
people ask how finding the potential genetic cause for a patient’s disease will actually 
help the patient. Some people would rather not know if they or their child harbour a 
mutation, and many choose not to find out which parent they inherited it from. 
Following genome or exome screening, one can choose not to be told whether they 
harbour variants known to contribute to common diseases. Therefore upon consent 
of the patient, researchers do not divulge such information to patients, and only inform 
them of a novel or known mutation that potentially contributes to their particular rare 
disease. If a novel potential variant is identified, then genetic counselling helps 
families understand what it may mean, for example how functional studies would most 
likely have to be carried out in order to further investigate whether it is pathogenic or 
actually benign. This is what would have had to have been explained to most of the 
families in this study. In a different context, genetic counselling can help give families 
advice as to what their options are with regard to family planning or options of in vitro 
fertilisation (IVF). It is now possible to screen and filter fertilised eggs before 
implantation that do not contain the pathogenic disease-causing mutation; a process 
known as pre-implantation genetic diagnosis (PGD), so that the child does not 
develop the disease that his or her sibling has (Vermeesch et al., 2016, Findlay, 
2000). This stops further inheritance of the pathogenic mutation and prevents future 
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generations manifesting the disease, thus improving their quality of life. This is a 
highly controversial topic which has split the opinion of many (Eskandarani, 2009); 
however, simply selecting an embryo that does not contain the mutation is not by any 
means changing any part of the genetic code. It is simply an alternative genotype of 
the parents that will give rise to a baby without that particular disease. Despite this, I 
believe that it should remain a restricted service that is only carried out for the 
prevention of severe diseases. It should not be extended to parents’ preference of 
gender or traits that they want their children to have, such as height or colouring, 
where certain variants may be included or excluded to result in these preferences. 
This information should remain anonymous and only the mutation in question should 
be excluded. Religious or ethical principles divide many where genetics is concerned 
(Fasouliotis and Schenker, 1998), with many believing that we should let nature take 
its course at all costs and not meddle with genetics as it is artificially influencing the 
gene pool. On rare occasions, genetic counselling may extend to discussing the 
possibility of gene therapy for the patient, which exists and differs in many countries 
for certain diseases (Kim et al., 2008). Options for this would currently only be if the 
family consented to being recruited to a clinical trial, if there is one that exists for their 
disease. It is a long way off from being routinely performed, and only certain clinical 
trials have been accepted both ethically and socially in specific disease areas in the 
UK. A recent example is the trial on maternal gene therapy of severe early-onset fetal 
growth restriction (Sheppard et al., 2016), which could potentially be the first trial of 
gene therapy during pregnancy. Phase 2b clinical trials have recently been 
undertaken for cystic fibrosis (CF). The respective patients have been recruited from 
18 sites in the UK, and were given either a nebulised gene–liposome complex; a non-
viral CFTR gene therapy delivered directly to the lungs, or a saline dose (placebo) 
every 28 days for 1 year. These trials noted a significant, albeit modest, treatment 
effect of the gene therapy in the CF patients, associated with a stabilisation of lung 
function versus the placebo, at 12 months follow up (Alton et al., 2015). Further 
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improvements in efficacy and consistency of response to this form of gene therapy is 
needed before it is considered for clinical care. Thus clinical trials have now 
progressed into the next phase in this study. Gene therapy in Duchenne muscular 
dystrophy, using adeno-associated viral delivery methods, is also being developed 
and has been accepted for clinical trials (Bowles et al., 2012). Another example is 
gene therapy for immunodeficiency disorders, such as X-linked severe combined 
immune deficiency (XSCID), whereby restoring gene expression in autologous 
hematopoietic stem cells has been shown to be an effective method of treatment. 
Thus resulting in the production of T-lymphocytes and subsequent immune 
reconstitution (Cavazzana-Calvo et al., 2000, Gaspar et al., 2004). However despite 
these revolutionary advancements serious complications have frequently occurred, 
such as 5 out of a total of 20 subjects developing leukaemia-like T lymphoproliferative 
disorder 2-5 years after XSCID gene therapy (Hacein-Bey-Abina et al., 2003a, 
Hacein-Bey-Abina et al., 2003b). Adverse effects of treatment such as these highlight 
the need for the development of new strategies to improve, not only the success rate, 
but most importantly the safety of gene therapy, such as accurate gene targeting 
(Kildebeck et al., 2012). Gene therapy is essentially the introduction of normal genes 
into patient cells in place of missing or defective ones, or the silencing of a particular 
gene using complex drugs, in order to correct genetic disorders. This treatment can 
potentially take place at any age, ranging from prenatally to being performed in an 
adult patient. Many research groups are fighting for the right to perform this procedure 
for a range of diseases to improve the quality of life for many families, however this 
also remains a highly controversial topic. The conventional rule is that only somatic 
cells should be genetically altered by gene therapy, and not germ cells that contain 
heritable information (Lanphier et al., 2015). However Ireland and Italy have recently 
permitted the genetic code of germ cells to be altered in an individual if and when 
gene therapy for a particular disease is possible. This means that there could 
potentially be no control over these modifications being incorporated into the gene 
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pool, and that they will become uncontrollable permanent fixtures in the DNA of future 
generations. Even though a long drawn out process of clinical trials always needs to 
be performed to allow any such treatment to be available to patients, there is always 
still a slim chance of adverse effects or consequences that will only come to light in 
the years to come. That is why in my opinion it is extremely important for genetic 
modifications to remain within the individual that has been treated. However, the fact 
that one country may have one law that confines gene therapy to somatic cells, and 
another may not, is a very worrying concept. It only takes one country to not abide by 
this rule for the future of the human race to potentially be affected by any unknown 
consequences of gene therapy. With regard to the patients investigated in this study, 
gene therapy would obviously not be an option at present, as extensive functional 
work would have to be undertaken on the variant in question. Only then could a strong 
grant proposal be written that, if accepted, would be followed by vigorous clinical trials 
before even having a chance of becoming an option for patients. However, it is not 
an impossible goal for the future with technology rapidly progressing year after year. 
The more we as scientists and clinicians can do to identify and characterize mutations 
in our area of research, the more options will then arise for patients. I believe that the 
more knowledge we have about a specific field, the more options we have to fight to 
change it for the better. 
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Appendices 
Appendix 1 
 
Construct 
transfected into 
HEK293T cells 
Average 
luciferase/total 
protein 1st assay 
Average 
luciferase/total 
protein 2nd assay 
Average 
luciferase/total 
protein 3rd assay 
AVERAGE 
LUCIFERASE/TOTAL 
PROTEIN 
 
STD DEV OF 
AVERAGE MEAN 
EV 103.38 67.28 99.58 90.08 19.83 
wtLHX4 3651.98 4685.17 6434.75 4923.97 1406.67 
T126M 4391.96 5075.28 7072.48 5513.24 1392.89 
 
 
 
 
 
 
 
Construct 
transfected into 
HEK293T cells 
Average 
luciferase 1st 
assay 
Average 
luciferase 2nd 
assay 
Average 
luciferase 3rd 
assay 
AVERAGE 
MEAN 
STD DEV 
OF 
AVERAGE 
MEAN 
T-TEST 
p value 
Significance 
EV 1 1 1 1 0 
  
wtlhx4 4.48 3.15 5.70 4.44 1.28 0.012675 * 
wtLHX4 10.58 7.42 12.87 10.29 2.74 
  
wtlhx4 + pou1f1 28.18 20.83 41.04 30.01 10.23 
  
pou1f1 3.79 3.42 3.84 3.68 0.23 
  
POU1F1 4.52 3.85 5.81 4.73 0.99 
  
t126m 4.48 2.76 4.52 3.92 1.01 0.006792 ** 
T126M 10.65 6.17 11.93 9.58 3.02 
  
t126m + pou1f1 36.02 22.66 42.10 33.60 9.95 
  
A 
B 
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Appendix 1: Transactivation assays investigating the LHX4 (p.T126M) variant. (A-C) Each table represents results from three 
separate luciferase assays performed in triplicate. (A) Transfection of HEK293T cells with LHX4 WT and the LHX4 (p.T126M) mutant 
construct, to investigate the effect of LHX4 on the αGSU promoter. Luciferase values were normalised to total protein. This relates to 
Figure 3.7 A in this study. (B-C) Transfection of constructs into HEK293T cells to investigate the effect of WT and mutant LHX4 on the 
prolactin promoter. Luciferase values were normalised to Renilla luciferase values. These tables relate to Figure 3.7 B and C respectively. 
EV, empty vector; WT, wild-type; STD DEV; standard deviation.    
Construct 
transfected into 
HEK293T cells 
Average 
luciferase 1st 
assay 
Average 
luciferase 2nd 
assay 
Average 
luciferase 3rd 
assay 
AVERAGE 
MEAN 
STD DEV 
OF 
AVERAGE 
MEAN 
T-Test 
p value 
Significance 
EV 1 1 1 1 0 
  
wtlhx4 3.18 3.62 5.85 4.22 1.43 0.000351 *** 
wtLHX4 8.22 7.72 15.73 10.56 4.49 
  
pou1f1 3.45 3.25 3.29 3.33 0.10 
  
POU1F1 4.57 4.15 4.65 4.46 0.27 
  
wtlhx4 +pou1f1 26.83 29.72 34.23 30.26 3.73 
  
r84c 1.76 1.98 2.62 2.12 0.45 0.001696 ** 
R84C 3.01 3.35 5.66 4.01 1.44 
  
wtlhx4 + r84c 5.89 6.20 10.51 7.53 2.59 
  
r84c + pou1f1 14.27 16.17 20.95 17.13 3.44 0.010974 * 
C 
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Appendix 2  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exome sequencing raw data 
Confidence filter 
• Call quality: ≥20.0 
• Read depth: ≥10.0 
Parameters set 
Heterozygous or 
Compound heterozygous 
Parameters set 
De novo 
Parameters set 
Homozygous recessive  
(usually for consanguineous 
pedigrees) or hemizygous, X-
linked 
Common variants filter 
Variants with allele frequency ≥ 0.5% that were observed in 
the 1000 genomes project, ExAC  
and NHLBI ESP will be excluded 
Predicted deleterious filter 
Filter using all/one of the following variants:  
* Pathogenic or possibly pathogenic                                  * Established gain of function in the literature 
* Inferred activating mutations by Ingenuity                    * Predicted to be gain of function by BSIFT 
* Frameshift, in-frame INDEL, or stop codon change      * Missense disrupt splice-site 
* Promoter loss 
Biological context filter 
Keep variants known or predicted to affect the disease in 
question e.g. Hypopituitarism 
Parameters set 
Variants not present  
in either parent  
Parameters set 
Variants only present in 
heterozygous form and in 
both parents 
Parameters set 
• Variants present in 
heterozygous form in 
parent. 
• If compound heterozygous 
parents each carry one 
heterozygous variant that are both 
present in the proband 
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Appendix 2: Flowchart showing the exome sequencing data filtering process. 
This criteria was used to identify novel variants and regions of interest in Pedigrees 
2-7. The parameter settings may be altered accordingly to analyse the data in 
different contexts e.g. to search for de novo or compound heterozygous variants 
respectively. All possible parameter settings were used to analyse all exome data. 
ExAC, Exome Aggregation Consortium; NHLBI ESP, National Heart Lung and Blood 
Institute Exome Sequencing Project; BSIFT, Bi-directional Sorting Intolerant from 
Tolerant.  
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Appendix 3 
A. De novo filter for Pedigree 2 
 
B. Homozygous recessive filter for Pedigrees 3-6 
Position Reference 
Allele 
Sample 
Allele 
Variation 
Type 
Gene 
Region 
Gene 
Name 
Transcript Protein 
Variant 
Patient 
genotype 
Parent 
genotypes 
Comment ExAC 
database 
Chr11_13
0332577 
A C SNV Exonic ADAMTS
15 
NM_139055 p.T482P Het Not 
present 
BAM – poor 
call 
Het: 91/ 241,052; 
40/ 106,064 in 
European  
Hom: 0 
Chr12_13
2628391 
G C SNV Exonic DDX51 NM_175066 p.P123R Het Not 
present 
BAM - poor 
call 
Present in old 
version of ExAC, 
but was filtered 
out as this site 
has poor 
coverage  
ChrX_167
11551 
G T SNV Exonic CTPS2 NM_001144
002 
p.F166L Het  Not 
present 
BAM OK and 
confirmed by 
Sanger 
sequencing  
Not present in 
ExAC 
Position Reference 
Allele 
Sample 
Allele 
Variation 
Type 
Gene 
Region 
Gene 
Name 
Transcript Protein 
Variant 
Patient/s 
genotype 
Parent 
genotypes 
Comment ExAC 
database 
Chr1_1040
93650 
A T SNV Exonic RNPC3 NM_017619 p.L483F Hom Het in 
both 
BAM OK 
and 
confirmed 
by Sanger 
sequencing  
Not present 
in ExAC 
Chr1_1076
00386 
C G SNV Exonic PRMT6 NM_018137 p.P350R Hom Het in 
both 
BAM OK 
and 
confirmed 
by Sanger 
sequencing  
Not present 
in ExAC 
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C(i). De novo filter for Pedigree 7 
 
C(ii). X-linked filter for Pedigree 7 
 
Position Reference 
Allele 
Sample 
Allele 
Variation 
Type 
Gene 
Region 
Gene 
Name 
Transcript Protein 
Variant 
Patient/s 
genotype 
Parent 
genotypes 
Comment ExAC 
database 
Chr2_1481
312 
A G SNV Exonic  TPO NM_000547 p.N425S Het Het in 
father 
BAM OK Not present 
in ExAC 
Chr3_1.96
E+08 
GGCGCG - Del Exonic  FBXO45 NM_0011055
73  
   
p.G25_A2
6del 
Het Het in 
both 
Failed QC -  
within unstable 
repeats 
Not present 
in ExAC 
Chr5_5525
6258 
- TCACT
CCAG 
Dup Exonic  IL6ST NM_002184 p.D312_S
314dup 
Het Not 
present 
Failed QC -  
within unstable 
repeats 
Not present 
in ExAC 
Chr17_775
1862 
CAC - Del Exonic  KDM6B NM_0010804
24 
p.T762del Het Not 
present 
Failed QC -  
within unstable 
repeats 
Not present 
in ExAC 
Chr17_800
39488 
G A SNV Exonic  FASN NM_004104 p.A2132V Het Not 
present 
BAM OK and 
confirmed by 
Sanger 
sequencing 
Not present 
in ExAC 
Position Reference 
Allele 
Sample 
Allele 
Variation 
Type 
Gene 
Region 
Gene 
Name 
Transcript Protein 
Variant 
Patient/s 
genotype 
Parent 
genotypes 
Comment ExAC 
database 
ChrX_5503
3575 
A G SNV Exonic APEX2 NM_014481 p.M422V Hemi Het in 
mother 
BAM OK and 
confirmed by 
Sanger 
sequencing  
Het: 1/86,652; 
8405 in African 
Hemi: 0 
ChrX_1.34
E+08 
G A SNV Exonic ZNF449 NM_152695 p.R324Q Hemi Het in 
mother 
BAM OK and 
confirmed by 
Sanger 
sequencing  
Het:20/87355 
Hemi: 5/87355 
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Appendix 3: Exome sequencing filtering results from Pedigrees 2-7. These tables present the variants generated from the exome 
sequencing filtering process performed by GOSgene. The exome data was filtered using all possible options of parameter settings that 
are illustrated in Appendix 2. Parameter settings that did not generate any potential variants are not shown. The tables displayed in this 
figure present all potential variants that were filtered using appropriate parameters for that given pedigree/s. The text highlighted in red 
represents variants that were ruled out as candidates. A: The de novo filter for Pedigree 2 revealed the variants listed in this table. The 
variants in ADAMTS15 and DDX51 were excluded due to the BAM file having a poor call; indicating that the exome regions containing 
these variants were not clearly covered by the software due to homologous regions elsewhere in the genome. In addition the ADAMTS15 
variant was present multiple times in heterozygous form in the ExAC database. This left the CTPS2 (p.F166L) variant as the remaining 
candidate generated from the exome sequencing data analysis. B: The homozygous recessive filter for the consanguineous Pedigrees 
3-6 revealed only two variants; RNPC3 (p.L483F) and PRMT6 (p.P350R), present in the six affected patients in homozygous form, and 
the one unaffected father in heterozygous form, that had exome sequencing performed, suggesting a founder effect from this 
geographically isolated population. C(i): The de novo filter for Pedigree 7 revealed the variants listed in this table. The variant in the TPO 
gene was excluded due to it being present in heterozygous form in the unaffected father. The variants in FBXO45, IL6ST and KDM6B 
failed the QC due to them being located within unstable repeats that have not been mapped accurately and are poorly represented by 
the software. In addition, the variant in FBXO45 was present in both unaffected parents in heterozygous form. This left the FASN 
(p.A2132V) variant as the remaining candidate generated from the de novo filter. C(ii): The X-linked filter for Pedigree 7 also revealed 
two variants. The variant in ZNF449 was excluded due to its multiple presence on the ExAC database, leaving the APEX2 (p.M422V) 
variant as the remaining candidate generated from the X-linked filter, as it only appeared once in the ExAC database in heterozygous 
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and not in hemizygous form. Therefore both FASN (p.A2132V) and APEX2 (p.M422V) variants are potential disease-causing candidates 
in Pedigree 7. There is no data shown from Pedigree 8 as only the X-chromosome was sequenced, revealing only one candidate gene; 
EIF2S3 (p.P432S). SNV, single nucleotide variant; BAM, binary alignment map; del, deletion; dup, duplication; QC, quality control.     
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Appendix 4 
Pedigree Consanguineous Ethnicity Variant 
identified 
Protein 
prediction  
model 
Mode of 
inheritance 
Age of 
patient at 
presentation 
Main 
diagnosis 
Endocrine 
deficits 
Accompanying 
phenotypes 
2 No Afro-
Caribbean 
CTPS2  
ChrX: 
16711551 
c.498C>A, 
p.F166L 
Polyphen2: 
Probably 
damaging 
 
SIFT: Tolerated 
De novo 
Heterozygous 
23 years Congenital 
pan-
hypopituitarism 
GH, TSH, 
ACTH, LH 
and FSH 
Left microtia; an 
absent pinna  
Severe conductive 
hearing loss 
Ciliary dyskinesia 
Complete situs 
inversus with 
dextrocardia 
Hypoplasia of the 
mandible 
Severe eczema 
Learning difficulties 
Left facial nerve 
palsy with left sided 
hemiparesis 
3-6 Yes Turkish RNPC3   
Chr1: 
104093650 
c.1449A>T, 
p.L483F 
 
RNPC3 
Polyphen2: 
Probably 
damaging 
SIFT: Damaging 
 
Autosomal 
recessive 
(Both 
homozygous) 
- -GHD in all 
patients 
GH - 
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PRMT6   
Chr1: 
107600386 
c.1049C>G, 
p.P350R 
PRMT6 
Polyphen2: 
Benign 
SIFT: Tolerated 
 
-Primary 
ovarian failure 
in the females  
7 No African 
(mother) 
White 
European 
(father) 
FASN  
Chr17:  
80039488 
c.6395C>T, 
p.A2132V 
 
 
 
APEX2 
ChrX: 
55033575  
c.1264A>G, 
p.M422V 
FASN 
Polyphen2: 
Probably 
damaging 
SIFT: Damaging 
 
 
 
APEX2 
Polyphen2: 
Benign 
SIFT: Tolerated 
De novo 
(Heterozygous) 
Autosomal 
recessive 
 
(Hemizygous) 
Inherited from 
asymptomatic 
heterozygous 
mother. 
19 years Congenital 
panhypopituitar
ism 
GH, TSH, 
ACTH, LH 
and FSH 
Short stature 
Dysmorphic 
features 
Developmental 
delay 
Sensorineural 
deafness 
Hypoparathyroidism 
Retinal dystrophy 
Reynaud’s 
syndrome 
Splenomegaly  
Aortic regurgitation 
Appendix 4: Genotypes and phenotypes of patients in Pedigrees 2-7. The table summarises the parental ethnic origins, and the 
protein prediction model results from databases Polyphen and SIFT, for each variant in patients from Pedigrees 2-7 discussed in Chapter 
4 in this study. 
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Appendix 5 
A 
 
 
 
Cell population Average 
mean 
luciferase 
1st assay 
Average 
mean 
luciferase 
1st assay 
Average 
mean 
luciferase 
1st assay 
Average 
mean 
luciferase 
of 
triplicates 
Standard 
Deviation 
2-tailed 
unpaired  
T-Test  
Basal activity 
v  
cyto addition 
 
2-tailed 
unpaired  
T-Test  
NS basal  
v 
 KO basal 
2-tailed 
unpaired  
T-Test  
NT basal 
 v  
KO basal 
2-tailed 
unpaired  
T-Test  
NS cyto 
 v  
KO cyto 
2-tailed 
unpaired  
T-Test  
NT cyto 
v  
KO cyto 
           
Clone 4 Cyto 2019 2695 2151 2288 358.31 0.0067 1.612E-04 4.232E-05 0.0021 0.0020 
     
 
     
Clone 4 Basal 1156 1275 1177 1203 63.52 
     
     
 
     
Non silencing 
Cyto 
767 352 285 468 261.10 0.2628 
    
     
 
     
Non silencing 
Basal 
373 211 189 258 100.49 
     
     
 
     
Non-transduced 
Cyto 
833 773 667 758 84.06 0.0009 
    
     
 
     
Non-transduced 
Basal 
265 161 264 230 59.76 
     
266 
 
B 
                                                                                                     
          (NT#cyto) vs (NS#basal)      500.4444    83.7513     5.98   0.0000     251.8794    749.0095
           (NT#cyto) vs (NS#cyto)      290.1111    83.7513     3.46   0.0136     41.54606    538.6762
         (NT#basal) vs (NS#basal)     -32.11111    83.7513    -0.38   0.9989    -280.6762    216.4539
          (NS#basal) vs (NS#cyto)     -210.3333    83.7513    -2.51   0.1411    -458.8984    38.23172
          (NT#basal) vs (NS#cyto)     -242.4444    83.7513    -2.89   0.0597    -491.0095    6.120611
     (NT#cyto) vs (Clone 4#basal)     -444.7778    83.7513    -5.31   0.0000    -693.3428   -196.2127
          (NT#basal) vs (NT#cyto)     -532.5556    83.7513    -6.36   0.0000    -781.1206   -283.9905
     (NS#cyto) vs (Clone 4#basal)     -734.8889    83.7513    -8.77   0.0000    -983.4539   -486.3238
    (NS#basal) vs (Clone 4#basal)     -945.2222    83.7513   -11.29   0.0000    -1193.787   -696.6572
    (NT#basal) vs (Clone 4#basal)     -977.3333    83.7513   -11.67   0.0000    -1225.898   -728.7683
(Clone 4#basal) vs (Clone 4#cyto)     -1085.667    83.7513   -12.96   0.0000    -1334.232   -837.1016
      (NT#cyto) vs (Clone 4#cyto)     -1530.444    83.7513   -18.27   0.0000    -1779.009   -1281.879
      (NS#cyto) vs (Clone 4#cyto)     -1820.556    83.7513   -21.74   0.0000    -2069.121   -1571.991
     (NS#basal) vs (Clone 4#cyto)     -2030.889    83.7513   -24.25   0.0000    -2279.454   -1782.324
     (NT#basal) vs (Clone 4#cyto)         -2063    83.7513   -24.63   0.0000    -2311.565   -1814.435
                     group1#group2  
                                    
                    basal vs cyto     -609.5185   48.35384   -12.61   0.0000    -706.7404   -512.2966
                            group2  
                                    
                         NT vs NS           129   59.22111     2.18   0.0853    -14.22554    272.2255
                    NT vs Clone 4     -1253.889   59.22111   -21.17   0.0000    -1397.114   -1110.663
                    NS vs Clone 4     -1382.889   59.22111   -23.35   0.0000    -1526.114   -1239.663
                            group1  
                                                                                                    
                                       Contrast   Std. Err.      t    P>|t|     [95% Conf. Interval]
                                                                  Tukey                Tukey
                                                                                                    
                            
group1#group2             15
       group2              1
       group1              3
                            
                 Comparisons
                   Number of
                            
      the 5% level.
      label are not significantly different at
Note: Margins sharing a letter in the group
                                                
 Clone 4#cyto      2288.333   59.22111
Clone 4#basal      1202.667   59.22111
      NT#cyto      757.8889   59.22111
      NS#cyto      467.7778   59.22111         A
     NS#basal      257.4444   59.22111         A
     NT#basal      225.3333   59.22111         A
 group1#group2  
                
         cyto      1171.333   34.19133
        basal      561.8148   34.19133
        group2  
                
      Clone 4        1745.5   41.87565
           NT      491.6111   41.87565         A
           NS      362.6111   41.87565         A
        group1  
                                                
                     Margin   Std. Err.   Groups
                                           Tukey
                                                
                            
group1#group2             15
       group2              1
       group1              3
                            
                 Comparisons
                   Number of
                            
Margins      : asbalanced
Pairwise comparisons of marginal linear predictions
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Appendix 5: Raw mean average data and statistical tests of apoptosis assays. (A): Apoptosis assays measuring cell death in 
EIF2S3 KO cells compared to controls. The table shows the average normalised luciferase values from the three apoptosis assays 
performed in triplicate wells. Caspase 3/7 activity is measured with and without (basal) the addition of cytokine treatment. This table 
relates to the average mean graph in Figure 5.11 in Chapter 5. Cyto; cytokine, Clone 4; EIF2S3 Knock out 1.1B4 cell line. (B): Pairwise 
comparisons of data from apoptosis assays based on a fitted two-way ANOVA model with Tukey adjustment for multiple 
testing. Comparisons of Clone 4 with both the NT and NS control populations were significantly different both at basal and with cytokine 
treatment. There was no significant difference between NS basal and NS after cytokine treatment, which is consistent with the two-tailed 
unpaired T-test analysis. There was no significant difference between both controls at basal level as shown in the table. 
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Appendix 6 
Borck et al. 2012 Mol Cell Moortgat et al. 2016 AJMG This study – Pedigree 8 
EIF2S3, p.I222T 
in the highly conserved GTP-binding (G) 
domain 
EIF2S3, p.I259M and p.I465Sfs*4 
in two unrelated pedigrees  
in the C-terminal domain 
EIF2S3, p.P432S 
in the C-terminal domain 
Three males: 2 brothers and maternal uncle 
• Intellectual disability (moderate to 
severe) 
• Microcephaly 
• Short stature with GHD in two 
patients 
• Facial dysmorphic features 
• Epilepsy 
• Thin corpus callosum on MRI 
• Enlarged lateral ventricles on MRI 
Three males: 2 brothers, 1 unrelated male 
• Severe intellectual disability 
• Microcephaly 
• GHD  
• Hypoglycaemia 
• Epilepsy 
• Thin corpus callosum on MRI 
• Normal pituitary and stalk on MRI 
• Global white matter loss on MRI 
Three males: 2 brothers and maternal male 
cousin 
• Central hypothyroidism 
• GHD  
• Unique pancreatic phenotype: 
fluctuation between 
hyperinsulinaemic hypoglycaemia 
and hyperglycaemia 
• Small anterior pituitary on MRI 
• Thin corpus callosum on MRI 
Unique additional features: 
• Cleft lip/palate  
• Behavioural problems 
• Postpubertal microgenitalism 
• Obesity 
Unique additional features: 
• Spastic quadriplegia 
• Convergent strabismus 
• Delayed puberty 
• Genital abnormalities 
• Micrognathia (undersized jaw) 
• Hypotonia 
• Global reduction of white matter on MRI 
Unique additional features: 
• Developmental delay 
• Behavioural problems 
• Micropenis 
• Undescended testes 
• Severe eczema 
• Convergent squint 
• Generalised white matter loss on MRI 
• Ventricular asymmetry on MRI 
Appendix 6: Clinical phenotypes of male patients with EIF2S3 mutations from three separate studies. Clinical phenotypes are 
from previous reports by Borck et al and Moortgat et al respectively, and from this current study. Not all unique additional features listed 
under each study were present in every patient described; each male within the study had various combinations of these features. 
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